background
despit
advanc
chines
hamster
ovari
cho
cell
bioprocess
optimis
product
larg
complex
protein
remain
costli
high
degre
variabl
among
final
product
problemat
novel
strategi
target
molecular
pathway
high
product
yield
consist
vital
overcom
bottleneck
develop
crisprdca
base
synthet
transcript
factor
stf
system
modul
express
endogen
mrna
mirna
target
involv
protein
transport
glycosyl
materi
method
stf
utilis
two
form
protein
endonucleas
inact
dead
transactiv
domain
vpr
attach
nativ
cut
fig
express
transient
express
sgrna
upstream
protein
transportrel
gene
promot
napg
transcript
activ
transfect
sgrna
promot
region
suppress
lower
galactosyltransferas
associ
mirna
express
cho
cell
coexpress
sgrna
mirna
promot
nativ
sgrna
matur
mirna
sequenc
mrna
mirna
level
target
gene
quantifi
qrtpcr
protein
level
western
blot
secret
igg
yield
iggelisa
result
approach
receiv
increas
igg
express
along
rise
napg
mrna
level
repress
transcript
lead
neg
effect
igg
yield
fig
c
result
show
posit
correl
pathway
involv
protein
transport
recycl
recombin
protein
rprotein
yield
approach
reduc
around
simultan
enhanc
express
could
use
futur
engin
rprotein
glycosyl
profil
specif
function
system
also
provid
platform
concurr
manipul
multipl
mrna
mirna
express
control
via
aid
ecdfrdegron
technolog
conclus
work
present
potenti
crisprai
system
easili
reengin
studi
cho
cell
metabol
pathway
effici
rprotein
product
chemic
induc
protein
express
offer
control
multipl
endogen
gene
manipul
acknowledg
author
thank
acknowledg
biotechnolog
biolog
scienc
research
council
fund
research
work
sn
thank
esact
provid
opportun
present
work
meet
refer
chang
h
yi
b
r
zhang
x
zhao
h
xi
novel
genom
tool
knock
microrna
vitro
vivo
scientif
report
kleinjan
wardrop
c
sou
rosser
toolkit
tunabl
degrontag
effector
multidirect
druginduc
control
synthet
gene
regul
nat
commun
press
background
increas
number
biolog
enter
develop
pipelin
pharmaceut
compani
today
prefer
product
host
therapeut
protein
cho
cell
line
howev
one
major
hurdl
especi
product
nonantibodi
glycoprotein
host
cellrel
proteolyt
degrad
drastic
impact
develop
timelin
pipelin
project
materi
method
spikein
cho
cell
cultiv
chemic
defin
cultur
medium
shakeflask
cell
reach
maximum
viabl
densiti
remov
centrifug
condit
medium
collect
model
mab
spike
condit
medium
incub
proteas
inhibitor
amount
proteolyt
degrad
analys
western
blot
lcm
transcriptom
total
rna
extract
day
cell
cultiv
rna
sequenc
librari
construct
process
hiseq
platform
illumina
gener
matriptas
knockout
cell
transfect
mrna
encod
transcript
activatorlik
effector
nucleas
zinc
finger
nucleas
target
matriptas
exon
transfect
cell
subsequ
sort
singl
cell
analys
frameshift
mutat
allel
via
sanger
sequenc
cell
cultiv
fed
batch
cultiv
perform
miniatur
bioreactor
result
approxim
proteas
known
rodent
reduc
number
candid
proteas
show
first
model
mab
prone
proteolyt
degrad
incub
condit
medium
cell
result
clip
mab
demonstr
involv
secretedshed
proteas
fig
broad
spectrum
inhibitor
differ
proteas
class
reveal
serin
proteas
inhibitor
prevent
clip
serin
proteas
inhibitor
higher
specif
highlight
group
trypsinlik
proteas
fig
comparison
proteolyt
degrad
profil
sever
therapeut
protein
anoth
cho
cell
line
choa
reveal
less
degrad
choa
therefor
express
involv
proteas
like
lower
choa
gene
express
profil
analysi
cell
line
show
five
secretedshed
serin
proteas
fold
lower
express
cho
choa
versu
fig
surprisingli
sirna
knockdown
experi
five
candid
identifi
matriptas
major
proteas
involv
degrad
recombin
protein
express
cell
fig
upper
panel
next
gener
matriptas
knockout
ko
cell
line
proteolyt
degrad
product
detect
model
mab
spike
condit
medium
ko
cell
line
fig
lower
panel
also
stabl
express
model
mab
ko
cell
line
result
nosignificantli
less
clip
fig
protein
titer
cell
growth
behaviour
matriptas
ko
cell
similar
correspond
wildtyp
wt
cell
fig
shown
compar
cultiv
ambr
system
conclus
one
major
challeng
product
recombin
protein
cho
host
cell
mediat
proteolyt
degrad
neg
impact
even
result
termin
project
use
varieti
techniqu
appli
proteas
inhibitor
transcriptom
sirna
mediat
knockdown
abl
identifi
matriptas
major
proteas
involv
degrad
recombin
protein
express
cell
subsequ
gener
matriptas
defici
cho
cell
line
protein
candid
divers
format
sever
degrad
wt
cell
line
significantli
less
cleav
matriptas
ko
cell
line
furthermor
cell
growth
viabil
product
level
compar
wt
matriptas
ko
cell
line
summari
gener
superior
platformcompat
cho
product
host
cell
line
favour
product
properti
parent
host
cell
line
allow
express
complex
glycoprotein
prone
clip
acknowledg
would
like
thank
moritz
frei
support
gener
ng
transcriptom
data
refer
walsh
biopharmaceut
benchmark
natur
biotechnolog
dorai
h
j
f
nemeth
e
cammaart
wang
q
tang
magil
j
lewi
raju
k
picha
k
oneil
ganguli
g
moor
develop
mammalian
product
cell
line
express
glucagon
like
factor
influenc
product
product
qualiti
biotechnol
bioeng
robert
f
h
bierau
rossi
agugiaro
soranzo
h
broli
c
mitchelllogean
degrad
fcfusion
recombin
protein
host
cell
proteas
identif
cho
cathepsin
proteas
biotechnol
bioeng
ritter
b
voedisch
j
wienberg
b
wilm
geiss
jostock
h
laux
delet
telomer
region
chromosom
correl
higher
product
stabil
cho
cell
line
biotechnol
bioeng
ritter
rauschert
oertli
piehlmaier
p
manta
g
kuntzelmann
n
lageyr
b
brannetti
b
voedisch
geiss
jostock
h
laux
disrupt
gene
lead
increas
product
recombin
cho
cell
line
biotechnol
bioeng
ritter
nuciforo
schulz
oertli
rauschert
b
voedisch
geiss
jostock
h
laux
play
role
product
stabil
recombin
cho
cell
line
biotechnol
bioeng
background
cho
cell
line
common
host
product
biopharmaceut
protein
far
consider
progress
made
increas
product
cell
cultur
meet
rapidli
grow
demand
antibodi
biopharmaceut
increas
cell
densiti
longer
cultur
time
downsid
increas
process
relat
impur
bring
new
challeng
process
harvest
develop
among
process
relat
impur
host
cell
protein
hcp
dna
potenti
impact
lipid
product
releas
cell
cultur
still
poorli
understood
due
complex
natur
divers
class
molecul
thank
recent
advanc
analyt
tool
especi
mass
spectrometri
advent
lipidom
offer
feasibl
studi
sever
thousand
lipid
speci
thu
unravel
possibl
understand
potenti
control
interact
high
perform
bioreactor
process
harvest
condit
purif
materi
method
order
analyz
quantifi
lipid
develop
three
step
method
first
step
lipid
extract
methyl
tertbutyl
ether
mtbe
accord
matyash
method
lipid
separ
liquid
chromatographi
use
either
hilic
revers
phase
column
prior
detect
quantif
mass
spectrometri
lipid
class
detect
esimsm
except
cholesterol
apcimsm
final
appli
method
analyz
lipid
content
differ
cell
line
express
differ
recombin
protein
day
fed
batch
process
result
lipid
cho
cell
success
extract
yield
depend
differ
lipid
class
stabl
isotop
label
lipid
use
intern
standard
order
compar
result
batch
obtain
result
fig
show
given
cell
line
lipid
distribut
chang
process
moreov
distribut
may
vari
significantli
depend
cell
line
lower
extend
show
accumul
triglycerid
day
end
process
seem
follow
trend
conclus
interestingli
cell
linesexperiment
condit
highlight
overproduct
triglycerid
cholesterol
lead
accumul
lipid
droplet
known
energi
storag
sink
metabol
level
find
suggest
rel
overflow
carbon
metabol
process
develop
perspect
find
consid
one
hand
resourc
wast
sinc
store
energi
use
proteinbiomass
biosynthesi
second
hand
root
caus
addit
process
challeng
especi
harvest
first
captur
step
given
hydrophob
natur
molecul
implement
lipidom
analysi
enabl
us
highlight
new
type
process
variabl
anticip
potenti
problem
downstream
step
applic
methodolog
platform
help
us
design
tailor
made
solut
pretreat
select
filter
select
clarif
step
implement
harvest
develop
platform
approach
acknowledg
mani
thank
valentin
chevalli
preciou
advic
stefano
grammatiko
support
whole
upstream
process
scienc
team
refer
matyash
v
liebisch
g
kurzchalia
tv
shevchenko
schwudk
lipid
extract
methyltertbutyl
ether
highthroughput
lipidom
j
lipid
re
background
glycosyl
therapeut
protein
critic
qualiti
attribut
cqa
need
analyz
cell
line
bioprocess
develop
current
method
analyz
glycosyl
mainli
base
enzymat
releas
glycan
tediou
offer
limit
throughput
make
unsuit
cell
line
develop
work
studi
evalu
novel
paia
assay
measur
intact
glycoprotein
captur
bead
fluoresc
label
plant
lectin
analyz
glycan
high
throughput
plate
format
materi
method
analyt
two
glycoengin
variant
one
igg
kindli
provid
merck
vevey
switzerland
analyt
spike
cell
cultur
supernat
buffer
dilut
denatur
solut
incub
minut
expos
fc
glycan
erbitux
sampl
analyz
denatur
condit
detect
fab
fcglycosyl
nativ
condit
fab
glycosyl
pretreat
sampl
ad
well
special
paiaplat
contain
label
lectin
captur
bead
micropl
incub
minut
rpm
orbit
shaker
room
temperatur
spun
xg
readout
done
fluoresc
microscop
synentec
elmshorn
germani
less
five
minut
result
figur
lectin
bind
profil
differ
igg
analysi
differ
igg
result
lectin
bind
profil
show
differ
degre
glycosyl
high
abund
sugar
lead
high
bind
rate
lectin
respect
sugar
avastin
low
degre
galactosyl
high
mannos
speci
compar
mabthera
arzerra
fig
arzerra
carri
glycan
link
sialic
acid
find
line
result
literatur
figur
distinct
fc
fab
glycosyl
erbitux
without
denatur
fab
glycan
detect
erbitux
denatur
lead
addit
exposur
fc
glycan
thu
higher
lectin
bind
rate
compar
nativ
erbitux
gna
npl
bind
denatur
erbitux
indic
high
mannos
glycan
present
fc
part
equal
sna
bind
rate
condit
confirm
link
sialic
acid
almost
exclus
found
fab
part
agreement
publish
data
figur
lectin
bind
rate
correl
level
galactosyl
fucosyl
increas
degre
glycosyl
mixtur
glycan
variant
merck
lead
higher
lectin
bind
rate
galactos
fucos
marker
prove
quantit
analysi
perform
assay
cona
lectin
bind
common
core
mannos
glycan
motiv
remain
level
suggest
fc
glycan
similarli
expos
sampl
conclus
result
demonstr
paia
assay
capabl
quickli
detect
differ
glycan
pattern
differ
antibodi
addit
shown
glycan
variant
igg
analyz
quantit
final
could
confirm
differ
fab
fc
glycosyl
erbitux
believ
beadbas
assay
lectin
great
potenti
monitor
product
qualiti
earli
develop
process
acknowledg
thank
david
bruehlmann
thoma
vuillemin
merck
vevey
switzerland
provid
igg
glycan
variant
glycan
data
refer
fuller
et
al
assess
variabl
innov
molecul
nglycan
profil
poster
prozym
inc
ayoub
et
al
correct
primari
structur
assess
extens
glycoprofil
cetuximab
combin
intact
middleup
middledown
bottomup
esi
maldi
mass
spectrometri
techniqu
mab
vol
background
gene
cell
therapybas
medicin
experienc
resurg
due
introduct
next
gener
transfer
viral
vector
demonstr
improv
safeti
efficaci
adeno
associ
virus
aav
lentivirus
commonli
use
therapeut
often
produc
transient
gene
express
use
peimedi
transient
transfect
cell
critic
raw
materi
need
cgmp
vector
product
must
sourc
approv
supplier
gone
rigor
test
program
reduc
risk
introduc
adventiti
agent
product
process
correspondingli
pei
transfect
reagent
must
also
sourc
qualifi
supplier
gone
rigor
test
ensur
reliabl
transfect
effici
henc
reproduc
viru
product
yield
present
uniqu
peibas
transfect
reagent
suitabl
use
process
develop
cgmp
biomanufactur
respect
unlik
commerci
avail
pei
benefit
extens
research
develop
polym
chemistri
formul
mammalian
cell
transfect
demonstr
reagent
choic
viru
product
run
cell
cultur
system
henc
facilit
transit
initi
optim
process
develop
largescal
therapeut
viral
vector
product
adher
suspens
cell
materiel
method
manufactur
process
reagent
fulli
synthet
reagent
free
animalorigin
compon
comparison
extens
number
qualiti
control
perform
enabl
use
qualifi
raw
materi
gmp
process
manufactur
clinic
batch
therapeut
product
lentiviru
aav
product
irrespect
cell
cultur
vessel
type
transfect
use
perform
follow
recommand
exampl
lentiviru
aav
cell
thaw
directli
medium
passag
everi
day
go
liter
benchtop
bioreactor
cell
resuspend
cultur
day
transfect
cell
transfect
thirdgener
system
four
plasmid
lentiviru
product
cell
cotransfect
three
plasmid
aav
product
lentivir
aav
titer
measur
hour
posttransfect
data
kindli
provid
result
reagent
choic
viru
product
run
adher
suspens
cell
cultur
system
process
develop
larg
scale
clinicalgrad
viru
product
irrespect
cell
culturebas
system
product
scale
led
effici
viral
vector
yield
standard
laboratori
cell
system
flask
cell
factori
roller
bottl
well
multilay
flask
fixedb
cultur
system
take
account
time
space
concern
scalingup
process
tabl
exampl
high
viral
vector
yield
superior
igml
vgml
obtain
respect
lentivirus
aav
suspens
cell
cultur
one
commerci
avail
synthet
cell
cultur
medium
irvin
conclus
higher
qualiti
grade
uniqu
pei
suitabl
effici
reproduc
product
therapeut
viral
vector
effici
viral
vector
product
yield
achiev
cell
cultur
system
irrespect
product
scale
appropri
advanc
qualiti
control
highest
qualiti
grade
commerci
avail
accompani
academ
biopharmaceut
compani
term
qualifi
raw
materi
gmpgrade
viral
vector
product
need
acknowledg
polyplustransfect
would
like
thank
kindli
provid
data
refer
merten
et
al
method
clinic
develop
background
mab
manufactur
process
product
bioreactor
step
consid
crucial
product
produc
step
howev
cell
spend
signific
portion
process
time
inoculum
stage
start
vial
thaw
expans
shake
flask
seed
bioreactor
stage
cell
encount
environment
chang
paramet
like
ph
osmol
concentr
nutrient
wast
metabolit
small
chang
profound
impact
cell
experienc
multipl
passag
effect
cumul
impact
appar
seed
stage
evid
product
step
work
present
data
experi
cell
maintain
differ
inoculum
cultur
condit
evalu
behaviour
term
growth
perform
product
bioreactor
follow
case
studi
conduct
chang
made
inoculum
step
cell
inoculum
step
expos
chang
multipl
passag
use
run
product
batch
control
condit
impact
product
step
observ
respons
case
studi
effect
incub
differ
level
case
studi
effect
incub
differ
temperatur
case
studi
modif
seed
medium
buffer
composit
materi
method
tabl
result
result
indic
cell
subject
variou
cultur
condit
multipl
passag
like
differ
temperatur
level
medium
composit
growth
inoculum
stage
doubl
time
viabil
get
impact
howev
cell
use
product
bioreactor
signific
impact
observ
process
perform
illustr
fig
cell
maintain
higher
level
lower
temperatur
inoculum
stage
show
improv
cell
concentr
product
bioreactor
howev
cell
subcultur
higher
temperatur
show
reduc
growth
perform
cell
maintain
media
two
differ
buffer
compon
fig
shift
lactat
product
observ
inoculum
stage
effect
becam
predomin
product
cultur
abil
modul
inoculum
condit
exploit
improv
cell
line
stabil
one
clone
cell
growth
viabil
product
bioreactor
observ
decreas
increas
age
inoculum
fig
howev
use
altern
medium
buffer
medium
compon
cultur
condit
use
subcultur
improv
cell
line
stabil
achiev
conclus
result
experi
indic
cell
maintain
differ
inoculum
cultur
condit
behav
significantli
differ
use
product
process
also
identifi
condit
impact
overal
cell
line
stabil
clone
henc
thorough
understand
cell
metabol
requir
paramet
predict
behavior
must
control
per
requir
process
manipul
cultur
condit
suitabl
earli
inoculum
propag
step
enabl
improv
perform
stabil
cell
line
therebi
increas
process
robust
also
propos
model
studi
inoculum
paramet
effect
includ
product
run
impact
inoculum
paramet
pronounc
acknowledg
cell
cultur
team
biocon
background
continu
perfus
process
make
comeback
compet
upstream
manufactur
technolog
product
biopharmaceut
compar
standard
fed
batch
process
primarili
cost
advantag
reduc
capit
cost
increas
product
yield
chang
statu
perfus
process
older
perfus
newag
perfus
due
avail
better
cell
retent
devic
lead
effici
process
improv
cell
line
cell
cultur
medium
capabl
support
high
cell
densiti
better
bioreactor
control
strategi
work
present
advantag
limit
challeng
fed
batch
perfus
type
process
case
studi
materi
method
tabl
result
case
comparison
fedbatch
perfus
process
perfus
run
yield
higher
titer
compar
fed
batch
run
fig
consid
number
run
could
execut
manufactur
facil
within
calendar
day
increas
product
output
achiev
perfus
process
fig
differ
attribut
higher
ivcc
higher
pcd
longev
cell
decreas
level
toxic
metabolit
concentr
lactat
ammonia
case
understand
product
retent
perfus
process
newag
perfus
process
util
hollow
fiber
filter
observ
caus
retent
product
within
bioreactor
especi
toward
end
product
run
two
type
experi
conduct
studi
factor
contribut
product
retent
spike
studi
role
product
titer
product
spike
chemic
defin
mediarol
differ
cell
viabil
differ
broth
vari
viabil
spike
product
titerevalu
differ
hollow
fiber
membran
product
retent
spike
studi
evid
cell
debri
poor
qualiti
cell
broth
lower
viabil
major
factor
contribut
product
retent
fig
differ
membran
experi
identifi
pilot
scale
show
much
higher
retent
first
perfus
cycl
increas
toward
end
batch
howev
membran
product
retent
start
late
batch
durat
remain
low
contrari
differ
observ
scale
due
usag
membran
larger
filter
area
fold
higher
compar
pilot
scale
filter
area
per
unit
volum
perfus
decreas
half
pilot
scale
even
show
retent
profil
similar
fig
conclus
present
data
show
perfus
process
increas
product
yield
perbatch
basi
increas
facil
throughput
consid
product
retent
technic
challeng
requir
optim
perfus
rate
filter
membran
type
believ
imper
lab
develop
process
biolog
consid
perfus
fedbatch
base
process
technolog
close
compet
choic
process
format
go
forward
sole
depend
requir
biolog
rather
earlier
percept
fedbatch
prefer
choic
simplic
acknowledg
asmita
mukerji
reetesh
pm
sasi
kumar
k
pilot
plant
team
background
chines
hamster
ovari
cho
cell
cultur
wide
use
product
monoclon
antibodi
pharmaceut
industri
previou
studi
shown
cell
specif
product
cho
cell
increas
glucos
limit
introduc
product
enhanc
effect
possibl
also
affect
qualiti
product
glycosyl
posttransl
modif
work
focus
impact
glucos
limit
increas
product
product
qualiti
monoclon
antibodi
produc
fedbatch
cultiv
cho
cell
materi
method
cho
cell
cultiv
limit
nonlimit
nutrient
condit
fedbatch
fedbatch
cultiv
reduc
rang
glucos
concentr
chosen
gl
refer
cultiv
perform
gl
cultur
fed
similar
volum
complex
nutrient
supplement
cultiv
perform
chemicallydefin
animalcompon
free
cho
growth
media
xell
ag
viabl
cell
densiti
viabil
determin
use
autom
cell
count
system
cedex
roch
diagnost
glucos
lactat
concentr
detect
via
ysi
ysi
life
scienc
amino
acid
quantifi
use
hplcfld
vitamin
quantifi
use
revers
phase
chromatographi
coupl
tripl
quadrupol
mass
spectromet
varian
select
reaction
monitor
amount
quantifi
via
protein
hplc
mab
purifi
anoth
cho
cell
clone
use
standard
analysi
product
qualiti
perform
intact
mass
analysi
use
revers
phase
chromatographi
coupl
microotofq
ii
mass
spectromet
bruker
daltonik
result
cho
cell
cultur
cultiv
low
nutrient
condit
reach
higher
viabl
cell
densiti
refer
cultur
fig
product
titer
even
increas
fig
spent
media
analysi
show
amino
acid
vitamin
present
presum
limit
concentr
day
mostli
low
nutrient
level
cultur
tyr
gln
arg
asn
pyridoxin
data
shown
product
qualiti
show
signific
chang
chang
feed
strategi
fig
expect
glycat
level
decreas
compar
refer
cultur
truncat
level
ctermin
lysin
heavi
chain
mab
increas
glycosyl
also
significantli
influenc
low
nutrient
level
fig
nonfucosyl
variant
increas
fig
degre
galactosyl
increas
fig
conclus
cultiv
low
nutrient
level
led
higher
viabl
cell
densiti
product
titer
increas
compar
refer
cultur
grown
nonlimit
nutrient
condit
analysi
product
qualiti
reveal
less
glycat
light
chain
cho
cell
grown
low
nutrient
condit
vs
refer
cultur
truncat
ctermin
lysin
decreas
degre
galactosyl
increas
also
observ
takuma
et
al
nonfucosyl
glycan
increas
low
nutrient
condit
product
qualiti
analysi
intact
mass
prove
highli
robust
averag
cv
four
replic
summari
cultiv
altern
feed
led
higher
igg
product
titer
better
product
qualiti
glycat
unwant
higher
amount
nonfucosyl
glycan
lead
higher
antibodydepend
cellmedi
cytotox
adcc
higher
amount
galactosyl
higher
complementdepend
cytotox
cdc
adcc
refer
wingen
j
albaum
h
noll
hoffrogg
r
screen
high
product
cho
cell
glucoselimit
basic
chang
proteom
equip
hint
epigenet
effect
journal
biotechnolog
takuma
hirashima
c
piret
jm
depend
glucos
limit
influenc
cho
cell
growth
metabol
igg
product
biotechnolog
bioengin
thomann
reckermann
k
reusch
prasser
j
tejada
ml
fcgalactosyl
modul
antibodydepend
cellular
cytotox
therapeut
antibodi
molecular
immunolog
reusch
tejada
ml
fc
glycan
therapeut
antibodi
critic
qualiti
attribut
glycobiolog
background
develop
autom
multiwel
plate
mwp
base
screen
system
suspens
cell
cultur
fig
routin
use
cell
cultur
process
develop
character
fulli
autom
workflow
integr
analyt
instrument
use
shaken
well
plate
bioreactor
run
batch
fedbatch
mode
capac
reactor
parallel
wide
rang
analyt
portfolio
monitor
cell
cultur
process
also
cooper
intern
high
throughput
ht
analyt
group
character
product
qualiti
avail
addit
use
benefit
spectroscop
method
cell
cultur
autom
shown
past
materi
method
autom
cell
cultur
system
enabl
broader
screen
within
shorter
time
frame
mani
applic
upstream
process
develop
higher
degre
parallel
autom
help
screen
promis
paramet
shorter
time
use
broad
doe
screen
design
allow
addit
identif
paramet
support
high
titer
keep
high
product
qualiti
multipl
factor
time
illustr
fig
show
exampl
combin
speed
process
develop
step
main
applic
cell
cultur
autom
exampl
identif
product
qualiti
lever
media
feed
optim
result
applic
cell
cultur
autom
shown
two
exampl
goal
first
applic
identifi
lever
reduc
trisulfid
screen
condit
parallel
replic
well
sum
reduct
trisulfid
normal
start
level
possibl
addit
lever
trisulfid
reduct
identifi
best
start
condit
verifi
bioreactor
scale
fig
goal
second
applic
increas
product
concentr
without
impact
product
qualiti
screen
condit
parallel
replic
well
sum
increas
titer
gl
gl
factor
possibl
media
platform
chang
media
optim
impact
product
qualiti
could
shown
best
condit
also
verifi
bioreactor
scale
fig
conclus
benefit
use
cell
cultur
autom
late
stage
process
develop
shown
base
two
exampl
current
applic
purpos
experiment
result
develop
work
two
late
state
project
use
inhous
develop
autom
cell
cultur
system
shown
first
exampl
show
capabl
autom
cell
cultur
system
reduc
trisulfid
significantli
one
experi
project
final
product
concentr
could
increas
factor
media
screen
chang
inhous
media
platform
two
exampl
show
potenti
cell
cultur
autom
routin
tool
process
develop
acknowledg
author
would
like
thank
cell
cultur
autom
team
j
hoffmann
g
pechmann
c
schuster
internship
diploma
student
spielmann
k
b
frommey
j
wisbauer
agutknecht
former
member
cell
cultur
autom
team
k
joeri
markert
roch
penzberg
pilot
plant
team
roch
penzberg
portfolio
project
team
refer
markert
joeri
k
develop
autom
multiwel
plate
base
screen
system
suspens
cell
cultur
bmc
proc
suppl
markert
musmann
c
joeri
k
develop
applic
autom
multiwel
plate
base
screen
system
suspens
cell
cultur
bmc
proc
suppl
markert
joeri
k
establish
fulli
autom
microtit
platebas
system
suspens
cell
cultur
applic
enhanc
process
optim
biotechnol
bioeng
musmann
c
joeri
k
markert
spectroscop
tool
autom
suspens
cell
cultur
screen
system
bmc
proc
musmann
c
joeri
k
markert
soll
scheper
review
spectroscop
method
highthroughput
character
mammalian
cell
cultur
autom
cell
cultur
system
engin
life
scienc
background
cell
line
develop
process
becom
faster
simultan
gener
clone
productrel
analyt
data
order
select
best
produc
cell
line
extrem
heterogen
data
type
need
systemat
compar
time
avail
data
need
decid
cell
line
pursu
becom
bottleneck
cell
line
develop
workflow
ensur
sound
decis
make
new
integr
workflow
support
data
analysi
method
need
materi
method
develop
new
endtoend
platform
bioprocess
develop
includ
cell
line
develop
workflow
system
support
seed
select
passag
analyz
cryoconserv
process
micro
bioreactor
platform
genedata
enabl
partial
fulli
autom
cell
line
select
assess
process
increas
process
effici
qualiti
system
track
full
histori
clone
initi
transfect
way
evalu
bioreactor
run
combin
inform
analyt
data
molecul
clone
product
qualiti
directli
integr
instrument
pipet
robot
bioreactor
bioanalyz
system
design
wide
rang
biolog
molecul
includ
antibodi
igg
novel
format
therapeut
protein
eg
fusion
protein
result
conclus
highlight
use
case
describ
identif
top
produc
cell
line
decis
make
support
bioreactor
data
manag
full
clone
histori
report
document
fig
genedata
bioprocess
develop
collabor
top
pharmaceut
compani
flexibl
support
variou
nonlinear
workflow
structur
collect
inform
way
foster
collabor
across
organ
increas
throughput
crucial
ensur
time
avail
optim
produc
cell
line
highthroughput
possibl
autom
process
laboratori
result
data
collect
aggreg
streamlin
genedata
bioprocess
help
establish
product
process
offer
support
integr
autom
station
measur
devic
thank
comprehens
workflow
support
possibl
integr
result
cell
line
stabil
experi
product
qualiti
assess
bioreactor
suitabl
test
genedata
bioprocess
provid
uniqu
way
evalu
cell
line
comprehens
analysi
data
collect
process
help
ensur
highest
possibl
qualiti
minim
time
resourc
need
data
analysi
manag
integr
bioreactor
data
analysi
visual
paramet
measur
cell
line
develop
streamlin
clone
evalu
microbioreactor
support
highthroughput
oper
genedata
bioprocess
comprehens
track
full
clone
histori
origin
host
cell
line
gener
valid
monoclon
produc
cell
line
promis
clone
clone
histori
report
gener
one
click
besid
support
cell
line
develop
genedata
bioprocess
comprehens
platform
capabl
track
complet
bioprocess
develop
process
acknowledg
allison
kurz
genedata
ag
basel
switzerland
background
million
peopl
suffer
cancer
make
major
concern
societi
sinc
common
cancer
treatment
limit
effect
late
stage
carcinoma
altern
method
need
reduc
high
mortal
rate
cancer
patient
one
altern
approach
applic
oncolyt
measl
viru
omv
omv
natur
affin
cancer
cell
major
drawback
omv
produc
extrem
high
amount
least
tissu
cultur
infect
dose
per
dose
need
solv
problem
high
titer
process
must
establish
includ
effici
downstream
process
dsp
develop
appropri
upstream
process
abl
produc
bioreactor
l
work
volum
focu
dsp
part
follow
studi
test
applic
charg
depth
filter
omv
clarif
contrast
common
dsp
scheme
deplet
viru
particl
loss
infect
desir
aim
reduct
protein
content
dna
minim
loss
infect
omv
investig
influenc
cell
cultur
medium
depth
filtrat
process
materi
method
explor
influenc
surround
cell
cultur
medium
depth
filtrat
perform
omv
either
produc
serumfre
medium
vpsfm
serumcontain
medium
dmem
fc
product
done
str
work
volum
l
describ
cell
carrier
separ
opticap
xl
polygardcr
merck
depth
filtrat
millistak
filter
merck
use
filter
materi
autoclav
rins
ml
mm
trishcl
viru
suspens
filter
load
l
use
peristalt
pump
ismatec
appli
flux
l
fig
sampl
collect
begin
end
filtrat
run
omv
titer
sampl
determin
accord
reed
protein
content
measur
pierc
bca
protein
assay
kit
thermofish
scientif
accord
manufactur
instruct
dna
measur
microtit
assay
use
quantit
picogreen
dsdna
reagent
thermofish
scientif
accord
manufactur
instruct
result
found
posit
charg
depth
filter
suitabl
clarifi
omv
suspens
cell
cultur
medium
omv
produc
influenc
outcom
depth
filtrat
log
reduct
valu
lrv
determin
omv
present
serumcontain
medium
scm
wherea
titer
omv
serumfre
medium
sfm
reduc
log
level
indic
without
serum
surround
liquid
omv
adsorb
filter
materi
howev
must
evalu
miss
serum
compon
present
sfm
respons
effect
total
protein
relevantli
reduc
clarif
use
charg
depth
filter
omv
present
scm
residu
protein
content
slightli
less
compar
omv
present
sfm
tabl
contrast
host
cell
dna
hcdna
bound
filter
materi
achiev
reduct
hcdna
omv
suspens
sfm
clarifi
omv
suspens
sfm
remain
hcdna
content
even
lower
conclus
charg
depth
filter
suitabl
first
clarif
step
omv
downstream
process
residu
protein
could
pass
depth
filter
almost
unhind
wherea
hcdna
content
alreadi
reduc
maximum
howev
omv
titer
also
reduc
depth
filtrat
undesir
effect
stronger
omv
present
sfm
agenc
requir
avoid
serum
clinicalgrad
product
process
disadvantag
nonetheless
sfm
soon
standard
omv
product
experi
done
prevent
omv
reduct
clarif
one
option
reduc
adsorpt
strength
viru
filter
materi
addit
salt
moreov
import
establish
standard
protocol
upstream
process
determin
batchtobatch
variat
within
clarif
indic
strong
impact
upstream
process
usp
outcom
dsp
therefor
studi
must
investig
influenc
usp
paramet
eg
time
harvest
ph
harvest
solut
omv
refer
torr
la
bray
f
siegel
rl
ferlay
j
lortettieul
j
jemal
global
cancer
statist
ca
cancer
j
clin
russel
sj
federspiel
mj
peng
kw
tong
c
dingli
moric
wg
et
al
remiss
dissemin
cancer
system
oncolyt
virotherapi
mayo
clin
proc
grein
ta
schwebel
f
kress
loew
dieken
h
salzig
et
al
screen
differ
host
cell
line
dynam
product
measl
viru
biotechnol
prog
g
beitrag
zur
kollektiven
behandlung
pharmakologisch
reihenversuch
archiv
f
experi
pathol
u
pharmakol
reed
lj
muench
h
simpl
method
estim
fifti
per
cent
endpoint
american
journal
epidemiolog
background
fedbatch
cultur
commonli
employ
maxim
cell
product
concentr
upstream
mammalian
cell
cultur
process
typic
standard
platform
process
reli
fixedvolum
bolu
feed
concentr
feed
supplement
regular
interv
howev
static
approach
might
result
underfeed
mimic
close
dynam
fedbatch
cultur
develop
dynam
feed
strategi
respons
actual
nutrient
need
mabproduc
recombin
cho
cell
line
materi
method
model
cell
line
mabexpress
cho
licens
cellca
gmbh
cultiv
ge
healthcar
supplement
glutamin
feed
media
hyclon
cell
feed
supplement
ge
healthcar
analyt
compris
cell
concentr
viabil
mab
titer
select
metabolit
osmol
amino
acid
fedbatch
develop
appli
design
experi
doe
approach
use
statist
softwar
umetr
ab
combin
threestep
strategi
follow
step
select
best
perform
cell
boost
supplement
batch
step
finetun
feed
ratio
select
cell
boost
supplement
fedbatch
step
feed
strategi
develop
constant
vs
dynam
fedbatch
bioreactor
verif
best
result
step
control
condit
fedbatch
result
discuss
improv
made
differ
step
fedbatch
develop
shown
fig
step
eight
cell
boost
supplement
ad
accord
doe
approach
batch
cultur
perform
evalu
allow
us
select
cell
boost
supplement
benefici
overal
cultur
perform
nonperform
cell
boost
supplement
remov
consid
step
select
cell
boost
supplement
ad
daili
cultur
differ
ratio
accord
doe
approach
fedbatch
cultur
conduct
expect
daili
feed
addit
replenish
consum
nutrient
substanti
improv
mab
peak
cell
concentr
well
viabl
cumul
cell
day
vccd
compar
batch
cultiv
result
enabl
us
finetun
feed
ratio
select
cell
boost
supplement
step
optim
best
perform
feed
ratio
investig
static
dynam
feed
protocol
fedbatch
protocol
reli
constant
feed
addit
distinct
day
howev
approach
often
lead
substanti
underfeed
bioprocess
improv
static
protocol
investig
three
differ
dynam
approach
shown
tabl
appli
select
cell
boost
supplement
optim
feed
ratio
investig
allow
us
improv
bioprocess
perform
best
perform
approach
constant
retrospect
feed
investig
fulli
autom
bioreactor
control
condit
gener
constant
cultiv
paramet
bioreactor
slightli
enhanc
mab
titer
compar
shake
flask
cultiv
retrospect
feed
strategi
yield
higher
titer
constant
strategi
overal
establish
methodolog
fedbatch
develop
allow
us
obtain
higher
mab
titer
batch
mean
gl
vs
fedbatch
gl
short
time
three
simpl
step
addit
product
qualiti
investig
compar
legaci
fedbatch
process
fedbatch
conduct
newli
select
basal
feed
media
alter
distribut
charg
glycan
variant
amount
aggreg
product
alter
conclus
establish
methodolog
fedbatch
develop
rapid
protocol
select
wellperform
feed
supplement
optim
ratio
cultur
requir
three
step
mab
titer
boost
gl
gl
product
glycosyl
charg
variant
could
influenc
newli
select
basal
feed
media
compar
legaci
fedbatch
process
amount
aggreg
product
alter
background
present
studi
investig
benefici
effect
spike
basal
medium
hyclon
cell
cell
boost
feed
supplement
growth
product
recombin
cho
cell
line
evalu
impact
feedspik
compar
cultiv
basal
medium
cell
line
grown
bioreactor
control
condit
determin
cellspecif
metabol
rate
nutrient
consumpt
byproduct
accumul
process
time
transcriptom
analysi
cultiv
cell
use
microarray
four
consecut
day
investig
differenti
gene
express
reveal
benefici
effect
feedspik
compar
cell
grown
basal
medium
materi
method
model
cell
line
mabexpress
cho
licens
cellca
gmbh
cultiv
either
actipro
basal
medium
ge
healthcar
actipro
basal
medium
feedspik
addit
supplement
cell
boost
cell
boost
ge
healthcar
cultur
grown
batch
mode
use
stirredtank
bioreactor
eppendorf
benefici
effect
feedspik
analys
transcriptom
analysi
use
microarray
technolog
k
design
agil
result
discuss
basal
feedspik
process
last
seven
day
viabil
day
day
seven
sharp
declin
viabil
indic
end
batch
process
fig
feedspik
medium
cell
initi
grew
slower
reach
almost
twice
high
peak
cell
concentr
cml
basal
medium
cml
remark
integr
viabl
cell
concentr
total
process
time
viabl
cumul
cell
day
vccd
similar
process
strategi
fig
mab
product
plateau
day
basal
medium
final
titer
gl
continu
increas
threefold
higher
final
titer
gl
observ
feedspik
medium
fig
higher
titer
could
attribut
gener
higher
cellspecif
product
qp
remain
rather
constant
pgcellday
feedspik
cultur
basal
medium
qp
continu
drop
day
day
day
pgcellday
basal
medium
cultur
averag
qp
higher
feedspik
cultur
fig
transcriptom
analysi
differenti
express
gene
cell
grown
basal
medium
feedspik
medium
use
identifi
relev
go
term
indic
activ
prolif
state
feedspik
cultur
data
shown
top
go
term
significantli
relat
cell
cycl
primari
metabol
cellular
divis
well
nucleobas
format
regul
furthermor
gsea
reveal
sever
significantli
enrich
set
gene
relat
gene
transcript
dna
replic
repair
cell
growth
prolifer
well
inhibit
apoptosi
feedspik
cultur
thu
feedspik
increas
prolif
activ
cultiv
cell
sever
identifi
gene
appear
promis
target
cell
line
engin
yet
describ
relat
highproduc
recombin
cell
line
need
evalu
futur
studi
conclus
feedspik
basal
medium
conveni
easi
way
consider
increas
product
concentr
simpl
batch
cultur
differenti
gene
express
reveal
gene
appear
import
high
cellspecif
product
rate
knowledg
leverag
cell
line
engin
approach
design
high
produc
cho
cell
media
latter
case
maxim
suppli
nutrient
enabl
selffuel
energi
metabol
data
shown
allow
mab
express
constantli
high
rate
describ
result
shown
applic
three
addit
recombin
mabexpress
cell
line
includ
cho
cho
data
shown
background
develop
candid
biosimilar
adalimumab
number
origin
molecul
analyz
determin
rang
critic
qualiti
attribut
cqa
order
obtain
high
similar
varieti
upstream
downstream
process
develop
strategi
appli
assur
cqa
fall
within
rang
determin
origin
drug
substanc
formul
stateofart
analyt
method
use
demonstr
similar
origin
adalimumab
materi
method
produc
genet
engin
chines
hamster
ovari
cho
cell
line
mass
spectrometri
experi
intact
reduc
mass
peptid
map
glycan
analysi
carri
xevo
qtof
mass
spectromet
equip
lock
spray
ion
sourc
water
corp
milford
usa
kinet
rate
constant
bind
measur
biacor
ge
healthcar
data
evalu
use
fit
model
charg
heterogen
acid
basic
variant
size
heterogen
aggreg
monom
fragment
level
determin
capillari
isoelectr
focus
cief
plu
beckman
coulter
sizeexclus
chromatographi
sec
water
corp
milford
usa
respect
addit
cesd
use
impur
analysi
secondari
structur
obtain
ftir
experi
bruker
tensor
ftir
bruker
optic
gmbh
ettlingen
germani
result
high
biosimilar
must
demonstr
physicochem
function
character
approv
requir
phase
phase
iii
studi
term
efficaci
safeti
immunogen
studi
round
upstream
downstream
process
run
reach
cqa
limit
origin
molecul
conduct
mani
differ
develop
strategi
mirror
plot
imag
intact
deconvolut
mass
found
ident
correspond
similar
level
glycoform
uv
chromatogram
revers
phase
ultraperform
liquid
chromatographi
rpuplc
tryptic
peptid
map
demonstr
primari
structur
ident
origin
shown
fig
posttransl
modif
ptm
oxid
deamid
ntermin
pyroglutam
acid
ctermin
lysin
truncat
level
also
compar
two
product
glycosyl
site
confirm
peptid
map
analysi
glycan
site
occup
proven
origin
glycosyl
pattern
two
product
highli
similar
term
major
glycan
etc
level
lower
compar
origin
product
may
clinic
effect
molecul
secondari
structur
determin
atrftir
spectroscopi
absorpt
band
amid
amid
ii
overlap
complet
amount
structur
compar
furthermor
sizeexclus
chromatographi
sec
analysi
reveal
product
level
puriti
aggreg
level
level
impur
determin
cesd
capillari
isoelectr
focus
cief
experi
show
charg
variant
profil
two
product
indistinguish
isoelectr
point
main
peak
observ
product
associationdissoci
rate
constant
bind
affin
origin
highli
similar
similar
score
calcul
greater
shown
fig
conclus
studi
stateofart
analyt
techniqu
use
assess
biosimilar
origin
adalimumab
headtohead
comparison
data
clearli
demonstr
highli
similar
origin
adalimumab
term
physicochem
function
characterist
base
analyt
similar
believ
compar
pkpd
potenc
efficaci
result
origin
adalimumab
acknowledg
author
thank
upstream
downstream
develop
team
turgut
ilaclari
merck
life
scienc
covanc
background
expand
interest
intensifi
continu
bioprocess
highlight
need
develop
small
scale
model
perfus
cell
cultur
direct
industri
increas
target
cell
densiti
decreas
perfus
rate
order
increas
throughput
perfus
media
develop
capabl
sought
develop
small
scale
model
perfus
use
instrument
sartoriu
germani
use
modifi
cell
settl
model
previous
publish
krey
et
al
achiev
cell
retent
necessari
reach
perfus
relev
viabl
cell
concentr
work
show
applic
small
scale
model
identif
specif
product
perform
steadyst
test
media
identif
csprmin
specif
cell
line
medium
combin
confirm
consist
product
qualiti
profil
small
scale
model
benchtop
perfus
data
shown
materi
method
cell
line
produc
evalu
sever
proprietari
chemic
defin
media
prototyp
gener
develop
catalog
advanc
hd
perfus
medium
fed
batch
medium
earli
prototyp
mid
prototyp
intermedi
prototyp
late
prototyp
small
scale
simul
perfus
experi
run
media
exchang
perform
time
per
day
equal
amount
agit
gass
liquid
handl
stop
optim
period
time
allow
cell
settl
bottom
spent
media
remov
amount
proport
daili
exchang
volum
agit
gass
liquid
handl
resum
fresh
media
ad
back
vessel
benchtop
perfus
cell
inocul
applikon
bioreactor
applikon
netherland
concentr
perfus
initi
use
repligen
massachusett
perfus
rate
limit
steadyst
result
use
cell
settl
method
describ
abl
achiev
cell
retent
effici
media
test
work
abl
reach
maintain
vcml
target
cell
densiti
fig
perform
media
formul
rank
base
specif
product
tabl
use
intermedi
prototyp
minimum
steadyst
cspr
determin
cell
line
nglycan
analysi
bioreactor
sampl
via
intact
mass
spectrometri
display
slight
differ
product
qualiti
profil
data
shown
conclus
work
shown
clear
distinct
variou
prototyp
perfus
media
demonstr
increas
specif
product
fed
batch
medium
use
perfus
addit
shown
applic
character
process
use
model
determin
csprmin
given
medium
cell
line
acknowledg
thank
bioreactor
team
irfan
hodzic
amer
allozi
jana
mahadevan
refer
krey
zoro
b
webinar
sedimentationperfus
model
cultiv
characterist
product
qualiti
predict
riesberg
j
hodzic
lyon
de
novo
high
densiti
perfus
medium
increas
product
reduc
perfus
rate
esact
background
medimmun
develop
proprietari
high
yield
scalabl
easi
use
chines
hamster
ovari
cho
cell
base
transient
express
system
system
use
routin
earli
stage
materi
suppli
varieti
biolog
protein
format
project
within
r
astrazeneca
medimmun
transient
process
success
oper
sartoriu
biostat
singl
use
bioreactor
sub
yield
crude
product
twoweek
express
cultur
tabl
success
scale
process
creat
potenti
suppli
transient
express
product
support
toxicolog
studi
even
earli
gmp
clinic
suppli
enabl
acceler
biopharmaceut
develop
project
timelin
scale
rock
bioreactor
rbr
sub
scale
identifi
scalabl
issu
lower
specif
product
due
increas
cell
growth
decreas
titr
observ
sub
fig
iii
iv
improv
predict
scale
new
process
develop
evalu
sub
vessel
utilis
modifi
transfect
method
result
compar
express
level
specif
product
rbr
sub
scale
materi
method
two
set
express
vector
compris
heavi
chain
light
chain
plasmid
express
human
kappa
mab
previous
describ
use
process
optimis
studi
cell
line
use
transient
express
pei
mediat
transfect
method
describ
previous
transfect
cultur
run
fed
batch
condit
day
ge
healthcar
wave
bioreactor
rbr
hyclon
sub
use
hyclon
bioreactor
bag
thermo
scientif
result
transfect
process
modifi
address
reduc
titr
higher
viabl
cell
densiti
vcd
seen
sub
cultur
shake
flask
cultur
use
assess
standard
modifi
transfect
process
b
c
fig
ii
process
c
identifi
process
studi
sub
scale
offer
potenti
mitig
high
viabl
cell
densiti
vcd
observ
scale
process
c
sub
result
cultur
produc
titr
exceed
desir
cell
growth
profil
conclus
scale
process
sub
vessel
result
decreas
product
compar
rbr
scale
optimis
sub
process
c
yield
increas
specif
product
express
titr
compar
seen
rbr
scale
tabl
medimmun
success
complet
first
known
success
cho
transient
cultur
scale
produc
mab
harvest
process
optimis
subsequ
demonstr
reproduc
titr
scale
exceed
compar
glycosyl
profil
sub
rbr
cultur
across
scale
acknowledg
steve
ruddock
richard
lugg
ken
lee
rob
stadelman
ruchika
bandekar
karen
dickson
faisal
uddin
jake
warrington
nick
myatt
clair
pearc
andi
smith
chri
sellick
refer
daramola
stevenson
j
dean
g
hatton
pettman
g
holm
w
field
r
highyield
cho
transient
system
coexpress
gene
encod
gs
enhanc
transient
protein
express
biotechnol
prog
doi
persic
l
robert
wilton
j
cattaneo
bradburi
hoogenboom
hr
integr
vector
system
eukaryot
express
antibodi
fragment
select
phage
display
librari
gene
background
stateoftheart
biopharmaceut
process
account
concomitantli
process
perform
product
qualiti
even
though
high
yield
robust
process
cornerston
process
develop
product
qualiti
paramet
structur
integr
charg
varianc
posttransl
modif
progress
becom
focu
development
work
conjunct
host
cell
line
select
process
perform
paramet
media
compon
crucial
continu
progress
ration
modul
product
qualiti
attribut
affect
biolog
activ
immunogen
halflif
stabil
among
media
compon
trace
element
te
particular
interest
play
pivot
role
variou
cell
metabol
pathway
base
comprehens
doe
approach
extens
process
perform
product
qualiti
evalu
combin
metabol
flux
analysi
impact
sever
trace
element
biopharmaceut
process
assess
materi
method
comprehens
ioptim
doe
approach
fig
effect
six
te
variou
concentr
level
combin
serumfre
media
studi
four
differ
cell
line
setup
scrutini
process
perform
paramet
cellular
growth
product
amino
acid
vitamin
consumpt
rate
condit
perform
process
perform
evalu
accompani
extens
product
qualiti
analysi
includ
size
charg
variant
glycosyl
pattern
oxid
methyl
furthermor
metabol
flux
analysi
perform
base
nitrogen
balanc
result
base
extens
analyt
data
obtain
respons
surfac
model
provid
clear
insight
impact
particular
te
combin
process
perform
product
qualiti
high
model
qualiti
enabl
discrimin
clone
depend
clone
independ
effect
elev
titer
best
condit
cell
line
clearli
show
even
stateoftheart
media
outperform
trace
element
rebalanc
analyz
specif
rate
combin
metabol
flux
analysi
improv
understand
metabol
restructur
cell
line
distinct
te
level
combin
modul
trace
element
level
tremend
effect
charg
heterogen
glycosyl
structur
differ
protein
provid
toolbox
fine
tune
control
product
qualiti
paramet
conclus
taken
togeth
data
pave
way
ration
fine
tune
process
perform
product
qualiti
attribut
background
due
regulatori
concern
econom
impact
ensur
product
qualiti
consist
one
main
challeng
face
biopharmaceut
industri
monoclon
antibodi
mab
glycosyl
one
import
qualiti
attribut
impact
mab
structur
integr
ultim
clinic
efficaci
safeti
mani
factor
affect
mab
glycosyl
inher
heterogen
includ
host
cell
cultur
medium
mode
oper
oper
condit
context
capac
monitor
control
onlin
antibodi
glycosyl
earli
latestag
process
develop
would
salient
interest
reduc
time
cost
market
materi
method
order
address
unmet
need
design
improv
spr
biosensor
assay
measur
kinet
interact
mab
extracellular
domain
receptor
bound
biosensor
surfac
result
salient
interest
also
demonstr
variou
bind
kinet
signatur
especi
differ
dissoci
kinet
could
correl
distinct
mab
glycosyl
pattern
therapeut
efficaci
deduc
mass
spectrometri
surrog
adcc
assay
respect
parallel
also
har
spr
biosensor
directli
bioreactor
permit
atlin
determin
concentr
antibodi
hybridoma
cell
bioreactor
cultur
conclus
plan
combin
approach
determin
onlin
glycosyl
profil
produc
mab
ultim
goal
design
uniqu
highli
innov
bioprocess
control
tool
readili
appli
industri
biomanufactur
set
acknowledg
work
support
canada
research
chair
proteinenhanc
biomateri
nation
research
council
canada
human
health
therapeut
portfolio
thank
gill
saintlaur
christian
gervai
technic
support
fruit
discuss
refer
dorionthibaudeau
j
c
raymond
e
lattova
h
perreault
duroch
g
de
crescenzo
toward
develop
surfac
plasmon
reson
assay
evalu
glycosyl
pattern
monoclon
antibodi
use
extracellular
domain
journal
immunolog
method
dorionthibaudeau
j
g
stlaurent
c
raymond
g
de
crescenzo
duroch
biotinyl
fc
gamma
receptor
ectodomain
mammalian
cell
cotransfect
applic
develop
surfac
plasmon
resonancebas
assay
journal
molecular
recognit
introduct
reduc
timelin
cost
key
factor
biopharmaceut
industri
acceler
process
develop
drug
deliveri
patient
enhanc
throughput
bioprocess
develop
becom
increasingli
import
screen
optim
cell
cultur
process
challeng
requir
high
throughput
tool
previou
studi
show
robot
driven
minibioreactor
system
develop
tapsartoriu
could
advantag
acceler
process
develop
use
system
allow
us
test
larg
number
experiment
condit
singl
experi
therefor
larg
amount
product
sampl
character
product
qualiti
attribut
pqa
increas
well
bottleneck
move
gener
sampl
product
bioreactor
step
inprocess
analysi
product
qualiti
attribut
analysi
lab
scale
protein
purif
gener
carri
column
incompat
size
bioreactor
moreov
appli
method
rel
low
throughput
develop
high
bind
capac
resin
mgml
combin
high
perform
new
cell
line
abl
produc
gl
recombin
monoclon
antibodi
allow
requir
develop
effici
high
throughput
ht
purif
method
robot
use
robot
equip
small
scale
purif
purpos
great
opportun
us
tackl
bottleneck
enabl
highthroughput
sampl
purif
smaller
scale
materi
method
recombin
monoclon
antibodi
produc
genet
engin
dihydrofol
reductas
dhfr
chines
hamster
ovari
cho
cell
line
clarifi
cell
cultur
fluid
cccf
obtain
liter
bioreactor
three
filtrat
step
minipurif
perform
tecan
freedom
robot
predictor
contain
mabselect
resin
larger
scale
purif
execut
use
aktaxpress
use
hitrap
column
prota
assess
monoclon
antibodi
purif
small
scale
first
test
repeat
minipurif
purifi
sampl
time
column
use
differ
column
focus
yield
purif
impact
product
qualiti
attribut
especi
hmw
compar
result
obtain
aktaxpress
larger
scale
purif
compar
yield
purif
pqa
proteina
eluat
obtain
purif
system
final
assess
capabl
robot
perform
ht
buffer
purif
condit
evalu
three
differ
buffer
differ
concentr
ph
valu
also
test
differ
load
column
capac
result
discuss
studi
establish
tecan
use
robust
platform
purif
small
scale
observ
similar
purif
yield
intra
inter
run
analysi
level
show
also
high
reproduc
ph
eluat
show
well
strong
compar
well
tabl
show
coeffici
variat
cv
yield
hmw
eluat
ph
low
demonstr
good
reproduc
purif
strong
reproduc
obtain
differ
purif
show
tecan
aktaxpress
similar
term
purif
perform
pqa
fig
b
tecan
versatil
autom
liquid
handler
allow
screen
huge
purif
condit
fig
possibl
purifi
larg
quantiti
sampl
sampl
amount
limit
tecan
potenti
purifi
samplesday
reduc
timelin
allow
us
deliv
faster
patient
refer
f
delouvroy
et
al
minibioreactor
highthroughput
tool
cultur
process
develop
acceler
transfer
stainless
steel
manufactur
scale
compar
studi
process
perform
product
qualiti
attribut
esact
barcelona
ghose
et
al
maxim
bind
capac
protein
chromatographi
biotechnol
prog
background
monitor
cell
densiti
viabil
mammalian
cell
cultur
bioreactor
necessari
task
present
today
number
remain
challeng
tradit
measur
bioreactor
cell
count
viabil
reli
use
trypan
blue
exclus
method
day
automat
cell
counter
reduc
statist
manual
error
sampl
bioreactor
remain
contamin
risk
prohibit
process
control
sampl
volum
becom
siginfic
lensless
imag
technolog
new
method
accur
determin
cell
concentr
viabil
without
stain
techniqu
directli
acquir
light
diffract
properti
individu
cell
hologram
imag
without
object
len
focu
set
live
dead
cell
signific
holograph
pattern
distinguish
precis
count
materi
method
lensless
imag
techniqu
directli
acquir
light
diffract
properti
individu
cell
hologram
imag
without
object
len
focu
set
live
dead
cell
signific
holograph
pattern
distinguish
precis
count
compar
cell
count
viabil
refer
method
lensless
imag
devic
cytonot
counter
measur
perform
day
sampl
bioreactor
inocul
end
cultur
also
assess
repeat
method
anoth
lensless
imag
prototyp
setup
measur
chamber
directli
connect
perfus
bioreactor
continu
receiv
bioreactor
broth
therefor
reproduc
situ
measur
result
discuss
concentr
rang
cellsml
fig
viabil
rang
obtain
correl
factor
two
compar
method
larg
field
view
allow
analyz
sever
thousand
cell
within
singl
imag
keep
statist
variabl
measur
low
measur
chamber
prototyp
demonstart
capabl
continu
viabl
cell
densiti
viabil
monitor
work
design
steam
streriliz
probe
envis
lensless
imag
becom
futur
method
choic
onlin
monitor
suspens
cell
cultur
conclus
lensless
imag
technolog
capabl
accur
precis
monitor
viabl
cell
densiti
viabil
combin
signific
advantag
start
low
sampl
volum
use
label
free
detect
quick
measur
simpl
devic
high
number
cell
analyz
let
us
think
good
candid
smallscal
bioreactor
highthroughput
measur
high
repeat
also
key
paramet
effort
narrow
batch
batch
deviat
addit
demonstr
techniqu
potenti
power
inlin
continu
monitor
lab
bioreactor
envis
lensless
imag
becom
futur
method
choic
onlin
insitu
monitor
suspens
cell
perfect
tool
process
control
fedbatch
perfus
mode
singleus
bioreactor
tradit
steam
steril
vessel
certainli
becom
first
vcd
measur
techniqu
work
cell
line
engin
process
develop
pilot
scale
manufactur
scale
acknowledg
acknowledg
cedric
allier
cea
leti
grenobl
franc
background
consist
product
qualiti
major
goal
product
biotherapeut
especi
recombin
glycoprotein
wherea
unlik
polypeptid
chain
chang
product
process
posttransl
modif
protein
fold
sensit
fluctuat
paramet
condit
focu
protein
glycosyl
one
import
indic
product
qualiti
batch
process
condit
chang
continu
begin
suppli
situat
cell
excel
secret
materi
stay
long
time
cultur
fluid
later
cultiv
substrat
provis
decreas
wherea
exposit
time
protein
cultur
fluid
much
shorter
altogeth
lead
product
heterogen
secret
protein
batch
cultur
materi
method
four
differ
cell
line
two
human
origin
two
cho
clone
produc
four
differ
recombin
glycoprotein
investig
studi
togeth
respect
parent
cell
line
clone
cultur
three
replic
shaker
supernat
cultur
harvest
four
time
point
remov
cultur
volum
replac
cultur
supernat
ident
cultur
correspond
parent
cell
line
product
isol
supernat
glycan
releas
one
part
releas
glycan
label
separ
hilicfld
part
glycan
permethyl
analyz
malditof
mass
spectrometri
fig
investig
protein
antibodi
antithrombin
iii
cho
clone
human
clone
result
conclus
antennar
glycan
quit
stabl
product
phase
degre
core
fucosyl
high
product
low
fucosyl
degre
antibodi
may
favor
higher
adcc
perform
product
show
antennari
fucosyl
seem
chang
much
differ
cultiv
phase
nevertheless
might
issu
due
antigen
impact
patient
antennari
galactosyl
chang
notic
antibodi
case
degre
highest
first
phase
incomplet
galactosyl
lead
truncat
glycan
lead
inevit
undersialyl
antenna
seen
sialyl
highest
earli
phase
decreas
cultiv
time
sialyl
therapeut
protein
import
halflif
patient
therefor
highli
sialyl
product
desir
studi
consist
galactosyl
sialyl
investig
fed
batch
long
term
continu
cultur
comparison
batch
cultur
due
feed
solut
fresh
media
present
process
suppli
situat
excel
whole
cultiv
time
differ
malditof
hilicfld
data
origin
complex
unresolv
chromatogram
fig
chromatogram
shown
reason
coupl
hilicfld
ms
much
recommend
acknowledg
would
like
thank
schemel
ehrlich
technic
assist
refer
parodi
armando
protein
glycosyl
role
protein
fold
annual
review
biochemistri
liu
chalouni
young
junttila
sliwkowski
low
afucosyl
antibodi
increas
activ
signal
compon
intensifi
process
promot
adcc
cancer
immunol
research
varki
schnaar
schauer
sialic
acid
nonuloson
acid
essentiel
glycobiolog
internet
edit
edit
varki
new
york
usa
cold
spring
harbor
laboratori
press
background
novel
biolog
often
select
larg
librari
lead
candid
initi
stage
preclin
clinic
develop
select
demand
highthroughput
product
recombin
protein
high
qualiti
suffici
quantiti
transient
gene
express
offer
rapid
approach
product
numer
recombin
protein
initialstag
develop
biolog
mammalian
cell
major
host
cell
transient
gene
express
disadvantag
complic
oper
high
cost
cultur
insect
cell
easi
handl
grown
high
cell
densiti
suspens
serumfre
medium
insect
cell
also
produc
larg
amount
recombin
protein
posttransl
process
modif
higher
eukaryot
henc
insect
cell
recogn
excel
platform
product
function
recombin
protein
present
studi
product
antibodi
fab
fragment
transient
gene
express
lepidopteran
insect
cell
examin
materi
method
dna
fragment
encod
heavi
chain
hc
light
chain
lc
gene
fab
fragment
mous
antibovin
rnasea
respect
clone
plasmid
vector
pihaneo
contain
bombyx
mori
actin
promot
downstream
b
mori
nucleopolyhedroviru
bmnpv
transactiv
bmnpv
enhanc
highlevel
express
trichoplusia
ni
high
five
cell
cotransfect
result
plasmid
vector
use
linear
polyethyleneimin
pei
mw
transfect
plasmid
pei
prepar
mm
nacl
ph
incub
room
temperatur
min
transfect
effici
check
plasmid
vector
encod
enhanc
green
fluoresc
protein
egfp
gene
also
cotransfect
transfect
cell
incub
serumfre
medium
static
shakeflask
cultur
cultur
supernat
analys
western
blot
enzymelink
immunosorb
assay
elisa
number
green
fluoresc
cell
total
cell
cultur
broth
determin
use
flow
cytomet
result
discuss
western
blot
analysi
elisa
cultur
supernat
show
transfect
high
five
cell
secret
fab
fragment
antigenbind
activ
static
cultur
transfect
cultur
condit
hc
lc
gene
ratio
serumfre
medium
dna
pei
ratio
dna
amount
per
cell
success
optim
flow
cytometri
egfp
express
transfect
cell
yield
secret
fab
fragment
measur
elisa
effect
cultur
temperatur
initi
cell
densiti
also
examin
compar
cell
growth
product
fab
fragment
shakeflask
cultur
optim
condit
medium
wako
pure
chemic
industri
japan
hc
lc
gene
ratio
dna
cell
pei
cell
initi
cell
densiti
x
temperatur
yield
mgl
fab
fragment
achiev
day
shakeflask
cultur
fig
transfect
significantli
affect
growth
high
five
cell
compar
untransfect
cell
transient
gene
express
use
insect
cell
may
offer
promis
approach
highthroughput
product
candid
protein
develop
biolog
refer
yamaji
h
product
antibodi
insect
cell
antibodi
express
product
cell
engin
volum
edit
alrubeai
dordrecht
netherland
springer
scienc
busi
media
yamaji
h
suitabl
perspect
use
recombin
insect
cell
product
viruslik
particl
appl
microbiol
biotechnol
katakura
kobayashi
e
kurokawa
omasa
fujiyama
k
suga
ki
clone
cdna
character
antirnas
monoclon
antibodi
j
ferment
bioeng
yamaji
h
manab
watakab
k
muraoka
fujii
fukuda
h
product
function
antibodi
fab
fragment
recombin
insect
cell
biochem
eng
j
background
increas
demand
biopharmaceut
produc
mammalian
cell
led
industri
increas
volumetr
product
bioprocess
differ
strategi
context
fedbatch
perfus
cultur
attract
interest
convent
batch
process
effici
applic
altern
process
requir
avail
reliabl
onlin
measur
tool
cell
densiti
cell
metabol
activ
estim
comparison
differ
cultur
strategi
cell
line
produc
present
batch
fortifi
batch
fedbatch
context
new
robust
feed
strategi
base
monitor
alkali
buffer
addit
appli
estim
nutrient
requir
method
allow
increas
cell
densiti
product
titer
compar
strategi
assess
materi
method
three
differ
cultur
strategi
carri
biostat
bdcu
ii
bioreactor
first
refer
batch
batch
use
fortifi
medium
nutrient
enrich
medium
run
assess
term
viabl
cell
densiti
vcd
product
titer
set
initi
refer
fedbatch
perform
appli
feed
strategi
base
nutrient
requir
estim
monitor
alkali
buffer
addit
use
control
ph
result
vcd
product
titer
achiev
differ
cultur
strategi
assess
batch
fortifiedbatch
fedbatch
present
tabl
fortifi
batch
increas
vcd
also
product
titer
obtain
compar
batch
fedbatch
cultur
carri
fig
observ
alkali
buffer
addit
profil
match
vcd
evolut
trend
thu
monitor
alkali
buffer
addit
use
estim
nutrient
requir
ie
volum
feed
medium
time
fed
batch
phase
feed
strategi
base
alkali
buffer
addit
enabl
maintain
glucos
concentr
set
point
therein
narrow
rang
fedbatch
phase
around
mm
result
higher
vcd
obtain
compar
batch
refer
vcd
enhanc
increas
product
titer
respect
batch
fortifi
batch
respect
result
prove
fedbatch
strategi
base
alkali
buffer
addit
robust
onlin
monitor
method
enabl
optim
feed
strategi
fedbatch
cultur
conclus
three
differ
cultur
strategi
test
bioreactor
cell
line
produc
result
show
higher
vcd
reach
higher
product
concentr
achiev
therefor
bioprocess
develop
point
view
interest
implement
strategi
higher
vcd
outcom
fedbatch
oper
mode
context
new
robust
method
vcd
estim
fedbatch
appli
alkali
buffer
addit
necessari
maintain
ph
setpoint
onlin
reliabl
easi
measur
variabl
provid
inform
byproduct
format
mainli
lactic
acid
monitor
variabl
provid
inform
cell
concentr
activ
metabol
detect
chang
cultur
besid
relationship
alkali
buffer
addit
vcd
establish
sinc
first
strongli
correl
cell
growth
metabolit
consumptionform
applic
alkali
buffer
addit
measur
implement
optim
feed
strategi
fedbatch
permit
enhanc
vcd
product
titer
compar
batch
strategi
acknowledg
author
would
like
mention
research
support
fidgr
spanish
govern
project
led
prof
jordi
joan
badillo
refer
j
lecina
c
j
j
f
optim
cell
cultur
product
adenovir
vector
bioreactor
use
onlin
measur
journal
r
miret
j
scalia
f
casablanca
lecina
j
j
enhanc
heterolog
protein
express
secret
cell
mean
combin
cmv
promot
signal
peptid
journal
biotechnolog
listecalleja
l
lecina
jj
cell
cultur
media
studi
toward
bioprocess
optim
anim
deriv
compon
free
anim
deriv
compon
contain
platform
journal
bioscienc
bioengin
casablanca
x
lecina
c
j
j
f
comparison
control
strategi
cultur
hybridoma
cell
base
monitor
oxygen
uptak
rate
optic
cell
densiti
glucos
concentr
journal
chemic
technolog
background
perfus
system
suspend
mammalian
cell
rais
grow
interest
biomanufactur
industri
continu
manufactur
grow
field
encourag
health
author
work
address
scale
limit
inher
continu
media
exchang
cell
retent
use
semicontinu
system
data
gener
set
differ
clone
previous
studi
fedbatch
mode
materi
method
cell
line
express
monoclon
antibodi
mab
issu
transfect
use
model
bioreactor
sartoriu
use
fedbatch
perfus
product
run
perfus
bioreactor
run
use
altern
tangenti
flow
filtrat
devic
repligen
atf
system
cell
biomass
control
remov
cell
bleed
line
control
use
biocapacit
probe
hamilton
incyt
perfus
rate
fix
one
vessel
volum
day
semicontinu
run
made
ml
shake
tube
tpp
bioreactor
day
tube
centrifug
min
g
supernat
remov
mimic
perfus
rate
replac
fresh
media
cell
resuspend
result
clone
growth
potenti
preserv
across
system
fig
clone
alway
reach
highest
viabl
cell
densiti
vcd
follow
clone
clone
show
similar
growth
characterist
interest
note
perfus
bioreactor
differ
pattern
term
vcd
observ
although
cell
biomass
signal
similar
run
reflect
fact
capacit
measur
biomass
absolut
cell
count
estim
minimum
cell
specif
perfus
rate
csprmin
semicontinu
experi
perfus
rate
divid
maximum
viabl
cell
densiti
vcdmax
valu
compar
cspr
obtain
setpoint
perfus
run
expect
bleed
fraction
decreas
capacit
setpoint
increas
went
less
total
perfus
rate
data
shown
sinc
bleed
remov
excess
biomass
indic
close
limit
system
therefor
cspr
calcul
consid
minimum
cspr
csprmin
obtain
system
close
tabl
semicontinu
system
therefor
use
identifi
csprmin
run
continu
bioreactor
therefor
facilit
decis
make
earli
develop
defin
target
cell
densiti
defin
perfus
rate
specif
product
qp
clone
quantifi
maximum
vcd
semicontinu
perfus
absolut
valu
repres
sinc
cell
environ
differ
system
nevertheless
rel
rank
prove
indic
respect
perform
tabl
maximum
cell
growth
fedbatch
semicontinu
perfus
also
compar
rank
alway
preserv
indic
use
assess
perform
rank
differ
clone
conclus
perform
clone
studi
differ
cultiv
system
fedbatchperfus
bioreactor
semicontinu
shake
tube
semicontinu
system
abl
precis
predict
csprmin
import
process
paramet
perfus
specif
product
maximum
cell
densiti
rank
preserv
across
system
therefor
scale
experi
use
assess
perform
rank
perfus
clone
screen
acknowledg
author
want
thank
biotech
process
scienc
team
merck
corsiersurvevey
support
also
member
morbidelli
group
eth
input
collabor
refer
farid
b
thompson
davidson
continu
bioprocess
real
thing
time
mab
k
b
konstantinov
c
l
cooney
white
paper
continu
bioprocess
j
pharm
sci
j
pharm
sci
chatterje
fda
perspect
continu
manufactur
ifpac
annu
meet
rouiller
bielser
jm
jordan
broli
h
stettler
screen
assess
perform
molecul
qualiti
attribut
industri
cell
line
across
differ
fedbatch
system
biotechnol
prog
c
f
opel
j
li
amanullah
quantit
model
viabl
cell
densiti
cell
size
intracellular
conduct
membran
capacit
batch
fedbatch
cho
process
use
dielectr
spectroscopi
biotechnol
prog
background
product
therapeut
antibodi
ab
requir
high
titer
excel
product
qualiti
ensur
effici
manufactur
potent
drug
efficaci
glycosyl
attach
sugar
organ
molecul
critic
qualiti
aspect
significantli
alter
ab
bind
function
therapeut
effect
galactos
key
sugar
interest
due
signific
impact
ab
function
abil
control
galactosyl
cell
cultur
medium
herein
irvin
scientif
assess
abil
media
compon
modul
galactos
level
model
therapeut
ab
variou
media
composit
abl
modul
galactosyl
level
without
compromis
cell
growth
ab
titer
addit
vitro
assay
util
evalu
function
abil
ab
bind
activ
complementdepend
cytotox
cdc
differ
galactosyl
significantli
alter
ab
abil
induc
cell
cytotox
furthermor
design
experi
analysi
determin
optim
ratio
supplement
maxim
galactosyl
optim
supplement
verifi
evalu
supplier
galactosyl
supplement
term
growth
titer
glycan
analysi
ab
function
optim
supplement
outperform
supplier
supplement
result
best
overal
cell
growth
titer
galactosyl
ab
function
materi
method
fedbatch
cultur
chines
hamster
ovari
cell
express
ab
grown
cho
growth
fed
cho
feed
day
cultur
viabl
cell
densiti
cell
viabil
assess
beckman
coulter
vicel
xr
ab
titer
assess
pall
qke
glycan
analysi
assess
perkinelm
labchip
gxii
function
cdc
assay
ab
incub
daudi
b
lymphoblast
cell
normal
human
complement
serum
cell
cytotox
assess
promega
cytotoxglo
kit
result
variou
supplement
evalu
fedbatch
cultur
result
ab
galactosyl
without
compromis
cell
growth
ab
titer
design
experi
analysi
determin
optim
composit
deem
optim
supplement
evalu
panel
galactosemodul
supplement
supplier
optim
supplement
result
similar
viabl
cell
densiti
vcd
cell
viabil
compar
fedbatch
cultur
control
supplement
fig
supplement
supplier
result
similar
half
vcd
control
supplement
supplier
result
low
vcd
percent
viabil
supplement
except
supplier
result
ab
titer
similar
control
fig
due
poor
growth
subsequ
low
titer
supplier
supplement
supplier
evalu
glycan
profil
analyz
present
fig
evalu
supplement
abl
rais
galactosyl
howev
optim
supplement
supplier
supplement
result
galactosyl
function
ab
evalu
cdc
assay
fig
ab
optim
supplement
effect
control
ab
significantli
lower
halfmaxim
effect
concentr
control
ab
supplier
supplement
similar
control
may
due
higher
ab
conclus
optim
supplement
produc
fedbatch
evalu
design
experi
analysi
optim
supplement
outperform
supplen
supplier
result
best
overal
cell
growth
glycan
profil
function
ab
activ
tabl
refer
hossler
p
khattak
sf
li
zj
optim
consist
protein
glycosyl
mammcalian
cell
cultur
glycobiolog
background
industri
practic
mammalian
cell
cultur
media
feed
develop
typic
employ
highthroughput
screen
ht
platform
along
larg
set
experi
modern
ht
system
often
includ
robot
liquid
handler
replac
labor
intens
step
align
advanc
field
semiautom
ht
platform
develop
facilit
inhous
media
feed
develop
earli
stage
biolog
project
materi
method
select
appropri
instrument
integr
seamless
system
key
ht
platform
develop
ht
platform
use
deep
well
plate
dwp
cultur
vessel
liquid
handler
advanc
microscal
bioreactor
mediafe
formul
prepar
asept
environ
nyon
cell
imag
viabil
cell
growth
analysi
tecan
freedom
evo
liquid
handler
activ
assay
sampl
prepar
cedex
bioht
highthroughput
metabolit
analysi
dwp
offer
compar
cell
growth
shake
flask
compat
layout
make
dwp
ideal
candid
platform
addit
user
friendli
design
experi
interfac
liquid
handler
function
expedi
formul
prepar
vari
doe
condit
macro
program
written
develop
excel
enabl
easi
import
design
major
statist
softwar
packag
jmp
simca
result
perform
qualif
compon
perform
prior
implement
ht
platform
compar
cell
growth
profil
product
achiv
shake
flask
dwp
fig
indic
compat
cell
cultur
environ
cell
cell
count
use
nyon
gave
ident
cell
growth
rank
tradit
count
vicel
xr
fig
freedom
evo
liquid
handler
optim
produc
compar
activ
result
manual
oper
expedit
sampl
prepar
improv
consist
fig
final
implement
liquid
handler
function
support
media
feed
formul
significantli
reduc
labor
experi
summari
capabl
comparison
ht
platform
tradit
method
list
tabl
case
studi
complex
feed
screen
definit
screen
design
complet
use
semiautomat
ht
platform
experi
contain
feed
formul
duplic
handl
one
oper
deliv
improv
product
within
week
period
data
shown
addit
implement
ht
platform
studi
also
result
reduct
labor
improv
traceabl
formul
prepar
conclus
semiautom
ht
platform
develop
support
media
feed
screen
develop
earli
stage
biolog
project
platform
util
dwp
nyon
cell
imag
freedom
evo
liquid
handler
system
bioht
metabol
analyz
acceler
screen
process
screen
platform
improv
process
throughput
oper
precis
traceabl
formul
prepar
also
reduc
labor
media
feed
formul
prepar
acknowledg
author
would
like
thank
dr
benjamin
youn
manufactur
scienc
technolog
msat
biomarin
help
code
excel
macro
program
dr
donald
l
traul
tap
biosystem
part
sartoriu
stedim
biotech
group
assist
oper
refer
radu
c
adrar
hs
alamir
hatherley
trinh
djaballah
h
journal
laboratori
autom
design
conceptreli
fulli
autom
high
content
screen
platform
delouvroy
f
siriez
g
tran
av
mukankurayija
l
kochanowski
n
malphett
l
bmc
proceed
ambrtm
minibioreactor
highthroughput
tool
cultur
process
develop
acceler
transfer
stainless
steel
manufactur
scale
compar
studi
process
perform
product
qualiti
attribut
suppl
background
perfus
medium
requir
high
concentr
specif
nutrient
balanc
compon
support
intensifi
perfus
process
use
combin
design
experi
doe
multivari
analysi
mva
spent
media
analysi
develop
catalog
de
novo
perfus
medium
work
multipl
cho
cell
line
protein
optim
medium
bioreactor
use
altern
tangenti
flow
atf
cell
retent
devic
reduc
minimum
cspr
cell
line
increas
specif
product
day
steadi
state
stabl
growth
rate
viabil
volumetr
product
product
qualiti
materi
method
high
throughput
screen
ht
perform
seven
cell
line
four
use
bioreactor
cho
two
gs
line
produc
differ
monoclon
antibodi
includ
fusion
protein
ht
experi
cell
inocul
ml
work
volum
ml
tube
cultur
day
multitron
shaken
rh
benchtop
perfus
cell
inocul
applikon
bioreactor
applikon
netherland
work
volum
bioreactor
oper
rpm
ph
depend
cell
line
oxygen
suppli
l
sparger
microsparg
need
antifoam
milliporesigma
germani
ad
maximum
rate
vv
control
foam
cell
concentr
perfus
initi
use
repligen
massachusett
bleed
set
maintain
cell
concentr
result
two
de
novo
prototyp
media
develop
use
doe
mva
ht
tpp
one
chosen
develop
compar
basal
medium
enrich
feed
bioreactor
eleven
compon
identifi
signific
effector
critic
paramet
perfus
process
across
evalu
cell
line
doe
central
composit
experi
run
compon
concentr
optim
select
prototyp
parallel
amino
acid
specif
consumpt
rate
calcul
bioreactor
spent
media
sampl
use
adjust
concentr
amino
acid
target
reduc
cspr
increas
specif
amino
acid
concentr
result
signific
reduct
minimum
cspr
across
test
cell
line
exampl
cspr
cho
reduc
tabl
howev
even
lower
cspr
spent
media
analysi
reveal
excess
concentr
amino
acid
specif
accumul
amino
acid
reduc
compon
streamlin
final
medium
advanc
hd
perfus
medium
use
medium
cho
gs
cell
line
produc
fusion
protein
cultur
cspr
less
vcd
metabol
profil
product
product
qualiti
constant
day
steadi
state
gs
cell
line
also
test
cspr
fig
conclus
develop
catalog
perfus
medium
first
principl
ensur
broad
applic
use
seven
cell
line
scaleddown
system
four
perfus
bioreactor
final
catalog
medium
show
signific
improv
product
across
cell
line
reduc
cspr
compar
enrich
fedbatch
medium
initi
prototyp
tabl
acknowledg
thank
bioreactor
team
dustin
davi
amer
allozi
jana
mahadevan
refer
davi
riesberg
j
lyon
perfus
media
develop
use
cell
settl
autom
cell
cultur
system
esact
background
rise
demand
acceler
process
develop
increas
effici
econom
biopharmaceut
product
process
furthermor
increas
process
understand
evolv
process
analyt
tool
initi
pat
qualiti
design
qbd
methodolog
contrast
onefactoratatim
method
statist
design
experi
doe
method
wide
use
develop
biopharmaceut
process
even
highthroughput
system
handl
number
experi
parallel
heurist
restrict
boundari
high
number
factor
result
stepwis
iter
multipl
run
therefor
combin
modelbas
simul
doe
method
mdoe
develop
sophist
cell
cultur
process
novel
tool
process
develop
use
reduc
number
experi
doe
time
need
develop
knowledgebas
cell
cultur
process
concept
appli
optim
initi
glutamin
glucos
concentr
cho
batch
process
materi
method
mechanist
model
adapt
modifi
use
describ
dynam
cell
metabol
antibodi
product
antibodi
produc
cho
cell
line
see
abbrevi
fig
cultiv
detail
experi
simul
compar
fulli
experiment
doe
seen
tabl
user
defin
constraint
chosen
get
stabl
reproduc
process
aim
maxim
cell
densiti
decreas
lactat
ammonia
product
result
first
experiment
space
estim
simul
respons
broad
concentr
rang
calcul
multipl
respons
desir
function
fig
result
small
area
turquois
suggest
experiment
space
experi
plan
within
boundari
respons
either
simul
fig
cultiv
fit
model
compar
pure
experiment
respons
fig
cultiv
optim
concentr
glutamin
glucos
respect
constraint
lower
right
corner
similar
method
red
frame
fig
conclus
compar
fulli
experiment
design
mdoe
result
reduct
number
experi
experi
model
vs
experi
experiment
doe
method
intend
optim
cultiv
strategi
mammalian
cell
line
evalu
experi
perform
laboratori
scale
result
signific
time
cost
reduct
process
develop
process
establish
strategi
especi
intend
use
multisingleusedevic
speed
process
develop
acknowledg
kindli
acknowledg
cell
cultur
technolog
group
bielefeld
univers
prof
dr
thoma
noll
provid
cell
line
use
work
feder
ministri
educ
research
fund
grant
refer
j
r
modelbas
design
process
strategi
cell
cultur
bioprocess
state
art
new
perspect
new
insight
cell
cultur
technolog
edit
intech
kern
plata
barrada
r
frahm
b
modelbas
strategi
cell
cultur
seed
train
layout
verifi
lab
scale
cytotechnolog
aug
doi
epub
mar
background
largescal
product
therapeut
glycoprotein
fedbatch
cultur
wide
use
oper
simplic
high
titer
howev
repeat
feed
medium
concentr
andor
addit
base
maintain
optim
ph
fedbatch
cultur
lead
increas
osmol
hyperosmol
affect
glycosyl
proteinspecif
manner
howev
mechan
behind
osmolalitydepend
variat
glycosyl
recombin
chines
hamster
ovari
rcho
cell
remain
unclear
materi
method
studi
better
understand
effect
hyperosmol
glycosyl
protein
produc
rcho
cell
investig
nglycosylationrel
gene
express
nlink
glycan
structur
fcfusion
proteinproduc
rcho
cell
expos
hyperosmot
condit
furthermor
valid
effect
hyperosmol
protein
glycosyl
perform
hyperosmot
cultur
supplement
betain
osmoprotect
analyz
nlink
glycan
structur
mrna
level
nglycan
branchingantennari
gene
result
three
day
hyperosmot
cultur
nine
gene
ugp
manea
differenti
express
control
gene
downregul
nlink
glycan
analysi
anion
exchang
hydrophil
interact
hplc
show
proport
highli
sialyl
di
tri
tetra
tetraantennari
nlink
glycan
significantli
decreas
upon
hyperosmot
cultur
addit
betain
osmoprotect
hyperosmot
cultur
significantli
increas
proport
highli
sialyl
tetraantennari
nlink
glycan
p
increas
express
nglycan
branchingantennari
gene
thu
decreas
express
gene
role
nglycan
biosynthesi
pathway
correl
reduc
sialic
acid
content
fcfusion
protein
caus
hyperosmolar
condit
conclus
taken
togeth
result
obtain
studi
provid
better
understand
detriment
effect
hyperosmol
nglycosyl
especi
sialyl
rcho
cell
identifi
gene
particularli
potenti
target
engin
cho
cell
overcom
impact
hyperosmol
glycoprotein
sialyl
acknowledg
research
support
part
grant
bio
medic
technolog
develop
program
nrf
fund
korean
govern
refer
pfizenmai
j
junghan
l
teleki
takor
r
hyperosmot
stimulu
studi
disclos
benefit
atp
suppli
reveal
mirnamrna
target
improv
recombin
protein
product
cho
cell
biotechnol
j
schmelzer
ae
miller
wm
effect
osmoprotect
compound
ncam
polysialyl
hyperosmot
stress
elev
biotechnol
bioeng
background
demand
highqual
monoclon
antibodi
grow
exponenti
call
new
product
capac
overcom
current
limit
convent
manufactur
strategi
name
high
capit
invest
product
cost
achiev
innov
process
design
base
latest
technolog
studi
present
process
design
combin
batchf
technolog
continu
multicolumn
captur
advanc
cell
cultur
clarif
method
introduc
simplifi
downstream
oper
increas
overal
costeffect
process
optim
product
recombin
protein
materi
method
studi
perform
cho
cell
express
monoclon
antibodi
target
coronoaviru
respons
middl
east
respiratori
syndrom
mer
develop
organ
vaccinestm
nih
kindli
provid
univercel
upstream
process
fedbatch
day
cultur
scale
cdcho
chemic
defin
media
feed
harvest
treatment
precipit
impur
product
bioreactor
use
organ
compound
vv
floccul
electroposit
organ
wv
acid
ph
physiolog
conduct
harvest
clarif
depth
filtrat
coars
fine
grade
depth
filter
follow
sterilisinggrad
filtrationprimari
depth
filter
clarisolv
merck
sartoclear
dynam
sartoriu
secondari
depth
filter
merck
sartoriu
steril
grade
filter
express
shc
merck
sartopor
xlg
sartoriu
captur
antibodi
affin
captur
captiva
primab
repligen
mab
captur
select
thermofish
amspher
jsr
toyopearl
afrproteina
tosoh
cation
exchang
captur
gigacap
tosoh
result
upstream
process
harvest
treatment
cultur
reach
gl
cellsml
viabil
harvest
treatment
found
effect
term
impur
clearanc
captur
captur
strategi
evalu
point
view
simplif
downstream
oper
hcp
impur
content
monitor
key
perform
indicatorprotein
affin
chromatographi
advanc
harvest
clarif
enabl
major
improv
affin
captur
term
eluat
puriti
reduct
host
cell
impur
ppm
condit
test
fig
cation
exchang
chromatographi
cex
allow
higher
capac
gl
protein
whilst
afford
cheaper
low
residu
hcp
ppm
observ
cex
resin
test
without
harvest
treatment
clarif
preced
captur
studi
either
affin
cex
result
show
lower
bind
capac
resin
higher
content
hcp
eluat
ppm
higher
content
hmw
speci
elut
fraction
higher
signific
turbid
neutral
eluatecontinu
multicolumn
chromatographi
option
increas
cost
effici
includ
use
continu
multicolumn
setup
tabl
two
model
assess
base
two
differ
static
bind
capac
sbc
demonstr
column
abl
process
product
less
conclus
method
provid
great
opportun
design
simplifi
low
footprint
mab
dsp
process
maintain
similar
achiev
superior
qualiti
profil
compar
standard
approach
harvest
treatment
follow
depth
filtrat
prove
costeffici
way
obtain
pretreat
feed
minim
burden
downstream
operationsprotein
resin
exhibit
advantag
extract
key
contamin
harvest
treatment
caex
confirm
competit
captur
strategyswitch
batch
continu
multicolumn
mode
allow
process
complet
batch
less
hour
requir
lower
media
resin
volum
follow
singl
polish
step
process
setup
strongli
support
reduct
oper
requir
deliv
highqual
product
acknowledg
organ
vaccinestm
nih
kindli
provid
univercel
background
immunoglobulin
igm
antibodi
secret
b
cell
first
defens
invad
pathogen
primari
immun
respons
igm
antibodi
alreadi
gain
orphan
drug
statu
show
uniqu
capabl
therapi
rare
diseas
potenti
field
applic
discov
increas
knowledg
molecul
seem
activ
form
pentamer
hexamer
igm
unfortun
recombin
product
igm
rather
difficult
secret
correct
polym
format
result
low
express
yield
mixtur
polym
materi
method
establish
stabl
produc
chines
hamster
ovari
cho
cell
line
analyz
cellular
extracellular
factor
influenc
quantiti
qualiti
produc
recombin
polymer
igm
futur
studi
one
qualiti
paramet
polym
distribut
measur
directli
cell
cultur
supernat
use
densitometr
analys
addit
develop
effici
singlestepaffin
purif
strategi
use
poro
captureselect
igm
affin
matrix
analyz
pure
igm
precis
measur
igm
isoform
distribut
separ
purifi
polym
high
perform
liquid
size
exclus
chromatographi
sec
hplc
result
cho
cell
line
grow
peak
cell
concentr
cellsml
erlenmey
flask
cellsml
bioreactor
similar
product
approxim
mgl
observ
cell
cultiv
cultiv
vessel
nonoptim
batch
cultur
use
chemic
defin
media
analys
cultiv
condit
affect
fraction
polym
may
offer
clue
assembl
polym
challeng
igm
product
quantifi
polymer
distribut
igm
directli
supernat
use
densitometr
method
cultiv
standard
condit
ph
produc
pentam
wherea
consist
approxim
pentam
purifi
analys
sechplc
contain
pentam
dimer
compar
result
achiev
densitometri
purif
igm
antibodi
quit
challeng
manufactur
recommend
acid
elut
led
aggreg
ineffici
elut
model
igm
therefor
screen
differ
elut
buffer
prevent
denatur
aggreg
combin
high
salt
concentr
moder
ph
reduct
optim
elut
condit
igm
recoveri
correspond
five
six
fold
improv
compar
manufactur
condit
sdspage
analysi
sechplc
show
elut
strategi
result
pure
product
singl
chromatograph
step
purif
strategi
verifi
conclus
model
igm
produc
ratio
approxim
pentamer
dimer
igm
measur
concordantli
analyt
method
process
develop
igm
purif
use
poro
captur
select
human
igm
affin
matrix
enabl
recoveri
highli
pure
fraction
optim
combin
mild
ph
high
salt
concentr
rel
low
elut
yield
increas
factor
appli
densitometri
sechplc
investig
cultur
condit
influenc
polym
format
futur
acknowledg
thank
polymun
scientif
immunbiologisch
forschung
gmbh
provid
antibodi
kind
gift
work
support
phd
program
biotop
biomolecular
technolog
protein
fund
austrian
scienc
fund
fwf
project
refer
chromikova
mader
steinfelln
kunert
evalu
bottleneck
recombin
igm
product
mammalian
cell
cytotechnolog
voraueruhl
wallner
lhota
kating
kunert
igm
character
directli
perform
crude
cultur
supernat
new
simpl
electrophoret
method
j
immunol
method
background
current
small
scale
cell
cultur
system
commerci
avail
high
cell
densiti
perfus
cultiv
use
high
throughput
screen
studi
increas
throughput
process
character
activ
janssen
vaccin
prevent
shaker
flaskbas
scale
model
develop
though
control
possibl
shaker
flask
cultur
technic
limit
differ
compar
bioreactor
control
process
addit
sensit
shaker
flask
model
allow
detect
effect
process
paramet
critic
qualiti
attribut
cqa
vaccin
produc
larg
scale
materi
method
iter
experi
perform
shake
flask
evalu
influenc
cultiv
paramet
shake
speed
work
volum
incub
daili
base
addit
cultiv
paramet
cell
growth
ph
addit
medium
exchang
test
mimic
perfus
mode
use
bioreactor
process
presen
shake
flask
reader
implement
allow
ph
monitor
condit
perform
reflect
specif
viru
titer
show
best
fit
select
condit
seri
parallel
shaker
flask
infect
conduct
demonstr
statist
equival
perform
paramet
cqa
cell
specif
iu
titer
vpiu
ratio
product
scale
reduc
scale
process
thu
qualifi
shake
flask
scaledown
model
result
daili
medium
exchang
centrifug
implement
cultiv
paramet
shake
flask
identifi
base
perform
paramet
cell
specif
vp
titer
cqa
vaccin
cell
specif
iu
titer
vpiu
ratio
equival
productionscal
scale
system
confirm
scale
model
data
fall
predict
interv
calcul
manufactur
data
wherea
scale
model
data
batch
mode
experi
use
non
optim
cultiv
condit
conclus
shaker
flask
scale
model
bioreactor
perfus
process
qualifi
model
tool
screen
subset
process
paramet
higher
throughput
therebi
reduc
process
character
timelin
background
today
market
therapeut
protein
especi
monoclon
antibodi
gain
import
pharmaceut
field
meet
increas
demand
product
industri
made
tremend
effort
gener
highli
effici
product
system
one
pharmaceut
industri
research
focus
improv
secret
process
eukaryot
cell
mammalian
cell
effici
protein
transport
strongli
depend
transloc
nascent
protein
er
mostli
conduct
signal
peptid
sp
coupl
nterminu
interchang
signal
peptid
product
even
speci
larg
varieti
use
enhanc
protein
express
alreadi
exist
product
system
materi
method
first
influenc
four
differ
natur
sp
sp
compar
secret
amount
model
antibodi
product
fed
batch
use
cho
host
cell
line
second
part
one
promis
spcandid
show
improv
secret
sp
identifi
influenc
sp
four
addit
antibodi
product
vari
express
good
midbad
investig
approach
standard
sp
implement
compar
reason
result
first
approach
four
signal
peptid
sp
sp
sp
sp
screen
potenti
improv
product
secret
cho
cell
express
model
antibodi
product
result
reveal
increas
averag
final
fedbatch
antibodi
titer
sp
compar
standard
sp
approach
standard
sp
gl
sp
gl
second
approach
enhanc
capac
sp
secret
four
igg
product
name
product
b
e
tabl
evalu
improv
perform
observ
product
compar
sp
standard
sp
fed
batch
process
fig
increas
averag
final
fedbatch
titer
rang
cellspecif
product
taken
togeth
posit
influenc
final
concentr
test
product
result
obtain
sp
contribut
optim
sartoriu
stedim
cellca
standard
cell
line
develop
process
conclus
signal
peptid
sp
identifi
promis
candid
averag
titer
increas
screen
four
signal
peptidessp
abl
improv
product
titer
compar
standard
spsp
abl
improv
cellspecif
product
compar
standard
spfutur
usag
sp
contribut
optim
sartoriu
stedim
cellca
standard
cell
line
develop
process
background
experi
use
assess
bioreactor
suitabl
stabil
clone
evalu
media
composit
process
paramet
start
upscal
campaign
result
major
bottleneck
due
increas
data
captur
process
aggreg
visual
statist
analysi
addit
associ
data
experiment
context
eg
ferment
protocol
media
recip
bioreactor
control
paramet
easili
accomplish
high
throughput
data
gener
process
must
analyz
also
manag
store
enabl
easi
track
relat
histor
record
furthermor
process
often
develop
global
team
interact
complex
enterpris
ecosystem
therefor
new
high
perform
system
data
captur
process
analysi
need
integr
order
enabl
storag
correl
experiment
context
inform
variou
type
time
cours
analyt
data
materi
method
develop
genedata
new
enterpris
platform
bioprocess
develop
platform
enabl
automat
captur
visual
onlin
offlin
data
eg
ph
metabol
data
autocalcul
aggreg
eg
ivcd
qp
consumpt
rate
multiparametr
assess
type
timeseri
bioreactor
data
context
experiment
protocol
data
eg
process
paramet
feed
genedata
bioprocess
come
dedic
interfac
integr
relev
laboratori
instrument
control
system
statist
analysi
softwar
packag
custom
enterpris
solut
enabl
model
track
complex
nonlinear
workflow
support
decis
make
bioprocess
develop
data
analyz
context
upstream
process
develop
also
correl
unit
oper
autom
support
assist
ever
increas
throughput
bioprocess
develop
oper
analysi
experiment
data
process
paramet
across
unit
oper
even
differ
project
overal
integr
enhanc
process
develop
workflow
result
conclus
highlight
use
case
describ
select
best
produc
clone
fig
identif
optim
media
feed
strategi
fig
comparison
clone
perform
across
differ
ferment
scale
fig
special
focu
analysi
data
micro
benchtop
bioreactor
system
oper
parallel
bioreactor
allow
increas
throughput
clone
select
process
optim
studi
turn
lead
increas
data
gener
genedata
bioprocess
support
integr
system
enabl
comparison
data
regardless
instrument
provid
scale
autom
bioreactor
data
analysi
allow
develop
group
take
advantag
even
richer
dataset
data
manag
builtin
system
data
easili
track
associ
histor
record
anoth
focu
crossreactor
scale
comparison
data
come
differ
bioreactor
scale
easili
import
platform
analyz
establish
best
condit
upscal
genedata
bioprocess
enabl
correl
process
paramet
eg
ferment
protocol
media
recip
bioreactor
control
paramet
key
perform
indic
process
eg
titer
qp
product
qualiti
attribut
eg
aggreg
glycosyl
profil
final
bioreactor
time
cours
data
track
togeth
clone
analyt
product
qualiti
paramet
make
platform
uniqu
abl
support
endtoend
biopharma
develop
acknowledg
allison
kurz
gian
andrea
signorel
genedata
ag
basel
switzerland
background
upstream
bioprocess
particular
risk
contamin
adventiti
agent
typic
filter
use
step
protect
bioreactor
bacteria
mycoplasma
offer
protect
viral
contamin
new
polyethersulfon
pe
upstream
viru
filter
barrier
demonstr
high
level
microorgan
retent
full
retent
bacteria
mycoplasma
lrv
log
reduct
valu
lrv
small
virus
parvovirus
also
improv
flow
capac
compar
viru
remov
filter
design
monoclon
antibodi
purif
given
small
pore
size
viru
retent
filter
implement
viru
filter
upstream
bioreactor
rais
question
whether
critic
cell
cultur
media
compon
remov
therefor
import
evalu
cell
cultur
perform
protein
qualiti
attribut
use
virusfilt
media
ensur
filtrat
neg
impact
process
materi
method
cho
media
correspond
feed
process
either
barrier
filter
filter
control
media
composit
postfiltr
evalu
high
perform
liquid
chromatographi
hplc
induct
coupl
plasmaopt
emiss
spectrometri
icpo
nuclear
magnet
reson
nmr
recombin
cho
cell
cultur
fed
batch
cultur
cell
densiti
viabil
measur
vicelltm
cell
viabil
analyz
metabolit
analyz
flex
analyz
shake
flask
bioreactor
util
verifi
surfact
poloxam
essenti
shear
protect
stir
tank
bioreactor
difficult
filter
remov
filtrat
monoclon
antibodi
titer
quantit
protein
hplc
character
antibodi
product
qualiti
assess
via
weak
cationexchang
chromatographi
charg
heterogen
size
exclus
chromatographi
aggreg
profil
fluoresc
label
npuplc
glycan
speci
result
media
feed
composit
unaffect
filtrat
viru
barrier
filter
signific
differ
concentr
observ
icpo
trace
metal
hplc
amino
acid
water
solubl
vitamin
nmr
show
chang
organ
composit
media
includ
poloxam
aromat
region
vitamin
amino
acid
signal
shown
fig
cell
cultur
show
differ
cell
growth
titer
either
shake
flask
bioreactor
fig
cell
viabil
unaffect
metabolit
level
within
limit
titer
consist
protein
qualiti
secret
antibodi
show
differ
glycosyl
pattern
fig
amount
aggreg
charg
variant
conclus
risk
viru
contamin
bioreactor
remain
concern
biotherapeut
manufactur
univers
technolog
provid
reliabl
cost
effect
solut
viru
remov
appli
compon
cell
cultur
media
studi
evalu
barrier
filter
provid
effici
easi
way
protect
bioprocess
adventiti
viru
contamin
studi
result
demonstr
media
feed
composit
cell
cultur
perform
product
qualiti
unaffect
filtrat
barrier
filter
implement
barrier
filter
provid
effici
filtrat
perform
high
viru
retent
minim
cell
cultur
impact
offer
viabl
option
improv
overal
viru
risk
mitig
strategi
manufactur
biotherapeut
refer
liu
et
al
develop
qualif
novel
viru
remov
filter
cell
cultur
applic
biotechnol
prog
background
bi
multispecif
antibodi
antibodycytokin
fusion
protein
nonimmunoglobulin
scaffold
chimer
antigen
receptor
car
engin
tcell
receptor
tcr
tcrbase
bispecif
construct
provid
signific
advantag
use
cancer
immunotherapi
howev
highli
engin
molecul
pose
new
challeng
design
engin
clone
express
purif
analyt
thu
implement
infrastructur
address
challeng
enabl
industri
variou
novel
therapeut
platform
materi
method
close
collabor
lead
biopharmaceut
compani
implement
workflow
data
manag
analysi
support
system
genedata
enabl
autom
design
screen
express
larg
panel
therapeut
candid
use
novel
technolog
also
built
tool
develop
manufactur
assess
complex
molecul
ensur
seamless
integr
data
gener
function
bulk
protein
vector
gener
use
silico
clone
engin
configur
librari
templat
vector
clone
strategi
fulli
annot
silico
protein
molecul
dna
construct
dna
synthesi
verif
support
use
newest
protein
format
molecul
topolog
result
discuss
implement
data
structur
data
handl
system
mirror
complex
nextgener
biolog
molecul
cell
line
design
screen
analyz
result
success
address
workflow
tcr
optim
engin
exemplifi
gener
evalu
panel
engin
tcr
alpha
chain
random
success
support
analysi
select
benefici
mutat
system
also
success
support
workflow
design
gener
panel
tcrbase
bispecif
tcr
coupl
use
autom
molecul
registr
silico
clone
tool
subsequ
captur
express
purif
function
analyt
character
data
cart
cell
front
system
abl
provid
traceabl
work
antibodi
gener
optim
car
engin
eg
attach
scfv
costimulatori
domain
mimic
natur
tcr
complex
engin
tcell
genedata
biolog
platform
success
enabl
autom
increas
data
integr
traceabl
research
develop
work
contribut
toward
industri
excit
novel
approach
cancer
immunotherapi
acknowledg
allison
kurz
gian
andrea
signorel
genedata
basel
switzerland
background
increas
cost
bring
new
drug
market
put
signific
pressur
biopharma
organ
increas
effici
r
process
reduc
cost
organ
need
evalu
potenti
drug
candid
earlier
r
process
elimin
undesir
characterist
focu
promis
candid
design
thorough
test
success
candid
effici
product
new
biolog
entiti
mammalian
cell
line
necessari
main
goal
find
suitabl
cell
line
optim
upstream
downstream
process
condit
lead
satisfactori
product
yield
also
product
desir
biochem
properti
evalu
product
cell
line
process
product
qualiti
attribut
perform
earlier
higher
throughput
increas
number
drug
candid
addit
new
method
molecular
cell
biolog
eg
novel
genom
engin
approach
analyt
eg
process
analyt
techniqu
pat
process
miniatur
autom
promis
make
process
develop
effici
howev
manag
analysi
increas
amount
experiment
data
candid
select
cell
line
process
develop
becom
bottleneck
addit
qualitycompromis
step
biopharma
organ
neg
impact
cost
good
substanti
prolong
drug
candid
time
market
therefor
system
integr
manag
analysi
wellstructur
curat
data
comprehens
integr
molecul
sampl
inform
manufactur
process
paramet
process
product
qualiti
attribut
need
critic
qualiti
attribut
cqa
assess
enabl
along
whole
bioprocess
develop
workflow
includ
cell
line
develop
upstream
downstream
process
develop
well
analyt
formul
develop
materi
method
develop
comprehens
platform
genedata
support
drug
candid
develop
manufactur
assess
bioprocess
develop
platform
captur
structur
cell
line
process
paramet
togeth
analyt
data
cell
line
process
protein
product
protein
analyt
data
track
includ
biolog
data
bioactiv
immunogen
physicochem
properti
properti
includ
glycosyl
chemic
liabil
deamid
oxid
aggreg
stabil
differ
condit
low
ph
low
high
temperatur
solubl
impur
genedata
simplifi
streamlin
labori
manual
process
support
tool
molecul
clone
process
select
furthermor
platform
allow
seamless
integr
laboratori
instrument
statist
softwar
packag
custom
solut
result
conclus
present
use
case
show
identifi
annot
liabil
site
prone
chemic
modif
fig
monitor
cqa
molecul
allow
assess
develop
effici
show
analyt
data
gener
cours
develop
assess
compil
select
best
drug
candid
fig
implement
trafficlight
system
indic
molecul
harbor
issu
case
antibodi
compromis
low
temperatur
repeat
freezethaw
oper
assess
view
also
appli
batch
cell
line
underli
data
visual
graphic
exampl
show
glycan
type
product
obtain
differ
cell
line
clone
gener
cell
line
develop
campaign
molecul
fig
even
though
select
clone
meet
glycosyl
criteria
e
g
afucosyl
galactosyl
sialyl
produc
molecul
harbor
stabil
issu
mention
therefor
attempt
would
need
either
formul
reengin
complimentar
determin
region
cdr
order
provid
develop
drug
candid
acknowledg
allison
kurz
gian
andrea
signorel
genedata
ag
background
environment
process
variabl
often
use
tool
optim
perform
mammalian
cell
cultur
achiev
higher
cell
densiti
high
product
rprotein
qp
manipul
cultur
temperatur
rang
mild
hypothermia
mh
well
differ
glucos
avail
scenario
shown
improv
product
differ
cell
line
howev
manipul
variabl
individu
togeth
concomit
effect
rate
cell
grow
mask
net
respons
exhibit
cell
order
identifi
effect
variabl
taken
advantag
use
chemostat
cultur
materi
method
chemostat
cultur
perform
two
dilut
rate
two
temperatur
three
feed
glucos
concentr
mm
respons
analys
consid
rprotein
product
cell
growth
key
metabolit
rtpa
protein
concentr
determin
immunoassay
trinil
tpa
kit
cell
count
use
hemocytomet
cell
viabil
determin
method
exclus
use
trypan
blue
sigma
usa
glucos
lactat
glutam
determin
enzymat
assay
use
biochem
analys
ysi
yellow
spring
instrument
statist
analysi
result
perform
anova
designexpert
window
result
decreas
cell
densiti
observ
respons
increas
glucos
feed
concentr
regardless
temperatur
specif
growth
rate
case
evalu
maximum
cell
densiti
reach
achiev
cellsml
x
cellsml
respect
fig
increas
glucos
concentr
result
qp
increas
fold
respect
lower
increas
fold
reach
respect
fig
highest
qp
reach
howev
posit
effect
mh
observ
contrast
observ
batch
cultur
behaviour
suggest
low
main
factor
increas
rprotein
product
batch
cultur
expos
mh
condit
specif
consumpt
rate
glucos
significantli
increas
glucos
increas
reduc
mh
fig
specif
product
rate
lactat
qlac
increas
glucos
increas
independ
cultur
temperatur
use
qlac
decreas
increas
glucos
concentr
maximum
consumpt
observ
mm
glucos
fig
lactateglucos
yield
fig
show
relev
chang
yield
show
effici
util
glucos
glucos
concentr
increas
howev
last
behaviour
reflect
increas
rprotein
product
conclus
concentr
glucos
greatest
impact
behaviour
cultur
increas
affect
posit
protein
product
mh
improv
protein
product
cho
cell
produc
tpa
differ
condit
evalu
low
dilut
rate
high
glucos
concentr
impact
posit
protein
product
metabol
exhibit
cell
acknowledg
work
support
fondecyt
fondecyt
refer
yoon
sk
choi
sl
song
jy
effect
cultur
ph
erythropoietin
product
chines
hamster
ovari
cell
grown
suspens
biotechnol
bioeng
lin
chi
huang
z
wen
w
enhanc
protein
express
cell
lower
cultur
temperatur
plo
one
berrio
j
c
relationship
tissu
plasminogen
activ
product
specif
growth
rate
chines
hamster
ovari
cell
cultur
mannos
low
temperatur
biotechnol
lett
liu
z
dai
bone
j
quantit
proteom
analysi
cellular
respons
high
glucos
media
chines
hamster
ovari
cell
biotechnol
prog
background
mammalian
cell
cultur
commonli
use
bioprocess
product
therapeut
recombin
protein
monoclon
antibodi
mab
face
increas
demand
biopharmaceut
fda
initi
process
analyt
technolog
pat
framework
order
encourag
pharmaceut
industri
use
innov
technolog
monitor
real
time
critic
process
paramet
cpp
ensur
final
product
qualiti
one
import
cpp
cell
cultur
bioprocess
specif
growth
rate
direct
indic
cellular
physiolog
state
inde
sensibl
cultur
condit
valu
decreas
cell
unfavour
environ
growth
may
greatli
influenc
mab
product
qualiti
howev
day
onlin
monitor
remain
great
challeng
mammalian
cell
cultur
bioprocess
materi
method
iggproduc
cho
cell
cultur
l
stir
bioreactor
equip
situ
dielectr
spectroscopi
hamilton
oper
condit
fix
rpm
air
satur
ph
permitt
cell
cultur
measur
everi
min
allow
calcul
real
time
vcd
use
previous
establish
linear
correl
model
onlin
estim
develop
base
vcd
predict
cell
mass
balanc
equat
sever
signal
nois
filter
variou
calcul
method
evalu
reach
better
model
stabil
cell
cultur
perform
batch
feedharvest
mode
feedharvest
cultur
consist
sequenti
renew
volum
cultur
medium
follow
differ
strategi
result
studi
propos
innov
methodolog
base
dielectr
spectroscopi
monitor
real
time
cellular
physiolog
state
onlin
estim
specif
growth
rate
cell
model
onlin
estim
develop
cultur
batch
mode
valid
compar
onlin
estim
experiment
one
calcul
end
cultur
model
moment
start
decreas
significantli
indic
cell
longer
exponenti
growth
phase
identifi
critic
moment
demonstr
interest
onlin
estim
develop
model
appli
feedharvest
cultur
medium
renew
perform
critic
moment
indic
model
cultur
compar
tradit
feedharvest
cultur
medium
renew
perform
follow
offlin
measur
glucos
glutamin
found
onlin
strategi
allow
maintain
valu
renew
medium
right
time
valu
vari
lot
use
offlin
strategi
moreov
use
onlin
estim
glycosyl
igg
kept
high
level
throughout
whole
cultur
howev
cultur
use
offlin
strategi
glycosyl
level
decreas
progress
end
cultur
fig
conclus
model
onlin
estim
develop
use
dielectr
spectroscopi
allow
monitor
physiolog
state
cell
cell
cultur
bioprocess
implement
model
feedharvest
cell
cultur
led
better
mab
glycosyl
demonstr
clearli
potenti
methodolog
mab
product
bioprocess
refer
hinz
dc
process
analyt
technolog
pharmaceut
industri
fda
pat
initi
anal
bioanal
chem
lao
ms
toth
effect
ammonium
lactat
growth
metabol
recombin
chines
hamster
ovari
cell
cultur
biotechnol
prog
background
monoclon
antibodi
normal
synthesis
transfect
mammalian
cell
heterogen
mixtur
glycoform
howev
clinic
efficaci
may
depend
upon
singl
glycoform
difficult
isol
develop
effici
method
gener
singl
glycoform
solid
phase
remodel
superior
previou
method
allow
sequenti
seri
enzymat
chang
without
need
intermedi
purif
antibodi
solidphas
bind
expos
antibodi
glycan
enabl
easier
access
transform
glycosyl
enzym
materi
method
antibodi
subject
modif
chimer
humancamelid
monoclon
antibodi
human
monoclon
antibodi
full
size
chimer
antibodi
cetuximab
polyclon
antibodi
obtain
pool
human
serum
antibodi
bound
protein
column
use
condit
typic
mab
purif
fig
wash
nonbound
impur
neutral
ph
buffer
antibodi
subject
enzymat
modif
direct
target
glycan
profil
tabl
antibodi
elut
low
ph
buffer
neutral
glycan
profil
analys
follow
glycan
remov
pngase
f
label
separ
hilichplc
column
result
prior
enzymat
modif
glycan
analysi
antibodi
show
variabl
galactosyl
sialyl
typic
human
ab
includ
distribut
galactosyl
indic
rang
minim
sialyl
glycan
modif
made
antibodi
held
protein
column
accord
procedur
shown
tabl
agalactosyl
glycan
enrich
treatment
singl
addit
galactosidas
neuraminidas
result
agalactosyl
structur
mab
polyclon
antibodi
galactosyl
antibodi
yield
produc
singl
stage
reaction
involv
sialidas
galactosyltransferas
udpgal
breakdown
glycan
trimannosyl
core
accomplish
treatment
agalactosyl
structur
hexosaminidas
produc
yield
structur
small
remaind
sialyl
antibodi
produc
stage
reaction
involv
sialidas
galactosyltransferas
final
treatment
sialyltransferas
presenc
cmpnana
latter
reaction
produc
equimolar
quantiti
monosialyl
disialyl
cetuximab
polyclon
antibodi
result
suggest
human
antibodi
kda
may
limit
sialyl
given
steric
constraint
two
domain
dimer
structur
abil
sialyl
smaller
camelid
antibodi
kda
greater
result
high
level
disialyl
glycan
suggest
steric
constraint
glycosyl
may
lower
sialyl
antibodi
signific
potenti
clinic
import
antinflammatori
activ
conclus
modifi
glycan
antibodi
follow
immobil
affin
ligand
column
allow
enzymat
transform
solid
state
distinct
advantag
equival
transform
solut
enzym
buffer
wash
complet
modif
leav
antibodi
still
attach
affin
ligand
enabl
repeat
round
enzymat
reaction
sequenti
reaction
step
without
need
intermedi
antibodi
purif
antibodi
remov
eventu
column
applic
elut
buffer
desir
glycan
modif
made
sinc
affin
ligand
purif
antibodi
perform
routin
initi
step
purif
cell
cultur
glycan
modif
easili
incorpor
process
enrich
result
antibodi
target
glycoform
enhanc
potenti
therapeut
efficaci
known
specif
glycoform
requir
certain
biolog
effect
acknowledg
financi
support
grate
acknowledg
natur
scienc
engin
research
council
canada
nserc
strateg
network
program
mabnet
refer
spearman
butler
glycosyl
cell
cultur
chapter
cell
engin
vol
anim
cell
cultur
ed
alrubeai
publ
springer
lu
j
sun
p
structur
mechan
high
affin
fcgammari
recognit
immunoglobulin
g
immunolog
review
krahn
n
spearman
meier
dorionthibaudeau
j
mcdougal
patel
tr
de
crescenzo
g
duroch
stetefeld
j
butlerm
inhibit
glycosyl
camelid
antibodi
uniqu
affect
bind
activ
european
journal
pharmaceut
scienc
misba
majood
sneha
arora
contribut
equal
shinjini
bhatnagar
susmita
chaudhuri
niraj
kumar
contribut
equal
background
cho
cell
main
workhors
product
recombin
protein
commerci
scale
improv
product
emin
import
meet
global
demand
afford
cost
cell
drive
microvesicl
inducereduc
cell
prolifer
henc
capabl
regul
bioprocessrel
cellular
phenotyp
like
cell
growth
cell
death
recombin
protein
product
andor
host
cell
protein
composit
mainli
microvesicl
enricheddepriv
specif
protein
base
function
purpos
cellular
origin
recent
microvesicl
purifi
supernat
bladder
cancer
cell
report
enrich
cyclin
antiapoptot
protein
depriv
bax
protein
proapoptot
protein
contribut
toward
immun
program
celldeath
howev
impact
microvesicl
chobas
bioprocess
evalu
yet
therefor
investig
aim
evalu
impact
cell
growth
recombin
protein
product
cho
cell
materi
method
cell
grown
chemicallydefin
proteinfre
cultur
medium
life
shake
flask
differ
fraction
spentmedia
microvesicl
microvesiclefre
spent
media
collect
use
ultracentrifug
method
qualiti
differ
fraction
ensur
use
western
blot
exosom
marker
coomassi
stain
gel
load
control
fig
evalu
impact
cell
growth
cell
seed
microvesicl
microvesiclefre
fraction
collect
logphas
cultur
cell
count
perform
vicel
use
trypanblu
dye
exclus
method
impact
product
cellfre
supernat
collect
microvesicletr
human
igg
secret
cho
cultur
stationaryphas
cultur
respect
control
evalu
use
elisa
microvesicl
collect
media
volum
routin
mainten
cultur
compar
work
volum
microvesiclesupplement
use
experi
result
growth
microvesiclesuppl
cultur
shorter
lagphas
achiev
fold
higher
maximum
cell
densiti
viabl
cellsml
compar
untreat
standard
cultur
viabl
cellsml
maintain
higher
remain
period
batch
cultur
fig
howev
microvesiclefre
fraction
signific
impact
growth
viabil
microvesiclesuppl
cultur
similar
microvesiclefre
media
supplement
also
higher
compar
standard
cultur
suggest
potenti
use
microvesicl
regul
cho
growth
product
cultur
could
possibili
microvesicl
alreadi
report
enrich
cell
growthdeathregul
protein
henc
facilit
cell
growth
also
observ
abund
cell
cycl
regul
includ
cyclin
microvesiclefract
compar
microvesiclefre
spentmedia
laboratori
data
shown
howev
investig
requir
prove
hypothesi
overal
product
human
igg
secret
cho
cell
also
observ
increas
fold
follow
supplement
microvesicl
cultur
without
significantli
affect
percel
product
sinc
microvesiclesupplement
facilit
cell
growth
increas
number
viabl
produc
cell
cultur
could
expect
basi
observ
increas
overal
product
cultur
work
ongo
indepth
explor
potenti
microvesicl
improv
recombin
protein
product
cho
cell
conclus
data
indic
microvesicl
secret
cho
cell
improv
cell
growth
henc
recombinat
protein
product
cultur
therefor
strategi
need
develop
steril
isol
cho
microvesicl
routin
mainten
cultur
supplement
product
cultur
improv
perform
chobas
product
process
acknowledg
translat
health
scienc
technolog
institut
india
scienc
engin
research
board
india
depart
biotechnolog
india
refer
chaudhuri
maurya
p
kaur
tiwari
borth
n
bhatnagar
kumar
n
investig
cho
secretom
potenti
way
improv
recombin
protein
product
bioprocess
j
bioprocess
biotech
yang
l
wu
xh
wang
luo
cl
chen
lx
bladder
cancer
cellderiv
exosom
inhibit
tumor
cell
apoptosi
induc
cell
prolifer
vitro
mol
med
rep
kumar
n
gupta
dg
kumar
maurya
p
tiwari
mathew
b
banerje
haldar
pillai
j
bhatnagar
chaudhuri
explor
packag
microvesicl
proteom
composit
chines
hamster
ovari
secretom
j
bioprocess
biotech
background
glycosyl
profil
recombin
protein
one
import
attribut
defin
product
qualiti
produc
protein
desir
characterist
requir
abil
modifi
target
specif
glycosyl
profil
tradit
approach
modifi
glycosyl
profil
protein
involv
supplement
cultur
compon
improv
galactosyl
experiment
use
supplement
approach
result
dramat
increas
termin
galactosyl
lack
abil
easili
repeatedli
target
specif
glycosyl
profil
use
novel
proprietari
technolog
develop
feed
uniqu
feed
process
maxim
growth
titer
abl
modul
glycan
profil
new
feed
ad
standalon
process
result
signific
shift
maximum
galactosyl
use
uniqu
fedbatch
process
glycantun
also
use
standard
feed
dial
target
glycosyl
profil
process
develop
creat
method
transit
point
use
switch
standard
feed
glycan
modul
feed
time
transit
point
determin
specif
glycan
profil
materi
method
materi
thermo
fisher
scientif
unless
otherwis
indic
cell
cultur
cho
deriv
recombin
cell
express
igg
molecul
grown
media
supplement
lglutamin
anticlump
agent
cultur
condit
maintain
rpm
cell
densiti
viabil
measur
use
counter
beckman
coulter
metabolit
glucos
ammonia
lactat
igg
measur
use
bioht
analyz
roch
flask
start
volum
inocul
viabl
cellsml
medium
c
supplement
efc
andor
c
total
feed
gtc
supplement
day
total
glycan
modul
condit
involv
transit
efc
gtc
cultur
day
glucos
supplement
requir
maintain
concentr
glycan
analysi
igg
purifi
supernat
use
poro
mabcaptur
resin
exchang
phosphat
buffer
use
spin
desalt
plate
mwco
nlink
glycan
digest
pngase
f
quantifi
use
maltohexosemaltopentos
intern
standard
label
acid
atp
describ
laroy
et
al
user
guid
glycan
label
analysi
kit
user
guid
thermo
fisher
scientif
ce
separ
perform
use
appli
result
time
transit
efc
gtc
made
possibl
target
specif
glycosyl
profil
modul
increas
increas
fig
transit
gtc
earli
cultur
result
greater
shift
transit
midway
late
cultur
result
greater
proport
compar
conclus
supplement
base
approach
use
glycosyl
modul
media
compon
modifi
target
specif
glycosyl
profil
prove
difficult
approach
abl
increas
termin
galactosyl
lack
abil
fine
tune
glycan
profil
could
result
numer
round
titrat
experi
target
specif
glycan
profil
would
like
remain
inconsist
cell
line
cultur
media
feed
process
scale
develop
uniqu
process
made
possibl
predict
target
specif
glycosyl
profil
transit
standard
feed
glycantun
allow
precis
target
glycan
profil
transit
glycantun
earli
cultur
result
increas
shift
transit
late
cultur
result
increas
decreas
refer
laroy
w
contrera
r
callewaert
n
glycom
map
dna
sequenc
equip
natur
protocol
background
surfac
activ
agent
surfact
commonli
use
cell
cultur
medium
compon
reduc
shear
stress
nonstat
suspens
cultur
despit
prefer
applic
poloxam
ongo
discuss
within
cell
cultur
commun
surfactantrel
process
deviat
furthermor
surfact
shown
interact
polyplex
well
polym
nanoparticl
within
variou
applic
eg
transfect
encapsul
better
understand
relat
mechan
action
facilit
find
altern
compon
progress
cell
cultur
media
formul
materi
method
hek
cell
line
cultiv
xell
chemic
defin
transfect
media
hek
tf
cho
tf
plain
baffl
shake
flask
evalu
impact
surfact
shear
stress
surfact
also
evalu
regard
impact
transient
gfp
express
via
flow
cytometri
localis
poloxam
hek
cultur
investig
use
fluoresceinlabel
blue
lysosom
deep
red
cell
membran
confoc
microscopi
sec
measur
structur
analys
perform
jcsm
jena
result
growth
perform
precultur
batch
curv
plain
shake
flask
show
differ
among
test
surfact
lot
thereof
cell
densiti
reach
cellsml
fig
b
experi
hek
cell
elev
power
input
baffl
shake
flask
reveal
distinct
differ
show
best
perform
peak
viabl
cell
densiti
reach
lot
b
compar
plain
shake
flask
lot
c
significantli
lower
peak
vial
cell
densiti
cellsml
fig
similar
transient
transfect
effici
mean
fluoresc
transfect
cell
independ
appli
surfact
lot
thereof
indic
major
impact
respect
poloxam
fig
interestingli
experi
use
fluoresceinlabel
show
timedepend
uptak
hek
cell
visual
track
reveal
endocyt
uptak
poloxam
cell
increas
signal
h
colocalis
cell
membran
lysosom
sec
fig
analys
show
differ
test
poloxam
especi
test
lot
reveal
notabl
deviat
low
molecular
weight
fraction
peak
fig
compar
poloxam
conclus
cultur
subject
vari
level
shear
stress
show
distinct
growth
differ
depend
use
poloxam
experi
plain
shake
flask
show
differ
growth
cultiv
elev
shear
stress
baffl
shake
flask
result
lower
peak
viabl
cell
densiti
lot
remain
unclear
whether
explain
differ
membran
protect
activ
alon
mechan
occur
cellular
uptak
contribut
effect
especi
test
lot
sec
surfact
show
differ
low
molecular
weight
fraction
fraction
mainli
repres
polyethylen
oxid
peo
reveal
nmr
like
remnant
synthesi
observ
indic
use
differ
poloxam
lot
thereof
care
evalu
especi
elev
shear
stress
experi
focu
investig
distinct
sec
fraction
poloxam
acknowledg
would
like
thank
german
feder
ministri
educ
research
bmbf
vectura
fund
background
transient
gene
express
tge
routin
perform
hek
cell
line
high
transfect
cho
chines
hamster
ovari
cell
line
proven
challeng
modern
tge
procedur
howev
scalabl
onestep
solut
highli
desir
media
compon
iron
essenti
cultur
growth
chelat
other
inhibit
polyethylenimin
pei
mediat
transfect
polym
shown
enhanc
effici
electropor
studi
variou
media
compon
investig
find
medium
allow
effici
tge
cho
cell
line
materi
method
chot
suspens
cell
line
investig
regard
growth
tge
differ
medium
variant
determin
transfect
effici
cell
analys
via
flow
cytometri
h
transfect
gfp
express
plasmid
use
linear
pei
transfect
reagent
recombin
monoclon
antibodi
express
batch
process
monitor
hplc
cotransfect
cell
two
plasmid
carri
gene
igg
heavi
igg
light
chain
express
respect
result
ammonium
iron
iii
citrat
iron
iii
chlorid
wellknown
inhibit
effect
studi
reveal
similar
impact
iron
ii
sulfat
heptahydr
ammonium
iron
iii
sulfat
dodecahydr
transfect
iron
iii
sulfat
heptahydr
complet
prevent
transfect
wherea
ammonium
iron
ii
sulfat
dodecahydr
reduc
effici
fig
aurintricarboxyl
acid
endonucleas
inhibitor
enhanc
use
eg
salivari
gland
transfect
polyvinylpyrrolidon
polym
benefici
electropor
found
neg
impact
peimedi
transfect
cho
cell
anoth
test
polym
enhanc
growth
well
transfect
effici
use
strong
chelat
led
high
transfect
effici
impair
cell
growth
base
result
independ
substanc
test
medium
formul
modifi
addit
weak
chelat
compon
includ
vitamin
differ
osmol
mosmolkg
mosmolkg
test
final
formul
major
impact
seen
neither
transfect
effici
viabil
day
posttransfect
final
cho
tf
medium
formul
support
high
cell
growth
final
test
cho
cell
line
peak
viabl
cell
densiti
cellsml
batch
cultiv
overal
cultiv
time
day
fig
transfect
effici
posttransfect
transient
gfp
express
growth
perform
transient
mab
express
similar
final
mab
titer
rang
mgl
reach
cho
cell
line
mgl
achiev
cho
cell
line
conclus
compon
ammonium
iron
iii
citrat
iron
iii
chlorid
iron
ii
sulfat
heptahydr
ammonium
iron
iii
sulfat
dodecahydr
reduc
complet
prevent
transfect
iron
composit
requir
care
optimis
support
high
transfect
effici
suffici
growth
cho
cell
line
similarli
composit
concentr
polym
chelat
test
care
order
balanc
oppos
effect
transfect
cell
growth
final
possibl
succes
develop
high
perform
transfect
medium
wherebi
possibl
counterbal
contrari
effect
present
substanc
improv
process
might
achiev
adapt
protocol
result
shown
base
simpl
precomplex
dnapei
moreov
product
yield
could
potenti
increas
use
feed
temperatur
shift
commonli
use
enhanc
eg
valproic
acid
refer
eberhardi
sr
radzniak
l
liu
zhong
iron
iii
citrat
inhibit
polyethyleniminemedi
transient
transfect
chines
hamster
ovari
cell
serumfre
medium
cytotechnolog
introduct
scale
cell
cultur
process
essenti
part
develop
typic
approach
scale
perform
keep
critic
process
paramet
constant
throughout
complet
bioreactor
rang
lead
nonbenefici
result
either
high
low
end
rang
instanc
specif
power
input
pv
might
result
good
agit
product
scale
wherea
lead
nonturbul
mix
behavior
process
develop
scale
overcom
issu
new
approach
easi
scale
procedur
develop
util
function
approach
agit
scale
base
individu
function
valuebas
map
independ
bioreactor
scale
materi
method
process
insight
inform
establish
either
doe
process
investig
exist
experi
process
platform
directli
formal
set
map
transform
bioprocess
valu
perceiv
benefit
bioreactor
scale
paramet
eg
stir
gass
chosen
maxim
product
result
util
function
model
cho
fedbatch
process
trial
compris
cho
cell
line
transfect
produc
human
antibodi
chemic
defin
media
system
use
process
includ
cell
line
medium
feed
strategi
design
develop
sartoriu
stedim
cellca
aim
gass
scaleup
achiev
similar
cell
densiti
addit
pure
oxygen
start
flexsaf
bag
oxygen
sparg
via
micro
sparger
part
combi
sparger
system
use
ring
sparger
hole
face
initi
air
flow
rate
set
oxygen
transfer
rate
kla
correspond
agit
rate
volum
process
engin
character
paramet
determin
accord
dechema
guidelin
use
util
function
discret
agit
rate
determin
tabl
result
discuss
util
function
led
discret
agit
rate
homogen
mix
also
turbul
flow
pattern
suitabl
specif
power
input
guarante
initi
gass
rate
air
suppli
enough
oxygen
x
cellsml
bioreactor
due
use
scale
method
growth
pattern
bioreactor
scale
compar
peak
viabl
cell
densiti
vcd
x
cellsml
achiev
viabil
point
harvest
scale
final
product
concentr
accept
rang
gl
product
qualiti
attribut
show
compar
complet
bioreactor
rang
fig
harvest
criteria
day
gave
combin
viabil
product
concentr
made
easi
process
cell
broth
cell
remov
downstream
step
conclus
process
implement
cho
product
system
express
mab
success
perform
use
util
function
cell
growth
product
product
qualiti
compar
complet
bioreactor
rang
refer
tai
et
al
effici
highthroughput
biolog
process
character
biotechnolog
progress
doi
zahnow
c
et
al
scaleup
stir
singleus
bioreactor
famili
poster
esact
meet
background
endoplasm
reticulum
er
central
part
secretori
pathway
eukaryot
cell
respons
control
qualiti
secret
resid
protein
regul
protein
transloc
protein
fold
earli
posttransl
modif
number
physiolog
condit
oxid
stress
hypoglycemia
acidosi
thermal
instabl
disturb
er
function
trigger
er
stress
prolong
er
stress
induc
apoptot
cell
death
oxid
stress
natur
accumul
er
result
mitochondri
energi
metabol
protein
synthesi
disturb
er
function
er
respons
protein
synthesi
qualiti
control
secret
protein
er
homeostasi
well
maintain
oxid
stress
induc
ad
recombin
chines
hamster
ovari
rcho
cell
cultur
reduc
cell
growth
monoclon
antibodi
mab
product
galactosyl
form
mab
dosedepend
manner
antioxid
reduc
oxid
stress
level
suppress
apoptot
cell
death
scaveng
oxygen
free
radic
inhibit
chain
reaction
oxid
detoxifi
peroxid
howev
despit
import
mass
product
mab
studi
effect
antioxid
product
qualiti
mab
rcho
cell
cultur
fulli
substanti
materi
method
find
effect
antioxid
rcho
cell
cultur
six
differ
antioxid
includ
baicalein
use
wide
mammalian
cell
cultur
evalu
chemic
supplement
two
differ
rcho
cell
line
produc
mab
plate
batch
fedbatch
cultur
perform
shake
flask
supplement
baicalein
show
best
effect
cultur
perform
among
antioxid
reactiv
oxygen
speci
ro
er
stress
level
measur
studi
effect
baicalein
mab
product
qualiti
result
among
antioxid
baicalein
show
best
mab
product
perform
addit
baicalein
significantli
reduc
express
level
bip
chop
along
reduc
ro
level
suggest
oxid
stress
accumul
cell
reliev
use
baicalein
result
addit
baicalein
batch
cultur
result
increas
maximum
mab
concentr
mmc
maintain
galactosyl
mab
fig
tabl
likewis
addit
baicalein
fedbatch
cultur
result
increas
mmc
maintain
galactosyl
mab
conclus
oxid
stress
neg
affect
product
galactosyl
mab
rcho
cell
cultur
among
variou
antioxid
test
studi
baicalein
show
best
mab
product
perform
batch
fedbatch
cultur
rcho
cell
baicalein
addit
significantli
enhanc
mab
product
maintain
galactosyl
form
mab
thu
baicalein
effect
antioxid
use
rcho
cell
cultur
improv
mab
product
acknowledg
research
support
danish
council
independ
research
technolog
product
scienc
ftp
novo
nordisk
foundat
ministri
scienc
ict
futur
plan
basic
core
technolog
develop
program
ocean
polar
region
nrf
refer
ruggiano
foresti
carvalho
p
qualiti
control
erassoci
degrad
protein
qualiti
control
beyond
j
cell
biol
ah
pharmacolog
target
endoplasm
reticulum
stress
signal
cancer
biochem
pharmacol
urra
h
dufey
e
lisbona
f
rojasrivera
hetz
c
er
stress
reach
dead
end
biochim
biophi
acta
birben
e
sahin
um
sackesen
c
erzurum
et
al
oxid
stress
antioxid
defens
world
allergi
organ
j
shimazaki
h
watanab
k
veeraveedu
pt
harima
et
al
antioxid
edaravon
attenu
erstressmedi
cardiac
apoptosi
dysfunct
rat
autoimmun
myocard
free
radic
re
background
product
mani
biopharmaceut
eg
antibodi
protein
diagnost
therapeut
purpos
requir
cultiv
mammalian
cell
line
demand
respect
variou
aspect
complex
cell
metabol
variabl
cell
behavior
scale
depend
influenc
chang
cultiv
condit
medium
composit
etc
although
increas
number
measur
paramet
avail
part
routin
util
industri
cell
cultur
process
correspond
seed
train
nevertheless
data
base
grow
statist
investig
data
gain
import
process
data
easili
access
context
industri
cell
cultiv
consid
complex
requir
eg
fedbatch
control
seed
train
design
furthermor
cultiv
strategi
adapt
new
product
cell
line
clone
well
differ
product
plant
transfer
process
one
approach
encount
variabl
includ
actual
inform
process
data
analysi
adapt
modelassist
control
method
two
softwar
tool
enabl
adapt
modelassist
control
appli
unstructur
unsegreg
model
develop
implement
use
winer
fortran
one
tool
fedbatch
control
anoth
one
seed
train
simul
optim
result
one
key
element
adapt
modelassist
control
underli
process
model
order
provid
adapt
charact
model
paramet
easili
identifi
routin
cultiv
data
avail
seed
train
fedbatch
without
addit
sophist
measur
therefor
usag
unstructur
unsegreg
model
recommend
exampl
unstructur
unsegreg
cell
cultur
model
adapt
modelassist
control
one
exampl
describ
cell
growth
cell
death
uptak
substrat
product
metabolit
via
first
order
system
ordinari
differenti
equat
monodtyp
kinet
shown
tabl
mathemat
model
includ
cell
specif
model
paramet
b
applic
exampl
contribut
illustr
usag
model
two
applic
control
calcul
fedbatch
feed
trajectori
softwar
tool
seed
train
design
analysi
optim
implement
shown
case
concern
structur
openloop
control
sequenc
fig
fedbatch
control
fig
seed
train
simul
optim
implement
divid
two
main
part
adapt
cell
line
ii
openloop
control
sequenc
adapt
cell
line
base
correspond
mathemat
cell
cultur
model
model
paramet
must
identifi
reflect
cell
line
cell
behaviour
ii
openloop
control
sequenc
fedbatch
control
base
model
priori
identifi
model
paramet
optim
cycl
includ
get
data
run
cultiv
autom
adapt
model
paramet
predict
futur
process
cours
comput
optim
feed
profil
realiz
ii
b
openloop
control
sequenc
seed
train
simul
optim
use
model
priori
identifi
model
paramet
start
concentr
valu
tempor
concentr
cours
predict
first
scale
subsequ
point
time
passag
start
valu
next
scale
comput
ad
passag
strategi
seed
train
condit
medium
concentr
predict
follow
scale
obtain
iter
integr
feedback
process
term
cultiv
data
enabl
increas
predict
accuraci
respond
possibl
chang
cell
behaviour
conclus
process
design
optim
eg
regard
seed
train
fedbatch
realiz
adapt
modelassist
softwar
tool
use
unstructur
unsegreg
model
enabl
feedback
process
via
routin
cultiv
data
allow
adapt
divers
circumst
differ
cell
line
product
cultiv
condit
plant
configur
etc
refer
r
et
al
advanc
process
control
strategi
bioreactor
book
chapter
pp
current
develop
biotechnolog
bioengin
bioprocess
bioreactor
control
elsevi
isbn
kern
plata
barrada
r
frahm
b
modelbas
strategi
cell
cultur
seed
train
layout
verifi
lab
scale
cytotechnolog
aug
doi
epub
mar
frahm
b
seed
train
optim
cell
cultur
chapter
anim
cell
biotechnologymethod
protocol
edit
edit
r
springerhumana
press
isbn
isbn
ebook
background
ex
vivo
expans
human
primari
cell
consider
scientif
medic
interest
eg
cell
therapi
current
time
consum
requir
addit
massiv
amount
stimuli
recent
show
human
leukemia
cell
jurkat
cell
expand
tissu
like
cell
densiti
cell
polyelectrolyt
capsul
signific
advantag
great
mechan
stabil
good
biocompat
good
mass
transfer
properti
character
capsul
base
sodium
cellulos
sulfatepoli
diallyldimethyl
ammonium
chlorid
scspdadmac
present
possibl
cultiv
human
cell
freshli
isol
blood
high
densiti
similar
semiperm
polyelectrolyt
microcapsul
within
less
day
materi
method
cell
encapsul
semiperm
scspdadmac
polyelectrolyt
microcapsul
confin
alginatepolyllysin
pll
bead
standard
approach
cell
immobil
permeabl
microcapsul
estim
use
dextranbas
molecular
weight
standard
kda
vitamin
kda
gentl
digest
endocellulas
allow
easi
releas
cell
capsul
cell
growth
cytokin
product
phenotyp
measur
nonencapsul
encapsul
cell
grown
standard
cultur
condit
moreov
analyz
interplay
secret
cytokin
sc
within
capsul
put
influenc
cell
growth
result
cell
mix
cellulos
sulfat
solut
physiolog
condit
safe
trap
within
liquid
core
capsul
format
encapsul
cell
reach
cell
densiti
x
cell
wherea
cell
confin
alginatepl
bead
nonencapsul
one
reach
x
cell
x
cell
ml
respect
one
major
advantag
polyelectrolyt
microcapsul
mm
low
mwco
kda
fig
restrict
permeabl
allow
condit
capsul
core
autocrin
factor
turn
permit
use
basal
cell
cultur
medium
instead
expens
cell
special
media
henc
necessit
high
amount
reduc
cultiv
cost
moreov
coencapsul
benefici
effect
growth
kinet
case
fig
evid
present
sc
use
form
polyelectrolyt
microcapsul
specif
adsorb
tabl
cytokin
provid
essenti
signal
tcell
prolifer
differenti
therefor
postul
sc
use
encapsul
biomimet
properti
creat
artifici
extracellular
matrix
mimick
heparin
sulfat
turn
posit
affect
cell
prolifer
via
transpresent
fig
conclus
primari
lymphocyt
expand
appropri
condit
outsid
bodi
latter
cell
growexpand
specif
environ
cell
tightli
pack
lead
multipl
contact
manifold
interact
extracellular
matrix
ex
vivo
suspens
cultur
dilut
cell
provid
microenviron
microcapsulesbas
cultiv
system
present
cell
suspend
viscou
scssolut
low
molecular
weight
cut
surround
polyelectrolyt
membran
assur
typic
signal
molecul
produc
cell
retain
thu
facilit
condit
cellular
microenviron
nutrient
metabolit
pass
expens
addit
coencapsul
expans
longer
requir
special
tcell
media
moreov
sc
seem
biomimet
properti
repres
artifici
extracellular
matrix
mimick
heparin
sulfat
consid
describ
method
may
appropri
altern
expand
cell
creat
local
microenviron
mimick
vivo
condit
acknowledg
research
support
dfg
deutsch
forschungsgemeinschaft
grant
bu
fr
refer
werner
schmoldt
hilbrig
f
v
raup
zambrano
k
h
buchholz
r
freitag
r
high
cell
densiti
cultiv
human
leukemia
cell
jurkat
cell
semiperm
polyelectrolyt
microcapsul
eng
life
sci
kaiser
p
werner
v
h
buchholz
r
freitag
r
cell
retent
encapsul
cultiv
jurkat
cell
fix
fluidiz
bed
reactor
biotechnol
bioeng
boyman
sprent
j
role
homeostasi
activ
immun
system
nat
rev
immunol
v
werner
kaiser
p
freitag
r
creat
biomimet
microenviron
ex
vivo
expans
primari
human
macromol
biosci
doi
background
digit
manufactur
dm
heighten
product
robust
exist
process
facil
also
enabl
effici
develop
previous
unmanag
product
process
provid
basi
wave
innov
dm
resid
onlin
sourc
continu
optim
process
perform
reli
upon
comprehens
realtim
interfac
human
machin
sourc
inform
one
central
system
legaci
distribut
control
system
dc
supervisori
control
data
acquisit
scada
integr
interconnect
realtim
access
diverg
sourc
inform
promis
deep
analysi
predict
lead
shorten
product
cycl
advanc
process
control
comprehens
analysi
extend
beyond
oper
perform
data
product
floor
data
drive
activ
raw
materi
secur
suppli
so
busi
continu
manag
system
bcm
materi
method
digit
biomanufactur
db
view
yet
anoth
larger
embodi
digit
biotechnolog
db
similar
digit
manufactur
promot
innov
manufactur
biolog
use
thing
comput
aid
design
manufactur
verif
deep
process
analysi
use
softwar
sensor
fig
howev
fact
live
compon
cell
involv
process
put
distinctli
differ
flavor
system
employ
desir
use
distinct
term
distinguish
term
bioproduct
biopharmacolog
db
address
mani
uniqu
aspect
biologicallybas
activ
result
reason
biotech
biopharma
industri
lag
behind
sector
automot
regard
transform
digit
manufactur
complex
dissip
natur
biolog
system
ii
distribut
heterogen
data
iii
limit
atlin
onlin
data
sourc
howev
cost
genom
sequenc
omic
data
gener
comput
resourc
decreas
rapidli
time
process
analyt
technolog
comput
power
predict
model
well
data
manag
infrastructur
greatli
improv
tabl
remov
roadblock
use
limit
approach
chang
pave
way
transform
bioeconomi
industri
base
digit
knowledg
new
optim
manufactur
technolog
continu
biomanufactur
bioprint
actual
demand
interfac
mani
sourc
inform
deep
data
analysi
includ
softwar
sensor
metabol
flux
modelbas
predict
digit
biomanufactur
applic
predict
model
bioprocess
optim
greatli
improv
establish
platform
final
lead
massiv
increas
mechanist
process
understand
conclus
four
essenti
benefit
result
increas
bioprocess
understand
develop
control
db
first
personnel
reliev
mani
manual
repetit
task
second
strateg
plan
oper
effici
improv
third
see
realtim
optim
endtoend
manufactur
base
highvalu
criteria
project
product
qualiti
profit
fourth
enabl
previous
unmanag
oper
creat
innov
solut
refer
whitford
w
era
digit
biomanufactur
bioprocess
intern
background
cellcultur
paramet
ccp
ph
may
continu
measur
onlin
subject
realtim
autom
adjust
eg
autom
addit
base
prevent
ph
drop
low
effici
method
maintain
paramet
within
specifi
limit
type
control
constraint
variabl
within
predefin
limit
provid
inform
betweenbatch
variabl
process
onlin
measur
ccp
provid
timedepend
curv
present
one
transit
differ
type
transit
observ
process
shift
state
adjust
need
keep
ccp
rang
state
typic
ccp
drift
away
limitth
process
shift
state
adjust
need
one
instanc
drift
ccp
reach
lower
upper
limit
accept
rang
timepoint
transit
take
place
call
changepoint
aspect
process
control
multipl
changepoint
case
approach
allow
earli
termin
run
show
earli
late
first
changepoint
materi
method
identif
changepoint
posit
base
simpl
rule
rather
complex
statist
model
keep
identif
methodolog
simpl
changepoint
identifi
multivari
bayesian
model
adjust
appropri
transform
data
predict
region
obtain
use
control
limit
result
result
obtain
case
shown
fig
point
righthand
graph
repres
new
batch
red
triangl
repres
fail
batch
appear
control
strategi
fail
identifi
fail
batch
two
reason
consid
limit
predict
region
establish
base
point
small
sampl
size
like
insuffici
definit
control
chartth
test
batch
produc
set
point
control
chart
use
stabl
process
ran
condit
order
realli
relev
work
base
avail
histor
data
never
ideal
situat
conclus
suggest
strategi
offer
simpl
approach
monitor
betweenbatch
behavior
cellcultur
limit
defin
approach
quit
straightforward
usabl
nonstatistician
howev
strategi
type
must
base
suffici
number
batch
definit
control
limit
order
good
estim
batchto
batch
variabl
refer
krishnamoorthi
k
mathew
multivari
normal
distribut
statist
toler
region
theori
applic
comput
edit
edit
bald
cressi
n
fitzmauric
g
johnston
molenbergh
g
scott
hoboken
john
wiley
son
inc
background
rabi
zoonot
viral
diseas
mortal
close
efficaci
treatment
avail
postexposur
vaccin
recommend
individu
contact
viru
hand
common
sourc
viru
transmiss
saliva
infect
anim
mostli
dog
wherebi
mass
vaccin
pet
way
reduc
human
infect
context
avail
human
veterinari
vaccin
critic
group
previous
develop
effect
vlpbase
rabi
vaccin
candid
produc
high
densiti
cell
cultur
serum
free
medium
sfm
one
aim
vaccin
product
process
achiev
good
product
low
cost
per
dose
mainli
case
vaccin
anim
use
case
sfm
one
princip
expens
work
show
adapt
produc
clone
nonexpens
inhous
develop
cultur
medium
order
reduc
global
cost
process
therefor
price
per
dose
experiment
approach
first
compar
direct
sequenti
adapt
protocol
produc
clone
commerci
sfm
safc
new
formul
sfm
minimum
essenti
medium
develop
laboratori
specif
rvvlp
product
new
formul
call
rvpm
rabi
vaccin
product
medium
specif
product
rvvlp
cultur
supernat
measur
sandwich
elisa
use
intern
standard
rabi
vaccin
quantifi
glycoprotein
content
nibsc
express
elisa
unit
per
ml
evalu
media
product
rabi
vaccin
use
stir
tank
bioreactor
oper
continu
mode
biostat
qplu
sartoriu
product
daili
evalu
elisa
obtain
harvest
analys
nih
potenc
test
rabi
vaccin
result
discuss
adapt
process
suspens
cultur
without
aggreg
clump
obtain
specif
growth
rate
lower
maximum
cell
densiti
rvpm
reach
achiev
compar
sfm
reach
cell
densiti
batch
mode
specif
product
per
cell
maintain
obtain
valu
clone
cultur
sfm
rvpm
respect
take
account
produc
clone
chang
directli
one
medium
without
lag
phase
cell
damag
rvpm
maximum
cell
densiti
reach
lower
medium
propos
analys
high
cell
densiti
perfus
mode
continu
cultur
bioreactor
therefor
perform
two
cultur
parallel
compar
efficaci
media
formul
perfus
shown
fig
obtain
similar
cultur
perform
bioreactor
rvvlp
commerci
sfm
rvpm
respect
harvest
evalu
nih
potenc
test
obtain
rabi
vaccin
potenc
cultur
minimum
potenc
requir
anim
vaccin
thu
result
obtain
repres
interest
advanc
optim
vaccin
product
process
sinc
use
new
medium
formul
repres
reduct
total
cost
reflect
consider
reduct
price
vaccin
dose
refer
jackson
recoveri
rabi
call
arm
j
neurol
sci
brigg
role
vaccin
rabi
prevent
curr
opin
virol
meslin
f
brigg
elimin
canin
rabi
princip
sourc
human
infect
take
antivir
re
fontana
kratj
r
etcheverrigaray
prieto
c
rabi
viruslik
particl
express
cell
vaccin
fontana
kratj
r
etcheverrigaray
prieto
c
immunogen
viruslik
particl
continu
express
mammalian
cell
veterinari
rabi
vaccin
candid
vaccin
background
vaccin
one
power
effect
health
invent
ever
develop
provid
tremend
econom
societ
valu
yet
sever
factor
hinder
comprehens
immun
coverag
tradit
method
biolog
product
base
stainless
steel
bioreactor
allow
pharmaceut
compani
achiev
economi
scale
limit
high
capit
expenditur
approach
stifl
manufactur
innov
lack
longterm
costeffect
sustain
current
innov
cut
biolog
product
cost
revolution
mainstream
use
biolog
treatment
focus
develop
fast
potent
costeffect
vaccin
product
univercel
mission
make
biolog
afford
initi
paradigm
shift
target
innov
singleus
manufactur
platform
incorpor
bioprocess
continu
oper
univercel
employ
process
intensif
use
high
volumetr
product
bioreactor
unit
step
integr
coupl
usp
dsp
continu
oper
object
downscal
highproduct
process
costeffect
manufactur
solut
result
microfacil
easilydeploy
develop
countri
break
entri
barrier
biomanufactur
fig
manufactur
distribut
advanc
central
distribut
forese
afford
treatment
obtain
via
suppli
local
popul
local
product
unit
materi
method
benchscal
fixedb
bioreactor
carrier
made
pure
nonwoven
hydrophil
pet
fiber
vero
cell
grown
serumfre
serum
contain
media
attenu
polio
strain
cell
nuclei
carrier
count
crystal
violet
method
polio
viru
product
estim
elisa
assay
dantigen
content
result
cultiv
vero
cell
medium
serum
serumfre
medium
carri
benchscal
compact
fixedb
bioreactor
determin
cultur
condit
result
highest
growth
rate
highest
cell
biomass
carrier
viru
product
cell
inocul
infect
midexponenti
phase
follow
complet
media
exchang
viral
infect
took
place
serumfre
media
inlin
clarif
purif
target
perform
step
maximum
one
two
without
intermediari
diafiltr
configur
measur
vero
cell
reach
cell
densiti
pdlday
serumcontain
media
new
facil
expect
manufactur
type
viral
vaccin
low
cost
could
deploy
site
manufactur
emerg
countri
kill
two
bird
cost
manufactur
distribut
one
stone
present
featur
descript
engin
develop
also
preliminari
result
cell
growth
infect
product
qualiti
well
descript
cog
calcul
conclus
univercel
develop
disrupt
polio
vaccin
manufactur
technolog
exceed
expect
compar
tradit
method
achiev
superior
result
via
allinon
solut
simpl
scalabl
fullydispos
vaccin
product
platform
result
longterm
costeffect
flexibl
sustain
upstream
downstream
inactiv
step
take
place
within
close
system
equip
contain
low
footprint
isol
creat
confin
area
polio
viru
handl
facilit
deploy
microfacilitiesthi
lead
dramat
reduct
capit
invest
time
requir
develop
increas
product
capacityin
conclus
simpl
eleg
solut
industri
product
human
vaccin
low
cost
microfacil
make
polio
vaccin
avail
acknowledg
univercel
grant
bill
melinda
gate
foundat
develop
breakthrough
vaccin
manufactur
platform
background
vector
vaccin
base
modifi
vaccinia
viru
ankara
mva
report
stabli
maintain
larg
transgen
safe
immunogen
toler
preexist
immun
mva
usual
produc
primari
chicken
embryo
fibroblast
continu
cell
line
investig
versatil
substrat
previous
report
develop
continu
suspens
cell
line
crpix
deriv
muscovi
duck
effici
product
process
mva
chemic
defin
media
process
allow
isol
hitherto
undescrib
genotyp
induc
fewer
syncytia
adher
cultur
replic
higher
infecti
titer
extracellular
volum
suspens
cultur
replic
remain
restrict
predominant
avian
cell
import
properti
mva
vector
materi
method
homolog
recombin
crpix
cell
use
gener
virus
variou
express
cassett
delet
site
iii
combin
differenti
point
mutat
backbon
wildtyp
viru
recombin
virus
plaquepurifi
success
introduct
mutat
confirm
sequenc
specif
design
restrict
fragment
length
polymorph
rflp
virus
analyz
serial
passag
diagnost
pcr
accross
delet
site
replic
kinet
plaqu
phenotyp
electron
microscopi
genom
investig
anchor
pcr
long
pcr
result
effici
spread
recombin
virus
fig
could
map
point
mutat
one
gene
howev
although
carri
mutat
three
structur
protein
detect
obviou
differ
wildtyp
electron
microscopi
fig
replac
left
viral
telomer
right
counterpart
surpris
result
new
studi
fig
extens
rearrang
affect
viral
genom
also
increas
area
complementar
two
telomer
recombin
site
precis
locat
shown
via
analysi
earlier
subsequ
passag
stabl
properti
variou
virus
includ
larger
dual
gfp
express
cassett
serial
passag
least
although
genotyp
advantag
replic
genom
genet
marker
wildtyp
stabli
maintain
passag
recombin
virus
independ
wildtyp
backbon
conclus
confirm
previou
result
suggest
replic
effici
singlecel
suspens
abl
connect
properti
mutat
structur
protein
surfac
virion
also
found
differ
wildtyp
mva
recombin
left
right
viral
telomer
due
event
sever
gene
encod
left
terminu
delet
wherea
gene
dosi
origin
encod
right
terminu
may
increas
current
know
much
variou
point
mutat
chang
genom
structur
combin
explain
improv
replic
sever
affect
gene
report
literatur
impact
interact
mva
host
would
expect
vivo
studi
may
reveal
addit
novel
properti
extrem
import
distinct
earlier
studi
one
concern
sourc
virus
investig
plaquepurifi
virus
confirm
high
genet
genom
stabil
mva
differ
express
cassett
insert
delet
site
iii
diagnost
rflp
pcr
variou
site
genom
within
viral
telomer
remain
unchang
throughout
least
serial
passag
independ
whether
recombin
virus
wildtyp
backbon
character
refer
jordan
vo
beilfuss
neubert
breul
sandig
v
avian
cell
line
design
product
highli
attenu
virus
vaccin
jordan
northoff
thiel
hartmann
horn
k
bernhardt
h
oehmk
von
horsten
h
rebeski
hinrichsen
l
zelnik
v
mueller
w
sandig
v
chemic
defin
product
process
highli
attenu
poxvirus
biol
j
int
assoc
biol
stand
jordan
horn
john
k
sandig
v
genotyp
modifi
vaccinia
ankara
mva
facilit
replic
suspens
cultur
chemic
defin
medium
virus
kremer
volz
kreijtz
jhcm
fux
r
lehmann
mh
sutter
g
easi
effici
protocol
work
recombin
vaccinia
viru
mva
method
mol
biol
clifton
nj
background
transient
gene
express
system
use
polyethylenimin
pei
consid
fast
flexibl
costeffici
recombin
protein
product
transfect
effici
depend
differ
factor
one
type
media
product
media
support
cell
growth
protein
product
high
transfect
effici
te
mediat
pei
therefor
media
select
transfect
follow
feed
product
media
improv
te
protein
product
two
differ
transfect
strategi
compar
convent
transfect
prepar
polyplex
plasmid
pdna
pei
interact
transfect
insitu
transfect
direct
addit
cell
suspens
polyplex
form
spontan
materi
method
cell
seed
hr
chomac
cd
media
transfect
transfect
time
point
equal
amount
cell
resuspend
media
type
transfect
appli
either
insitu
convent
polyplex
prepar
mm
nacl
incub
min
media
addit
perform
hour
posttransfect
hpt
media
type
transfect
condit
illustr
tabl
result
media
screen
result
exhibit
highest
transfect
effici
around
transfect
cell
optimem
medium
come
along
low
cell
growth
viabil
improv
transfect
effici
basic
paramet
includ
cell
densiti
pdna
pei
concentr
vari
higher
transfect
effici
reach
reduc
media
accordingli
increas
cell
densiti
pei
pdna
concentr
transfect
optim
result
show
transfect
cell
optimem
transfect
medium
hour
follow
addit
chomac
cd
product
medium
enhanc
transfect
cell
count
cell
viabil
transfect
effici
te
increas
coincid
increas
viabl
cell
concentr
vcc
compars
transfect
cultiv
optimem
media
alon
fig
convent
insitu
method
success
transfect
similar
high
te
shown
fluoresc
microscop
imag
fig
insitu
transfect
show
superprior
suspens
cell
transfect
concern
reduct
handl
step
one
step
compar
convent
way
two
step
insitu
transfect
avoid
optim
step
requir
incub
period
prepar
transfect
polyplex
requir
higher
amount
pdna
pei
convent
way
shown
tabl
acknowledg
would
like
thank
daad
phd
grant
thank
institut
technic
chemistri
leibniz
univers
hannov
support
requir
facil
refer
pham
pl
kamen
duroch
largescal
transfect
mammalian
cell
fast
product
recombin
protein
mol
biotechnol
meleadi
p
heterolog
protein
product
cho
cell
vol
baldi
l
hacker
dl
adam
wurm
fm
recombin
protein
product
largescal
transient
gene
express
mammalian
cell
state
art
futur
perspect
biotechnol
lett
backliw
g
hilding
hasija
v
wurm
fm
high
densiti
transfect
hek
cell
allow
doubl
transient
titer
remov
need
priori
dna
complex
format
pei
biotechnol
bioeng
background
order
deal
grow
demand
larg
quantiti
therapeut
protein
time
fashion
express
system
optim
reduc
time
gener
stabl
clone
well
increas
level
protein
secret
achiev
combin
express
cassett
optim
cell
engin
select
process
materi
method
previous
develop
cumat
geneswitch
effici
express
system
protein
product
result
shown
cumateinduc
promot
strongest
promot
test
far
chines
hamster
ovari
cho
cell
promot
abl
gener
stabl
cho
pool
capabl
produc
high
level
fc
fusion
protein
mgl
outperform
fold
gener
hybrid
constitut
promot
besid
strength
promot
demonstr
abil
control
time
level
express
pool
gener
mainten
gave
real
advantag
induc
express
system
inde
observ
keep
express
select
enabl
gener
pool
superior
product
compar
pool
whose
express
maintain
moreov
preliminari
result
suggest
keep
recombin
protein
express
increas
frequenc
high
produc
clone
conclus
know
one
main
bottleneck
success
bioprocess
recombin
protein
use
cho
cell
rapid
isol
high
produc
data
suggest
cumat
geneswitch
system
could
valuabl
platform
gener
stabl
clone
acknowledg
work
support
nation
research
council
canada
human
health
therapeut
portfolio
refer
mullick
xu
r
warren
koutroumani
c
guilbault
broussau
f
malenf
l
bourget
l
lamoureux
r
lo
cumat
geneswitch
system
regul
express
mammalian
cell
bmc
biotechnolog
poulain
perret
f
malenf
mullick
b
massi
duroch
rapid
protein
product
stabl
cho
cell
pool
use
plasmid
vector
cumat
geneswitch
journal
biotechnolog
background
main
regulatori
author
organ
demand
proof
monoclon
biotechnolog
produc
cell
increas
pressur
shorten
timelin
improv
drug
safeti
technolog
advanc
method
establish
ensur
product
cell
line
deriv
singl
progenitor
cell
sartoriu
stedim
cellca
singl
cell
clone
approach
base
one
round
fluorescenceactiv
cell
sort
fac
use
becton
dickinson
bd
facsariatm
fusion
cell
sorter
combin
photodocument
synentec
cellavista
microscop
imag
system
approach
critic
process
paramet
differ
cell
line
viabil
cell
aggreg
level
investig
separ
assess
contribut
probabl
monoclon
materi
method
varieti
produc
cell
pool
gener
sartoriu
stedim
cellca
cho
host
cell
line
use
evalu
probabl
monoclon
singl
cell
clone
experi
perform
use
facsaria
fusiontm
bd
three
one
day
prior
experi
cell
seed
x
cellsml
day
experi
cell
centrifug
stain
dylight
conjug
protein
subsequ
cell
wash
resuspend
pb
filter
fac
tube
cell
strainer
cap
analyz
flow
cytometri
top
popul
regard
dylight
fluoresc
select
fac
droplet
sort
flat
bottom
plate
contain
clone
medium
doublet
discrimin
done
use
fcswfcsh
dot
plot
sscwssch
dot
plot
immedi
singl
cell
clone
plate
cellwel
plate
centrifug
follow
imag
use
cellavista
day
cellavista
imag
taken
day
day
one
day
day
outgrowth
defin
day
result
cell
line
express
differ
recombin
product
investig
calcul
probabl
cellswel
fac
sort
p
appar
probabl
p
ghostcel
cell
outoffocu
thu
visibl
initi
microscop
imag
appar
probabl
p
k
ghostcel
outgrow
stage
fig
use
result
probabl
obtain
monoclon
cell
use
sartoriu
stedim
cellca
singl
cell
clone
approach
determin
tabl
conserv
examin
p
monoclon
conserv
p
x
p
realist
examin
p
monoclon
realist
p
x
p
k
cell
pool
low
viabil
theoret
impact
probabl
monoclon
eg
diminish
microscop
imag
qualiti
cell
debri
therefor
pool
cell
line
low
viabil
use
demonstr
probabl
monoclon
still
case
low
viabil
day
sort
p
monoclon
conserv
p
x
p
p
monoclon
realist
p
x
p
k
furthermor
cell
pool
high
aggreg
level
theoret
impact
probabl
monoclon
stick
togeth
fac
sort
therefor
increas
probabl
p
cellsdroplet
therefor
pool
cell
line
high
aggreg
level
use
demonstr
probabl
monoclon
still
case
highli
aggreg
cell
pool
day
sort
p
monoclon
conserv
p
x
p
p
monoclon
realist
p
x
p
k
conclus
summari
obviou
correl
protein
product
type
determin
probabl
monoclon
furthermor
pool
viabil
low
pool
aggreg
level
high
use
scc
result
accept
probabl
monoclon
background
ich
guidanc
requir
cell
line
use
produc
biopharmaceut
origin
singl
progenitor
cell
recent
increas
scrutini
method
use
achiev
requir
review
suitabl
legaci
capillari
aid
cell
clone
cacc
method
light
chang
landscap
expect
cacc
method
base
spot
techniqu
reli
independ
visual
conform
two
scientist
presenc
singl
cell
droplet
method
achiev
high
probabl
monoclon
one
clone
round
although
method
sinc
replac
fac
singl
cell
deposit
routin
use
remain
viabl
clone
method
materi
method
perform
train
scientistsdilut
cultur
cellsml
doubletsdraw
cell
suspens
pipett
tip
capillari
action
tap
tip
centr
base
well
well
plates
result
droplet
fig
two
scientist
independ
view
well
use
microscop
initi
use
magnif
entir
rim
droplet
visibl
within
fieldofview
next
examin
particl
use
magnif
confirm
cell
individu
record
number
cell
present
well
droplet
fig
exclud
droplet
analysi
full
visualis
hinder
fig
h
add
growth
medium
incub
plate
record
well
contain
coloni
progress
coloni
well
scientist
agre
contain
one
celldata
analysi
scientist
observ
categoris
cell
cell
cellobserv
outcom
well
growth
growthprob
monoclon
estim
data
use
statist
model
result
advantag
cacc
method
compar
limit
dilut
clone
ldc
increas
accuraci
p
monoclon
caccldc
weak
visualis
seed
check
well
seed
subsequ
growth
coloni
well
describ
poisson
distribut
potenti
overestim
p
monoclon
address
cacc
visual
examin
coloni
aris
well
seed
cell
distinguish
seed
cellvisualis
step
strengthen
use
control
exclus
well
measur
error
base
presenc
absenc
coloni
well
two
scientist
independ
report
cell
formal
analys
data
use
suitabl
statist
model
decreas
time
resourc
requir
cacchigh
p
monoclon
possibl
singl
round
well
examin
individu
contain
singl
cell
progress
error
rate
incorrect
score
consid
low
frequenc
error
cacc
method
possibl
visual
observ
error
consid
two
scientist
miss
cellon
cell
sit
top
anoth
two
thu
appear
one
experi
perform
estim
error
frequenc
conclusionscientist
miss
cell
infrequ
rang
error
frequenc
invalid
use
direct
observ
method
cell
cloningsingl
cell
seen
scientist
highli
like
monoclon
summari
strategi
place
control
error
method
develop
strategi
establish
control
potenti
sourc
error
tabl
conclus
use
contemporan
visualis
approach
strict
control
strategi
suitabl
statist
model
take
account
potenti
error
result
cacc
method
least
robust
ldc
methodth
cacc
method
reliabl
singlestep
method
clone
achiev
high
p
monoclon
acknowledg
r
boraston
photograph
fig
refer
intern
committe
harmonis
ich
wwwichorg
clark
jb
spier
arch
virol
onadip
oa
metcalf
km
freeman
pr
jame
c
e
lindnerolsson
et
al
ed
anim
cell
technolog
target
market
background
vector
design
key
step
cell
line
develop
express
therapeut
biolog
essenti
vector
design
result
high
stabl
express
encod
protein
consider
includ
eas
clone
stabil
propag
e
coli
well
mammalian
host
cell
line
eas
sequenc
amplif
verif
vector
construct
detect
insert
site
copi
number
stabli
express
cell
reason
use
promot
polya
tail
dual
cassett
vector
common
express
heavi
light
chain
monoclon
antibodi
problemat
order
minim
sequenc
similar
two
express
cassett
modifi
promot
intron
polya
tail
light
chain
heavi
chain
express
cassett
dual
express
vector
commonli
use
express
therapeut
antibodi
gs
cell
line
develop
platform
materi
method
gene
synthesi
vector
construct
fluorophoreexpress
vector
done
atum
vector
transfect
gs
cell
via
electropor
analysi
gfp
rfp
express
achiev
use
macsquant
instrument
select
gener
stabl
pool
singl
cell
clone
transfect
vector
perform
describ
platform
technic
bulletin
titer
analysi
perform
static
well
plate
day
tpp
assay
day
fed
batch
assay
use
qk
fortebio
result
initi
screen
experi
identifi
lead
vector
vector
produc
low
titer
rel
minipool
express
detect
level
analysi
gfp
rfp
express
modifi
vector
indic
rel
high
express
rfphc
express
cassett
vector
stronger
promot
result
overabund
hc
known
toxic
cell
provid
possibl
explan
poor
result
vector
interestingli
swap
posit
lc
hc
result
vector
outperform
initi
identifi
lead
vector
fig
chang
made
vector
without
result
improv
titer
vector
fig
interestingli
vector
smaller
differ
rel
promot
strength
base
mean
channel
fluoresc
ratio
gfp
rfp
suggest
overabund
hc
impedi
express
poor
titer
also
seen
modifi
version
vector
vector
fig
glutamin
synthethas
select
cassett
revers
orient
second
screen
identifi
vector
lead
vector
design
fig
full
compar
studi
vector
control
vector
perform
cumul
gener
comparison
singlecel
clone
studi
demonstr
equival
vector
term
titer
conclus
work
result
identif
character
dual
express
vector
minim
similar
two
express
cassett
eas
clone
propag
analysi
vector
integr
stabl
cell
line
maintain
high
stabl
express
encod
protein
origin
vector
design
acknowledg
acknowledg
atum
contribut
vector
design
construct
background
tradit
cell
line
engin
strategi
mainli
includ
antibiot
resist
select
process
cell
transfect
goi
gene
interest
togeth
antibiot
resist
gene
cell
select
surviv
treatment
respect
antibiot
although
gene
respons
surviv
cell
transfect
togeth
goi
resist
necessarili
link
high
goi
express
thu
signific
proport
resist
cell
may
express
goi
necessit
search
altern
close
link
select
system
sirna
silenc
induc
rna
short
rna
bind
complementari
mrna
inhibit
translat
function
use
mani
approach
silenc
express
certain
gene
short
length
sirna
hidden
intron
nontransl
region
gene
make
possibl
coupl
express
sirna
gene
way
cell
produc
correl
amount
sirna
transcrib
gene
without
ad
translat
burden
cell
coexpress
sirna
use
select
marker
one
follow
method
knockdown
suicid
gene
enabl
cell
surviv
suicid
gene
mrna
transfect
downregul
surfac
marker
use
mac
magnet
cell
separ
filter
want
unwant
cell
inhibit
fluorophor
marker
select
use
fac
without
product
specif
antibodi
sirna
base
cell
select
system
sirna
replac
commonli
use
antibiot
resist
marker
cell
produc
goi
also
produc
sirna
protect
cell
suicid
gene
select
protein
suicid
gene
fluorophor
surfac
marker
etc
transfect
mrna
express
select
materi
method
gener
process
outlin
fig
tradit
antibiot
resist
marker
replac
sirna
goi
unlik
antibiot
resist
marker
protein
reduc
translat
burden
provid
resourc
goi
product
b
transcript
produc
goi
mrna
togeth
either
resist
gene
splice
process
sirna
c
select
done
addit
antibiot
tradit
approach
transfect
select
marker
mrna
target
site
complementari
product
depend
sirna
tradit
select
cell
select
base
amount
antibiot
resist
produc
sirna
knock
marker
gene
suicid
gene
marker
mac
fac
process
need
addit
protein
select
genet
coupl
sirna
goi
ensur
select
base
goi
product
result
transfect
suicid
gene
prove
lethal
within
day
outgrowth
two
week
protect
express
sirna
shown
effici
current
comparison
stabl
cell
line
develop
program
base
sirna
select
neomycin
select
ongo
conclus
novel
select
system
speed
cell
line
develop
system
kill
rapidli
directli
select
cell
transcrib
product
gene
high
level
expect
see
high
produc
earlier
process
allow
easier
faster
select
follow
step
sirna
base
select
offer
great
opportun
directli
select
base
goi
transcript
proxi
marker
expect
relev
cell
pool
level
addit
elimin
antibiot
resist
allow
cellular
resourc
goi
product
system
offer
multipl
way
applic
either
enrich
want
deplet
unwant
cell
acknowledg
austrian
bmwfw
bmvit
sfg
standortagentur
tirol
govern
lower
austria
busi
agenc
vienna
austrian
ffgcomet
refer
bandaranayak
ad
almo
sc
recent
advanc
mammalian
protein
product
feb
letter
wilson
rc
doudna
ja
molecular
mechan
rna
interfer
annual
review
biophys
kallehaug
tb
li
pedersen
le
ha
tk
ley
andersen
mr
kildegaard
hf
lee
gm
lewi
ne
ribosom
profilingguid
deplet
mrna
increas
cell
growth
rate
protein
secret
scientif
report
background
singlecel
clone
essenti
step
use
upstream
develop
transform
cell
line
therapeut
protein
product
singlecel
clone
typic
use
ensur
product
consist
low
cell
densiti
cultur
present
surviv
challeng
cell
grow
slowli
may
even
surviv
low
densiti
proteinfre
media
cost
industri
time
money
limit
pool
candid
coloni
choic
product
clone
address
problem
aim
develop
highli
effici
serumfre
medium
suitabl
optimis
singlecel
clone
effici
studi
rang
condit
media
cm
sampl
isol
differ
chines
hamster
ovari
cho
cell
line
materi
method
cho
adapt
cho
sfmii
gibco
medium
minimum
three
passag
condit
media
collect
cultur
reach
cell
densiti
typic
day
depend
growth
profil
cell
line
whether
grew
suspens
attach
condit
sampl
centrifug
twice
remov
cell
pelletdebri
store
abil
condit
media
support
cho
coloni
format
assay
use
plate
seed
cell
low
cell
densiti
dilut
cho
cultur
mediacondit
media
incub
day
clone
effici
assay
use
standard
xtt
assay
initi
screen
nine
cm
sampl
perform
use
cell
due
widespread
use
industri
antibodi
product
success
media
candid
subsequ
screen
use
addit
cho
cell
line
result
test
four
condit
media
identifi
support
improv
clone
effici
compar
uncondit
media
result
sfmii
media
condit
suspens
sfmii
media
poli
vinyl
alcohol
pva
condit
suspens
sfmii
media
chossfmiicm
condit
suspens
cho
sfmii
media
achossfmiicm
condit
adher
cho
highest
clone
effici
observ
chossfmiicm
display
growth
well
seed
sfmiipva
cm
suspens
cultur
also
improv
uncondit
media
perform
display
growth
well
seed
achossfmiicm
well
character
date
test
two
cho
cell
line
cho
cm
cho
cell
grow
sfmii
media
adher
cultur
chossfmii
adher
cm
increas
cell
clone
effici
sever
cho
cell
line
compar
sfmii
uncondit
media
increas
ii
cho
increas
iii
increas
tabl
product
improv
cell
clone
effici
cell
avg
increas
cho
cell
avg
increas
fig
also
adher
cell
line
grow
fb
conclus
abil
condit
media
support
cho
growth
limitingdilut
condit
cellsml
investig
rang
nine
condit
media
sampl
four
compel
product
identifi
improv
lowcel
densiti
growth
cell
compar
sfmii
control
media
feel
earlystag
condit
media
product
may
increas
clone
effici
upstream
cho
cell
line
develop
result
financi
save
industri
increas
possibl
identifi
particularli
highperform
transform
clone
acknowledg
research
support
sfi
grant
refer
ming
lim
u
gek
sim
yap
pin
lim
goh
l
kong
ng
identif
autocrin
growth
factor
secret
cho
cell
applic
singlecel
clone
media
j
proteom
re
vol
zhu
j
wooh
jw
hou
jj
hugh
bs
gray
pp
munro
tp
recombin
human
albumin
support
singl
cell
clone
cho
cell
chemic
defin
media
biotechnol
prog
vol
background
main
ratelimit
step
upstream
stage
protein
biomanufactur
isol
stabl
high
produc
cell
clone
ubiquit
chromatin
open
element
consist
least
one
promot
region
associ
methylationfre
cpg
island
housekeep
gene
possess
domin
chromatin
open
capabl
thu
confer
stabl
transgen
express
promot
eg
cmv
base
plasmid
vector
markedli
reduc
time
take
isol
high
stabli
produc
cell
clone
although
promot
combin
test
thoroughli
evalu
chines
hamster
ovari
cho
cell
materi
method
plasmid
vector
contain
combin
either
human
murin
link
differ
viral
promot
hcmv
gpcmv
sffv
drive
express
egfp
report
gene
function
analys
stabl
transfect
cell
express
analys
flow
cytometri
qpcr
determin
vector
copi
number
result
discuss
result
day
posttransfect
select
clearli
indic
hcmv
combin
give
highest
transgen
express
shown
fig
construct
next
efficaci
lower
vector
sffv
promot
link
either
two
least
effect
express
level
lower
construct
construct
modifi
includ
element
provid
optim
posttranscript
premrna
process
splice
polyadenyl
transcript
termin
mrna
stabil
therebi
maximis
stabl
cytoplasm
transgen
mrna
level
protein
product
refer
nevil
jj
orlando
j
mann
k
mccloskey
b
antoni
mn
ubiquit
chromatinopen
element
uco
applic
biomanufactur
gene
therapi
biotechnol
adv
background
last
year
grow
number
innov
biolog
biosimilar
form
competit
environ
speed
effici
gener
robust
highli
product
cell
line
need
improv
continu
variou
advanc
especi
media
develop
process
optim
product
titer
high
gl
achiev
pharmaceut
industri
kim
et
al
standard
product
monoclon
antibodi
nevertheless
protein
eg
bispecif
antibodi
fcfusion
protein
fabrel
product
difficulttoexpress
dte
chines
hamster
ovari
cho
may
result
delay
even
termin
cell
line
develop
process
develop
new
robust
pool
gener
approach
cld
address
easi
difficulttoexpress
molecul
reduc
timelin
month
cld
standard
month
improv
reliabl
cell
line
develop
well
clearli
increas
obtain
titer
materi
method
order
creat
stabl
cell
line
transfect
cho
host
cell
electropor
cell
process
use
standard
approach
cultiv
select
medium
medium
contain
addit
nm
methotrex
mtx
three
week
amplif
step
nm
mtx
three
week
stabl
individu
cell
pool
expand
clone
gener
facssort
clone
analyz
growth
perform
product
concentr
fedbatch
studi
new
cld
approach
increas
mtx
concentr
nm
nm
nm
mtx
first
select
phase
three
week
afterward
omit
nm
mtx
amplif
step
therebi
pool
gener
finish
four
week
earlier
standard
approach
evalu
stabil
cell
clone
deriv
mini
pool
mp
gener
accord
cld
approach
stabil
studi
perform
eight
week
includ
stabil
fed
batch
week
week
altogeth
three
differ
protein
interest
six
cell
clone
test
result
adapt
cell
line
develop
process
increas
initi
select
first
select
phase
therebi
allow
omiss
nm
mtx
amplif
step
observ
capac
amplifi
vari
differ
product
cell
line
protein
titer
rang
gl
gl
dte
shake
flask
fedbatch
show
suscept
increas
initi
mtx
level
thu
amplifi
nm
mtx
contrast
cell
line
high
protein
titer
gl
observ
adapt
nm
mtx
easili
amplifi
final
shake
flask
fedbatch
data
cld
clone
highexpress
product
show
compar
titer
clone
standard
approach
cld
clone
titer
dte
protein
reveal
averag
fold
increas
compar
clone
gener
standard
approach
titer
top
produc
clone
rang
gl
gl
fig
furthermor
stabil
data
cell
clone
differ
dte
product
show
stabl
specif
product
rang
eight
week
cultiv
fedbatch
titer
week
week
normal
rang
standard
nm
project
conclus
result
demonstr
cld
robust
reliabl
process
standard
product
mab
dte
protein
new
process
abl
increas
titer
difficulttoexpress
protein
omit
amplif
step
nm
mtx
gener
clone
stabl
eight
week
cultiv
time
addit
use
approach
time
line
dna
rcb
reduc
month
background
cho
cell
becom
popular
platform
product
therapeut
protein
howev
gener
highproduc
cell
timeconsum
laborintens
process
requir
screen
larg
amount
cell
get
clone
high
titer
stabil
sinc
express
titer
stabil
clone
highli
depend
site
integr
demonstr
new
cell
line
develop
strategi
use
ng
identifi
integr
site
use
gener
target
integr
high
produc
cell
line
materi
method
identifi
high
express
site
cho
cell
employ
ng
analyz
integr
site
high
produc
cell
line
titer
pairend
read
one
read
map
vector
read
map
cho
refer
genom
extract
identifi
integr
site
test
express
activ
integr
site
employ
specif
integr
antibodi
gene
cho
genom
express
result
data
show
integr
site
high
produc
cell
line
among
integr
site
integr
site
test
target
integr
antibodi
gene
express
integr
cell
pool
present
higher
express
titer
cell
pool
gener
target
integr
integr
site
fig
singl
cell
clone
deriv
integr
cell
pool
low
copi
number
goi
fig
normal
copi
number
singl
cell
clone
deriv
integr
cell
pool
show
high
titer
per
copi
mglcopi
fig
conclus
studi
demonstr
gener
highproduc
cell
line
mediat
target
integr
approach
cost
less
time
labor
tradit
method
activ
integr
site
serv
platform
like
cassett
player
therapeut
antibodi
product
acknowledg
studi
fund
ministri
econom
affair
roc
refer
fischer
handrick
r
ott
k
art
cho
cell
engin
comprehens
retrospect
futur
perspect
biotechnol
adv
dec
inniss
mc
bandara
k
jusiak
b
lu
tk
weiss
r
wroblewska
l
zhang
l
novel
integras
rmce
system
high
fidel
sitespecif
integr
mab
express
cassett
cho
cell
biotechnol
bioeng
aug
background
cho
hek
domin
host
cell
biolog
drug
product
achiev
high
level
recombin
protein
product
cell
line
still
remain
challeng
order
understand
potenti
role
lipid
protein
product
secret
vesicular
transport
energi
metabol
coupl
highthroughput
transcriptom
lipidom
technolog
quantit
lipidom
emerg
omic
technolog
help
us
understand
physiolog
limit
cell
line
two
type
major
lipid
group
cell
nonpolar
polar
lipid
polar
lipid
glycerophospholipid
pl
includ
phosphatidylethanolamin
pe
phosphatidylcholin
pc
phosphatidylinositol
pi
phosphatidylserin
ps
phosphatidylglycerol
pg
phosphatid
acid
pa
studi
integr
two
dimension
high
perform
thin
layer
chromatographi
mass
spectrometri
ms
lipid
analysi
cho
hek
cell
line
understand
major
differ
lipid
content
host
materi
method
blighdyer
method
use
extract
lipid
extract
analyz
hptlc
ms
polar
lipid
separ
differ
categori
hptlc
use
vvv
solvent
system
first
dimens
vvvv
solvent
system
second
dimens
nonpolar
lipid
separ
hptlc
use
hexanediethyl
etheracet
acid
dye
use
visual
polar
nonpolar
lipid
detail
analysi
perform
qqq
mass
spectromet
thermo
tsq
vantag
san
jose
ca
use
negativeion
positiveion
esi
mode
well
negativeion
esi
mode
presenc
lithium
hydroxid
result
studi
quantit
lipidom
coupl
transcriptom
understand
physiolog
pathway
hek
chom
cell
initi
hptlc
analysi
indic
major
lipid
industri
cell
line
pe
pc
polar
lipid
pi
ps
pg
pa
sm
lower
compar
pc
pe
exponenti
stationari
phase
cell
line
figur
repres
hptlc
result
hek
rel
quantit
polar
lipid
order
investig
lipid
subgroup
shotgun
ms
analysi
conduct
exponenti
stationari
growth
phase
three
cell
line
ms
analysi
indic
lysophosphatidylethanolamin
lpe
lysophosphatidylcholin
lpc
amount
fold
fold
higher
hek
cell
compar
cho
cell
line
sphingomyelin
sm
anoth
lipid
subgroup
shown
major
differ
mammalian
cell
line
sm
fold
lower
cell
line
compar
cho
hek
understand
metabol
differ
transcriptom
analysi
use
illumina
highseq
gene
express
omnibu
conduct
mammalian
cell
kyoto
encyclopedia
gene
genom
kegg
databas
use
map
transcriptom
data
lipid
synthet
pathway
transcriptom
data
map
kegg
pathway
demonstr
differ
lpe
lpc
pathway
correl
express
profil
secretori
phospholipas
lysophospholipid
acyltransferas
lpeat
lysophosphatidylcholin
acyltransferas
lpcat
lysophospholipas
lypla
conclus
hptlc
lcm
find
demonstr
high
level
lpe
lpc
exist
hek
cell
line
low
level
sm
observ
cell
line
coupl
lipidom
transcriptom
provid
us
improv
understand
physiolog
differ
across
cho
hek
cell
line
could
use
guid
cell
engin
effort
goal
increas
recombin
protein
express
capabl
three
cell
line
refer
zhang
baycin
hizal
kumar
priola
j
bahri
heffner
k
wang
han
x
bowen
betenbaugh
j
hightroughput
lipidom
transcriptom
analysi
compar
cho
mammalian
cell
line
anal
chem
background
biopharmaceut
class
biolog
macromolecul
includ
antibodi
antibodi
deriv
gener
produc
cultur
mammalian
cell
line
via
secret
directli
media
manufactur
medimmun
requir
gener
chines
hamster
ovari
cho
clonal
cell
line
capabl
produc
biopharmaceut
product
commerci
relev
quantiti
optim
product
qualiti
isol
cell
clone
base
random
singl
cell
deposit
via
fluoresc
activ
cell
sort
fac
provid
heterogen
panel
express
hypothes
applic
fac
provid
addit
sort
step
base
desir
cell
attribut
correl
product
product
qualiti
cell
growth
attribut
could
lead
isol
higher
produc
cell
line
enhanc
product
qualiti
attribut
materi
method
panel
cell
line
express
model
recombin
monoclon
antibodi
characteris
term
growth
product
intracellular
recombin
protein
mrna
amount
assay
also
develop
investig
cell
attribut
use
commerci
avail
imagestream
instrument
imag
flow
cytomet
enabl
investig
cellular
characterist
correl
cell
product
singl
cell
level
result
characteris
reveal
cell
line
exhibit
rang
valu
product
growth
intracellular
ic
antibodi
mrna
protein
express
ideal
imagestream
characteris
western
blot
qrtpcr
analysi
demonstr
final
titr
correl
ic
heavi
chain
hc
protein
mrna
amount
pearson
correl
coeffici
pcc
pcc
respect
assess
product
singl
cell
level
assay
multiplex
ic
hc
protein
mrna
cell
attribut
therefor
develop
initi
assay
develop
focus
hc
mrna
protein
amount
reveal
interest
result
four
cell
line
display
two
distinct
popul
one
produc
antibodi
anoth
nonexpress
popul
ratio
popul
vari
amongst
cell
line
imag
obtain
imagestream
shown
cellular
local
express
hc
lc
messag
protein
fig
messag
protein
hc
lc
coloc
cell
whether
relationship
ic
hc
protein
cell
attribut
singl
cell
level
also
investig
well
correl
cell
cultur
paramet
popul
level
popul
level
correl
found
titr
ic
hc
protein
mrna
pcc
pcc
respect
confirm
data
obtain
western
blot
qrtpcr
analysi
conclus
panel
cell
line
characteris
popul
level
show
wide
rang
antibodi
express
profil
mrna
protein
level
parallel
assay
develop
imagestream
measur
hc
lc
messag
protein
amount
singl
cell
level
protein
messag
quantif
imagestream
consist
tradit
approach
western
blot
qrtpcr
oper
popul
level
develop
assay
use
investig
singl
cell
product
attribut
isol
product
clone
acknowledg
author
would
like
thank
gari
pettman
charlott
godfrey
sarah
dunn
alison
mason
lina
chakrabarti
gareth
davi
michel
garrett
background
product
stabil
key
factor
select
cell
line
protein
drug
product
larg
amount
target
gene
integr
cell
genom
could
lead
instabl
product
therefor
cell
low
copi
target
gene
integr
high
yield
site
could
ideal
product
cell
manufactur
known
transposon
system
control
integr
copi
number
target
gene
gener
high
yield
produc
cell
could
great
approach
gener
stabl
high
yield
produc
cell
line
carri
low
copi
target
gene
transposon
system
materi
method
intend
develop
platform
gener
high
yield
produc
cell
line
carri
copi
integr
target
gene
use
transposon
system
two
cho
cell
line
cho
cell
cell
appli
cell
cotransfect
transposon
target
gene
express
plasmid
drug
select
cell
pool
highest
product
per
target
gene
copi
appli
singl
cell
clone
product
copi
number
cell
clone
determin
stabil
cell
clone
analys
cultur
gener
result
stabl
pool
cho
cell
product
per
integr
target
gene
copi
mglcopi
mglcopi
batch
cultur
respect
singl
cell
clone
integr
copi
number
cell
clone
less
three
copi
per
cell
cho
cell
clone
product
per
integr
target
gene
copi
mglcopi
mglcopi
batch
cultur
respect
product
per
integr
target
gene
cell
clone
develop
transposon
system
much
higher
cell
clone
develop
random
integr
fig
b
evalu
product
stabil
cell
clone
develop
transposon
system
ten
cell
clone
gener
appli
analysi
interest
cell
clone
stabl
gener
lost
product
gener
fig
impli
cell
clone
could
maintain
stabil
within
month
conclus
use
optim
condit
transposon
system
develop
stabl
gene
express
cell
product
per
integr
target
gene
higher
random
integr
result
suggest
platform
capabl
develop
high
yield
produc
cell
copi
integr
target
antibodi
gene
appli
identifi
high
yield
integr
site
refer
rajendra
peeri
rb
barnard
gc
gener
stabl
chines
hamster
ovari
pool
yield
antibodi
titer
gl
use
piggybac
transposon
system
biotechnol
prog
balasubramanian
rajendra
baldi
l
hacker
dl
wurm
fm
comparison
three
transposon
gener
highli
product
recombin
cho
cell
pool
cell
line
biotechnol
bioeng
background
mammalian
cell
show
ineffici
metabol
character
high
glucos
uptak
product
high
amount
lactat
wide
known
growth
inhibit
byproduct
recent
observ
differ
glucoselact
metabol
cell
line
cell
line
unabl
metabol
lactat
other
cometabol
simultan
glucos
lactat
certain
cultur
condit
even
exponenti
growth
phase
metabol
differ
differ
mammalian
cell
line
cho
hybridoma
studi
mean
flux
balanc
analysi
fba
materi
method
three
differ
cell
line
cultur
bioreactor
cho
hybridoma
fba
two
adapt
genomescal
metabol
model
use
reconstruct
mu
musculu
cho
hybridoma
reconstruct
human
metabol
model
recon
result
cultur
ph
control
two
differ
metabol
phase
observ
cho
cell
first
phase
cell
line
produc
larg
amount
lactat
consequ
high
glucos
consumpt
rate
interestingli
ph
drop
due
acid
lactic
secret
accumul
second
metabol
phase
identifi
concomit
consumpt
glucos
lactat
observ
even
exponenti
growth
phase
convers
hybridoma
cell
unabl
coconsum
lactat
glucos
simultan
even
noncontrol
ph
condit
therefor
hybridoma
physiolog
data
use
fba
correspond
phase
phcontrol
cultur
summari
main
cell
growth
metabol
paramet
obtain
differ
experi
perform
present
tabl
fba
show
fig
cell
cultur
lactat
produc
phase
pyruv
convert
lactat
fulfil
nadh
regener
cytoplasm
small
amount
pyruv
transport
tca
acetylcoa
cell
metabol
phase
highli
ineffici
major
carbon
sourc
use
gener
energi
biomass
phase
mitochondri
ldh
consid
tca
flux
could
maintain
phase
maxim
rate
encount
henc
energi
avail
cell
grow
similar
phase
obtain
similar
growth
rate
conclus
two
differ
glucos
lactat
metabol
behavior
observ
cho
cultur
depend
cultur
condit
phase
glucos
consumpt
lactat
product
phase
glucos
lactat
simultan
consumpt
contrast
phase
observ
hybridoma
cultur
even
ph
noncontrol
fba
show
tca
flux
phase
phase
similar
obtain
similar
cell
growth
rate
glucos
uptak
rate
much
lower
phase
due
lactat
coconsumpt
author
hypothes
cell
metabol
extracellular
lactat
strategi
ph
detoxif
glucos
lactat
cometabol
result
betterbalanc
cell
metabol
seen
metabol
flux
calcul
minor
effect
cell
growth
observ
glucos
lactat
coconsumpt
metabol
behavior
deeper
studi
character
could
open
door
novel
cultur
strategi
aim
increas
bioprocess
product
acknowledg
author
would
like
mention
research
support
fidgr
spanish
govern
project
led
prof
jordi
joan
badillo
refer
ozturk
riley
r
palsson
b
effect
ammonia
lactat
hybridoma
growth
metabol
antibodi
product
biotechnolog
bioengin
listecalleja
l
lecina
lopezrepullo
j
albiol
j
c
j
j
lactat
glucos
concomit
consumpt
selfregul
ph
detoxif
mechan
cell
cultur
appli
microbiolog
biotechnolog
v
dietmair
quek
l
e
hodson
p
gray
p
nielsen
l
k
flux
balanc
analysi
cho
cell
metabol
switch
lactat
product
consumpt
biotechnolog
bioengin
quek
l
e
dietmair
hanscho
v
borth
n
nielsen
l
k
reduc
recon
steadyst
flux
analysi
hek
cell
cultur
journal
biotechnolog
background
transient
protein
express
mammalian
cell
line
gain
increas
relev
enabl
fast
flexibl
product
highqual
eukaryot
protein
consider
effort
thu
made
overcom
exist
limit
aspect
transient
gene
express
system
term
cell
line
cell
culturebas
system
protein
product
costeffect
manner
milligram
amount
protein
per
liter
produc
within
sever
day
allow
signific
shorten
bioproduct
process
comparison
protein
product
stabl
clone
ensur
robust
process
essenti
reliabl
easytous
transfect
method
palliat
need
reliabl
transfect
reagent
develop
commerci
avail
pei
optimis
mid
largescal
transient
protein
product
process
develop
nonpolydipers
fullycharacteris
polym
becom
gold
pei
standard
due
reliabl
reproduc
high
dna
deliveri
effici
ensu
high
protein
product
yield
present
experiment
data
show
benefit
use
protein
product
comparison
pei
demonstr
compat
use
recombin
protein
product
commonli
use
chemicallydefin
media
materiel
method
suspens
cho
cell
cultur
shaker
flask
variou
synthet
media
list
tabl
cho
cell
resuspend
cellsml
serumfre
medium
day
transfect
cell
transfect
mg
plasmid
dna
encod
luciferas
gene
report
use
pei
max
lpei
kda
polysci
warrington
pa
resuspend
mgml
accord
manufactur
recommend
protein
express
luciferas
report
gene
assay
hour
posttransfect
affin
chromatographi
use
protein
g
hplc
result
comparison
commerci
avail
pei
achiev
transfect
suspens
cho
cell
plasmid
dna
encod
luciferas
gene
report
luciferas
product
yield
obtain
cho
cell
least
respect
higher
use
similar
amount
peipro
comparison
pei
fig
furthermor
pei
led
similar
luciferas
product
yield
decreas
amount
plasmid
dna
per
liter
cell
cultur
convers
least
mg
plasmid
dna
pei
max
lpei
kda
need
obtain
similar
luciferas
express
rang
cho
cell
assess
compat
versatil
measur
protein
product
yield
obtain
commonli
use
animalfre
synthet
media
shown
fig
lead
high
protein
product
yie
sever
commerci
avaialbl
media
formul
anc
cho
cell
line
conclus
fulli
characteris
pei
transfect
reagent
suitabl
reliabl
reproduc
recombin
protein
product
irrespect
scale
product
type
adher
suspens
cell
cultur
system
background
monoclon
antibodi
mab
wide
use
anticanc
therapi
mainli
produc
mammalian
cell
line
mab
conjug
biolog
molecul
enhanc
antitumor
activ
offer
new
power
tool
anticanc
therapi
assess
product
commerci
approv
therapeut
antibodi
trastuzumab
tzmb
also
fusion
two
clone
strategi
consist
transfect
cho
cell
line
two
bicistron
singl
tricistron
plasmid
assess
vitro
efficaci
antibodi
test
compar
side
side
matheri
method
tzmb
heavi
light
chain
clone
two
bicistron
plasmid
clontech
tricistron
plasmid
deriv
splice
tzmb
heavi
chain
overlap
extens
pcr
result
fusion
protein
also
clone
express
vector
way
nonmodifi
tzmb
select
cell
pool
cultur
ml
shake
flask
contain
sfmtransfx
supplement
vv
cell
boost
hyclon
mm
glutamax
gibco
puromycin
also
neomycin
case
cell
transfect
cell
cultiv
condit
describ
elsewher
purifi
product
use
protein
chromatographi
hitrap
mabselect
sure
avant
quantifi
elisa
sdspage
antigen
bind
test
perform
breast
cancer
cell
line
mean
flow
cytometri
analysi
biolog
activ
differ
candid
test
mtt
assay
result
tzmb
fusion
protein
success
express
cho
use
heterolog
protein
express
previous
optim
prior
work
tricistron
strategi
result
effici
show
increas
term
product
respect
bicistron
doubletransfect
tzmb
cho
cell
increas
cell
fig
case
tricistron
strategi
also
allow
achiev
higher
product
bicistron
one
fig
regard
differ
specif
product
cell
line
test
emerg
best
product
host
candid
two
test
strategi
tricistron
bicistron
two
produc
protein
show
increas
term
product
respect
cho
cell
tzmb
use
tricistron
strategi
tzmb
analys
term
antigen
bind
capac
find
effici
bind
cell
fig
thu
antibodi
affin
antigen
affect
fuse
final
antiprolif
activ
tzmb
assess
cell
concentr
nm
tzmb
incub
cell
present
growth
respect
untreat
control
howev
antiprolif
effect
observ
fig
conclus
tricistron
strategi
provid
higher
product
yield
cho
cell
line
recombin
protein
trastuzumab
regard
cell
line
best
product
host
candid
achiev
higher
product
cho
cell
two
protein
test
construct
perform
preserv
bind
affin
antigen
trastuzumab
bind
effici
antigen
present
cell
final
present
improv
antiprolif
effect
respect
trastuzumab
compar
mean
vitro
assay
refer
clifford
hudi
md
trastuzumab
mechan
action
use
clinic
practic
n
engl
j
med
listecalleja
l
lecina
jj
cell
cultur
media
studi
toward
bioprocess
optim
anim
deriv
compon
free
anim
deriv
compon
contain
platform
j
biosci
bioeng
r
miret
j
scalia
f
casablanca
lecina
jj
enhanc
heterolog
protein
express
secret
cell
mean
combin
cmv
promot
signal
peptid
j
biotechnol
background
genet
engin
patientspecif
cell
lentivir
vector
lvv
express
chimer
antigen
receptor
car
late
phase
clinic
trial
requir
larg
scale
manufactur
hightit
vector
stock
stateoftheart
product
lvv
base
cell
factori
transient
transfect
presenc
serum
manufactur
process
extrem
limit
labor
intens
opensystem
handl
oper
requir
signific
incub
space
plu
cost
patienc
risk
due
presenc
serum
circumv
limit
studi
aim
develop
stabl
serumfre
process
produc
lvv
pei
mediat
transfect
addit
studi
also
focus
develop
product
system
use
gfp
marker
also
therapeut
relev
transgen
materi
method
therefor
three
differ
cell
line
hek
investig
concern
product
lvv
grow
behavior
inhous
serumfre
medium
transmac
part
design
experi
use
investig
optim
condit
peidnatransfect
furthermor
statist
approach
use
focus
ideal
ratio
gener
plasmid
transfer
plasmid
gfp
envelop
plasmid
packag
plasmid
addit
differ
enhanc
sodium
butyr
lithium
acet
caffein
trichostatin
cholesterol
hydroxyurea
valproic
acid
investig
concern
effect
product
compar
hek
cultur
produc
lvv
encod
gfpmarker
result
concern
product
grow
behavior
hek
favor
cell
line
serumfre
lv
manufactur
process
addit
addit
screen
reveal
sodium
butyr
alon
promis
effect
gfplvv
product
peidna
titrat
final
could
increas
lvv
product
lower
peidna
amount
higher
cell
densiti
refer
standard
transfect
protocol
furthermor
titrat
optim
plasmid
ration
reveal
larg
transfer
construct
higher
amount
transfer
plasmid
requir
smaller
construct
achiev
high
product
fig
conclus
outcom
experi
enabl
develop
robust
base
process
produc
clinic
relev
lvv
serumfre
condit
furthermor
provid
insight
therapeut
gene
express
transgen
influenc
cell
product
refer
merten
ow
et
al
product
lentivir
vector
mol
ther
method
clin
dev
doi
background
chines
hamster
ovari
cho
cell
promin
cell
line
use
biopharmaceut
product
although
optimis
effort
led
vast
increas
product
cho
cell
yield
less
express
system
like
yeast
bacteria
improv
yield
find
benefici
bioprocess
phenotyp
genet
engin
play
essenti
role
recent
research
cluster
genom
paralogu
first
identifi
differenti
express
temperatur
shift
suggest
role
prolifer
product
common
approach
deplet
mirna
use
spong
decoy
requir
introduct
report
gene
altern
work
aim
knockdown
mirna
express
use
recent
develop
system
requir
report
transcript
system
consist
two
main
compon
singl
guid
rna
sgrna
endonucleas
induc
doubl
strand
break
dsb
dsb
result
insert
delet
indel
base
pair
disrupt
mirna
function
process
materi
method
cell
line
stabli
express
igg
use
knockdown
experi
sgrna
design
target
seed
region
mirna
member
stabl
mix
popul
gener
fig
total
rna
form
mix
popul
revers
transcrib
cdna
use
mirna
specif
stemloop
primer
express
quantifi
rtqpcr
analys
rang
indel
cluster
amplifi
standard
highfidel
pcr
amplicon
clone
vector
posit
clone
analys
sanger
sequenc
cell
growth
monitor
use
viacounttm
viabil
stain
guavatm
benchtop
flow
cytomet
product
assess
elisa
student
ttest
use
statist
analysi
result
shown
mirna
express
significantli
reduc
mix
popul
knockdown
achiev
knockdown
express
consider
less
p
p
p
fig
furthermor
shown
variou
size
indel
gener
target
seed
region
smaller
indel
bp
seem
common
larger
delet
detect
well
fig
show
increas
viabil
late
stage
cultur
deplet
reduc
growth
significantli
wherea
knockdown
show
increas
prolifer
well
boost
igg
titer
tabl
conclus
work
shown
success
appli
tool
knockdown
mirna
express
cho
cell
data
gener
use
mix
pool
remain
establish
allel
success
target
eg
use
nextgener
sequenc
individu
clone
acknowled
work
fund
scienc
foundat
ireland
sfi
grant
refer
wurm
f
product
recombin
protein
therapeut
cultiv
mamammalian
cell
natur
biotechnolog
gammel
p
barron
n
kumar
n
clyne
initi
identif
low
temperatur
cultur
stage
induct
mirna
express
suspens
cell
journal
biotechnolog
jiang
q
meng
x
meng
l
chang
n
xiong
j
cao
h
liang
z
small
indel
induc
region
microrna
lead
deplet
drosha
process
retard
rna
biolog
background
chines
hamster
ovari
cho
cell
wide
use
host
cell
line
product
therapeut
antibodi
pre
posttransl
modif
optim
cultur
method
contribut
increas
product
result
high
titr
howev
point
intracellular
secret
process
bottleneck
product
therapeut
antibodi
addit
detail
process
secret
human
recombin
antibodi
cho
cell
well
investig
studi
thu
analys
detail
process
secret
therapeut
antibodi
use
cho
cell
line
alreadi
establish
high
produc
aim
obtain
inform
ration
effici
establish
highproduc
cell
materi
method
perform
chase
assay
immunofluoresc
microscopi
observ
size
exclus
chromatographi
sec
analysi
investig
durat
secret
bottleneck
posit
format
recombin
igg
respect
highproduc
cho
cell
express
human
use
chase
assay
cell
cultiv
shake
flask
serumfre
medium
contain
cycloheximid
chx
stop
nascent
peptid
synthesi
amount
igg
remain
cell
secret
medium
time
point
measur
quantit
western
blot
immunofluoresc
microscopi
observ
cell
cultiv
coverslip
chx
h
immunofluoresc
stain
recombin
igg
endoplasm
reticulum
er
golgi
apparatu
perform
chemic
fixat
sec
cell
cultur
chx
resuspend
buffer
contain
inject
column
amount
igg
fraction
measur
quantit
western
blot
result
discuss
amount
supernat
increas
h
inhibit
protein
synthesi
chx
howev
hardli
chang
thereaft
fig
upper
panel
point
time
howev
around
igg
still
remain
cell
fig
lower
panel
mean
synthes
igg
could
secret
medium
remain
cell
sever
hour
result
almost
studi
use
cell
local
igg
cell
check
addit
chx
result
show
remain
er
hardli
seen
golgi
apparatu
igg
seem
effici
transport
golgi
apparatu
sec
experi
show
remain
cell
seem
form
fullsiz
antibodi
could
secret
despit
conclus
highproduc
cell
could
secret
synthes
igg
around
igg
remain
cell
sever
hour
incomplet
secret
common
phenomenon
among
cho
cell
produc
differ
type
recombin
igg
igg
could
transport
er
golgi
despit
format
fullsiz
antibodi
solv
bottleneck
transport
igg
er
golgi
andor
achiev
effici
glycosyl
igg
format
fullsiz
antibodi
might
next
target
improv
product
acknowledg
work
financi
support
project
focus
develop
key
technolog
discov
manufactur
drug
nextgener
treatment
diagnosi
ministri
economi
trade
industri
japan
grantsinaid
scientif
research
japan
societi
promot
scienc
jsp
refer
wurm
fm
product
recombin
protein
therapeut
cultiv
mammalian
cell
nat
biotechnol
haredi
nishizawa
honda
k
ohya
ohtak
h
omasa
improv
antibodi
product
chines
hamster
ovari
cell
overexpress
cytotechnolog
peng
rw
guetg
c
tigg
fussenegg
vesicletraffick
protein
increas
secretori
capac
mammalian
cell
metab
eng
onitsuka
omasa
rapid
evalu
nglycosyl
statu
antibodi
chemiluminesc
lectinbind
assay
j
biosci
bioeng
kaneyoshi
k
uchiyama
k
onitsuka
yamano
n
koga
omasa
intracellular
secret
pathway
analysi
construct
highli
produc
engin
cho
cell
annual
peptalk
san
diego
ca
usa
januari
oral
poster
kaneyoshi
k
uchiyama
k
onitsuka
yamano
n
koga
omasa
intracellular
secret
analysi
therapeut
antibodi
engin
highproduc
cho
cell
biochem
molecular
engin
xx
newport
beach
ca
usa
juli
poster
kaneyoshi
k
uchiyama
k
onitsuka
yamano
n
koga
omasa
analysi
intracellular
recombin
igg
secret
engin
cho
cell
annual
intern
meet
japanes
associ
anim
cell
technolog
kobe
kobe
hyogo
japan
novemb
oral
background
human
monoclon
antibodi
mab
among
promis
drug
defin
strategi
modif
still
avail
work
deal
human
murin
superhuman
approach
lead
loss
bind
affin
partial
restor
singl
humantomous
backmut
residu
select
synergist
combin
sequenc
analys
antibodi
framework
region
structur
inform
use
novel
silico
simul
structur
stabil
conglomer
tyrosin
residu
surround
identifi
call
tyrosin
cage
analysi
tyrosin
cage
done
alanin
scan
mutat
doubl
mutat
variant
tripl
mutat
variant
recent
seri
experi
tri
enhanc
bind
affin
three
new
variant
backmut
variabl
light
chain
vl
origin
residu
vl
select
base
spatial
proxim
loop
variabl
heavi
chain
affin
improv
evalu
vldoubl
backmut
variant
tripl
backmut
variant
materi
method
five
variant
express
transient
cell
bind
affin
investig
two
individu
set
biolay
interferometri
first
approach
concentr
cell
cultur
supernat
directli
appli
mab
captur
protein
tip
block
associ
dissoci
igg
measur
second
approach
cultur
supernat
purifi
affin
determin
streptavidin
biosensor
first
biotinyl
igg
bound
associationdissoci
purifi
variant
measur
result
affin
evalu
concentr
cultur
supernat
protein
sensor
tip
show
decreas
bind
affin
loss
bind
protein
measur
show
increas
bind
strength
compar
result
higher
bind
affin
compar
result
confirm
purifi
variant
streptavidin
bioassay
fig
conclus
alanin
scan
tyrosin
cage
demonstr
reduct
bind
affin
sever
loss
bind
conclud
tyrosin
cage
play
import
role
support
correct
cdr
loop
conform
affin
improv
singl
mutat
variant
could
reach
via
mutat
vl
demonstr
underestim
role
vl
interact
bind
partner
acknowledg
financi
support
austrian
scienc
fund
fwf
grant
number
p
grate
acknowledg
refer
mader
kunert
r
human
strategi
antiidiotyp
antibodi
mimick
hivi
protein
eng
de
sel
margreitt
c
mayrhof
p
kunert
r
oostenbrink
c
antibodi
human
molecular
dynam
simulationsinsilico
guid
select
critic
backmut
j
mol
recognit
background
although
cho
cell
major
express
system
product
recombin
biopharmaceut
molecular
cellular
background
character
high
produc
larg
unknown
observ
produc
cell
line
import
signal
pathway
like
aktsign
alter
characterist
way
thu
analyz
accord
signal
event
lead
identif
key
element
character
high
produc
cell
investig
emphasi
lie
phosphoryl
statu
involv
protein
revers
switch
signal
pathway
aim
establish
workflow
chospecif
phosphoproteom
focus
igf
signal
cell
cultur
media
often
supplement
growth
factor
two
produc
cell
line
accord
parent
cell
cultiv
stabl
isotop
label
amino
acid
cell
cultur
silac
experi
follow
quantit
ms
phosphoproteom
analysi
includ
chospecif
data
evalu
materi
method
chosen
cho
cell
line
cultiv
triplic
silac
media
contain
isotopicallylabel
lysinearginin
hlysharg
parallel
ident
standard
media
llyslarg
xell
cell
densiti
viabil
metabol
cell
cycl
distribut
monitor
ml
batch
cultur
day
day
igf
ad
hlysharg
cultur
min
later
part
cell
harvest
ms
analysi
igftreat
hlysharg
cultur
control
cultur
llyslarg
cultur
combin
follow
ms
sampl
prepar
workflow
includ
digest
whole
protein
lysat
phosphopeptid
enrich
via
nanolcesiorbitrap
ms
q
exact
plu
thermo
fisher
scientif
phosphopeptid
excecut
subsequ
identif
quantif
maxquant
addit
silac
quantif
hl
ratio
investig
igf
effect
aquir
data
also
use
perform
labelfre
quantif
lfq
maxquant
comparison
cell
line
statist
signific
calcul
via
ttest
p
anova
permutationbas
fdr
perseu
result
igf
effect
growth
product
igf
treatment
result
prolong
viabil
cell
line
howev
increas
vcd
observ
produc
cell
line
yield
enhanc
integr
vcd
ivcd
parent
cell
growth
inhibit
igf
although
sphase
cell
enrich
least
temporari
fig
regard
antibodi
product
igf
led
decreas
qp
product
titer
concomitantli
increas
sphase
cell
fig
invers
correl
prolifer
cell
specif
product
known
differ
product
enhanc
molecul
like
butyr
ms
investig
signal
event
phosphoproteom
experi
result
identif
class
iphosphoryl
site
statist
evalu
phosphopeptid
abund
perseu
show
signific
differ
cell
line
led
produc
vs
parent
classif
fig
quantit
evalu
via
silac
yield
quantifi
phosphosit
least
biolog
replic
rapid
phosphoryl
chang
growth
factor
treatment
indic
signal
toward
protein
synthesi
cell
cycl
regul
actin
cytoskeleton
amongst
other
phosphosit
significantli
differ
hl
ratio
calcul
two
group
parent
vs
produc
four
list
tabl
conclus
workflow
studi
phosphoryl
state
reveal
differ
relat
cell
line
gave
insight
signal
transduct
respons
igf
one
hand
igftreat
result
fast
widespread
upregul
phosphoryl
site
within
akt
mapksign
hand
differ
phosphoryl
statu
produc
compar
parent
cell
line
uncov
distinct
biolog
process
like
rna
dnabind
regul
cytoskeleton
sum
sucess
establish
phosphoproteom
approach
allow
detect
import
signal
key
player
cho
cell
subsequ
target
cell
engin
small
molecul
treatment
acknowledg
would
like
thank
australian
institut
bioengin
nanotechnolog
univers
queenslandbrisban
australia
aibn
provid
cho
clone
refer
cox
mann
maxquant
enabl
high
peptid
identif
rate
individu
ppbrang
mass
accuraci
proteomewid
protein
quantif
nat
biotechnol
tyanova
temu
sinitcyn
carlson
hein
geiger
mann
cox
perseu
comput
platform
comprehens
analysi
prote
omic
data
nat
method
heinrich
jab
schmidt
rodrigu
de
carvalho
albaum
baessmann
noll
hoffrogg
labelfre
protein
quantif
sodium
butyr
treat
cho
cell
esiuhrtofm
j
biotechnol
background
improv
antibodi
product
cho
cell
express
system
seem
use
downregul
gene
express
includ
antibodi
fold
secret
cell
metabol
mani
cell
engin
approach
includ
gene
introduct
knockout
knockdown
employ
enhanc
recombin
antibodi
product
howev
identifi
product
enhanc
gene
ratelimit
step
cho
cell
engin
convent
method
requir
seri
experi
includ
genom
integr
test
gene
select
stabl
cell
clone
cell
cultur
experi
sever
clone
studi
propos
approach
rapid
evalu
product
enhanc
gene
base
episom
express
system
materi
method
plasmid
vector
carri
viru
ebv
encod
nuclear
antigen
transfect
cho
cell
line
produc
antibodi
select
singl
coloni
isol
express
check
capillari
electrophoresi
system
we
proteinsimpl
ebv
use
detect
primari
antibodi
express
vector
gene
interest
prepar
insert
bp
orip
dna
sequenc
plasmid
vector
carri
cag
promot
result
potc
vector
pei
max
polysci
inc
balancd
transfectori
cho
irvin
scientif
use
transfect
number
viabl
cell
gfpposit
cell
count
use
countess
ii
fl
autom
cell
counter
thermo
fisher
scientif
transfect
cell
cultur
cellstar
cellreactor
tube
tube
incub
climoshak
kuhner
antibodi
product
measur
use
biolay
interferometri
octet
qk
system
fortebio
result
construct
four
cho
cell
line
stabli
express
term
capillari
electrophoresi
analysi
observ
clear
peak
correspond
express
four
cell
line
test
transfect
effici
potcgfp
plasmid
best
transfect
condit
peidna
ratio
cell
show
highest
gfpposit
cell
number
cellml
transfect
effici
among
four
cell
line
therefor
cell
line
select
studi
transfect
number
gfpposit
cell
continu
increas
even
passag
fig
suggest
potcgfp
plasmid
stabli
retain
replic
system
cell
line
preliminari
experi
introduc
three
gene
gss
gclm
cell
line
cotransfect
three
gene
led
increas
product
mgl
control
mgl
day
p
ttest
result
suggest
three
gene
work
product
enhanc
gene
convent
method
base
stabl
cell
take
month
determin
whether
gene
interest
benefici
recombin
product
contrast
identif
product
enhanc
gene
achiev
within
day
propos
method
base
system
conclus
propos
method
make
possibl
evalu
product
enhanc
gene
rapid
manner
propos
method
promis
approach
identifi
gene
enhanc
recombin
antibodi
product
acknowledg
research
partial
support
develop
key
technolog
discov
manufactur
pharmaceut
use
nextgener
treatment
diagnos
meti
ame
japan
refer
fischer
handrick
r
ott
k
art
cho
cell
engin
comprehens
retrospect
futur
perspect
biotechnol
adv
background
technolog
compris
set
protect
genet
element
improv
protein
product
act
transcript
well
translat
element
either
insert
exist
platform
vector
provid
complet
readytous
vector
technolog
use
stabl
transient
transfect
boost
protein
product
product
develop
appli
cld
pharmaceut
protein
combin
antibiot
select
dhfr
select
technolog
routin
result
fold
increas
express
client
antibodi
fusion
protein
pool
clonal
select
previous
success
combin
technolog
glutamin
synthetas
gs
select
cho
gs
null
cell
horizon
discoveri
result
clonal
cell
line
produc
gl
biosimilar
mab
fedbatch
assay
present
data
success
applic
technolog
enhanc
express
larg
kda
human
heterotrimer
glycoprotein
renown
difficulttoexpress
dte
protein
materi
method
express
vector
compris
hcmv
promot
bgh
polyadenyl
sequenc
express
cassett
gene
interest
select
marker
gene
promot
polyadenyl
sequenc
vector
also
contain
genet
element
technolog
proteon
cho
gs
null
cell
horizon
discoveri
transfect
duplic
refer
express
vector
select
media
lack
glutamin
contain
appropri
antibiot
bulk
pool
seed
equal
viabl
cell
densiti
obtain
maximum
viabil
cultur
day
without
feed
batch
express
target
protein
cell
cultur
supernat
stabl
bulk
pool
measur
elisa
result
three
protein
subunit
gene
express
vector
differ
select
marker
refer
construct
without
chain
express
vector
marker
gene
zeocin
blasticidin
gs
respect
similar
vector
combin
also
gener
element
integr
vector
addit
vector
subunit
separ
element
promot
polyadenyl
signal
gener
gs
marker
gene
cho
gs
cell
transfect
appropri
vector
combin
equimolar
ratio
select
bulk
medium
lack
glutamin
antibiot
transfect
cell
pool
recov
first
due
presenc
antibiot
medium
fig
pool
transfect
three
vector
recov
maximum
viabil
day
pool
recoveri
refer
pool
took
week
longer
pool
product
pool
assess
batch
product
run
shaker
flask
pool
recov
first
produc
titer
around
gl
almost
higher
compar
product
refer
pool
fig
highest
titer
gl
obtain
pool
data
show
genet
element
success
use
obtain
signific
increas
titer
difficulttoexpress
protein
similar
result
obtain
dte
protein
includ
fcfusion
protein
bispecif
antibodi
shown
conclus
express
larg
glycosyl
multimer
difficult
express
protein
increas
tenfold
cho
gs
pool
applic
genet
element
highest
express
obtain
use
separ
vector
subunit
background
chines
hamster
ovari
cho
cell
commonli
use
host
cell
produc
biopharmaceut
howev
number
chromosom
cho
cell
vari
previous
cell
line
modal
chromosom
number
isol
parent
cell
cell
line
name
establish
respect
cell
pool
show
higher
specif
product
rate
cell
pool
even
though
clone
half
clone
contain
number
vector
integr
site
singl
integr
site
cell
clone
produc
follow
cultur
singlecel
clone
clone
studi
perform
transcriptom
analysi
investig
characterist
highproduc
cell
chromosom
aneuploidi
materi
method
transcriptom
analys
use
amplifi
fragment
length
polymorph
aflp
base
highcoverag
express
profil
hicep
de
novo
mrnaseq
perform
compar
cell
line
differ
number
chromosom
transcriptom
data
mrnaseq
adjust
cell
number
use
rna
refer
materi
nmij
crm
nation
institut
advanc
industri
scienc
technolog
mix
equal
amount
per
cell
pathway
relat
differenti
express
gene
search
use
keymolnet
km
data
result
discuss
highchromosomenumb
cho
cell
show
larger
cell
diamet
determin
vicel
beckman
coulter
measur
predict
volum
ratio
base
diamet
level
product
gene
detect
mrnaseq
differ
approxim
comparison
base
analysi
gene
express
level
per
cell
volum
approxim
detect
gene
show
lower
express
compar
level
respect
addit
number
gene
whose
express
level
decreas
compar
larger
show
opposit
pattern
result
comparison
indic
differenti
express
gene
mainli
relat
cell
growth
eg
myc
smad
apoptosi
eg
caspas
lipid
metabol
eg
srebp
epigenet
histon
modif
eg
brca
hat
pathway
mrna
level
myc
smad
caspas
brca
hat
relat
gene
lower
srebp
relat
gene
higher
effect
pathway
antibodi
product
examin
futur
conclus
studi
found
highchromosomenumb
cho
cell
lower
amount
mrna
rel
volum
reduct
per
unit
volum
express
gene
requir
surviv
might
gener
addit
energi
recombin
protein
product
highchromosomenumb
cell
evolutionari
perspect
increas
set
chromosom
underli
rapid
evolutionari
adapt
although
issu
consid
stabil
may
also
advantag
use
highchromosomenumb
aneuploid
cho
cell
product
host
cell
recombin
protein
acknowledg
work
fund
partli
ministri
economi
trade
industri
japan
meti
japan
agenc
medic
research
develop
ame
project
focus
develop
key
technolog
discov
manufactur
drug
nextgener
treatment
diagnosi
partli
kakenhi
grant
japan
societi
promot
scienc
jsp
refer
yamano
n
takahashi
haghparast
onitsuka
kumamoto
frank
j
omasa
increas
recombin
protein
product
owe
expand
opportun
vector
integr
high
chromosom
number
chines
hamster
ovari
cell
journal
bioscienc
bioengin
background
human
growth
factor
enorm
therapeut
potenti
among
bone
morphogenet
induc
de
novo
bone
format
endow
protein
high
therapeut
potenti
howev
find
suitabl
recombin
product
system
protein
still
remain
challeng
materi
method
recombin
express
investig
transient
transfect
cell
stabl
clone
establish
cell
cultiv
excel
medium
respect
protein
stabil
interact
produc
cell
investig
vitro
use
commerci
avail
addit
investig
cellfre
protein
synthesi
system
harbor
transloc
activ
microsom
structur
henc
potenti
perform
posttransl
modif
altern
product
method
result
show
growth
rate
viabil
cell
similar
parent
cell
line
entri
death
phase
delay
case
recombin
cell
maximum
concentr
detect
cultur
supernat
low
stabl
clone
greatli
improv
combin
cell
transient
express
system
batch
reactor
cultiv
reflect
better
compat
codon
usag
human
cell
tabl
protein
sensit
slightli
acid
ph
lesser
extend
proteas
fig
bind
produc
cell
line
fig
could
incident
contribut
low
product
titer
cellfre
protein
synthesi
propos
altern
difficulttoexpress
protein
sinc
nativ
glycosyl
cellfre
system
base
eukaryot
cell
lysat
requir
product
cho
cell
lysat
chosen
sinc
previous
establish
product
eukaryot
system
hand
concomitantli
enabl
direct
comparison
product
stabl
clone
establish
abil
perform
posttransl
modif
major
advantag
eukaryot
system
cho
lysat
prepar
protocol
use
previous
shown
contain
signific
amount
endogen
microsom
deriv
endoplasmat
reticulum
lysi
enforc
transloc
target
protein
microsom
structur
melittin
signal
peptid
fuse
cdna
glycosyl
protein
assess
enzymat
treatment
pngase
endoh
confirm
use
de
novo
protein
synthesi
upon
cellfre
protein
synthesi
yield
higher
best
one
cell
differ
becom
even
dramat
product
consid
tabl
ie
fact
maximum
product
titer
reach
within
h
cellfre
system
compar
h
cellbas
one
demonstr
cellfre
express
system
suitabl
compar
mammalian
cell
express
method
product
glycosyl
human
tabl
conclus
human
growth
factor
complex
molecul
make
product
mammalian
cell
desir
howev
low
product
titer
caus
varieti
cell
process
relat
effect
may
hinder
develop
highli
product
process
case
cellfre
protein
product
use
cho
cell
lysat
contain
endogen
microsom
posttransl
process
may
eventu
present
attract
altern
particular
sinc
lysat
use
tightli
control
condit
assur
higher
degre
reproduc
eg
transient
transfect
system
cellfre
system
known
circumv
typic
bottleneck
cellbas
one
eg
metabol
regul
cell
mainten
mechan
consequ
product
recombin
protein
neither
inhibit
accumul
interact
cell
eg
activ
inhibitori
signal
pathway
refer
k
sonnabend
robert
l
stech
kubick
iresmedi
translat
membran
protein
glycoprotein
eukaryot
cellfre
system
plo
one
k
sonnabend
kubick
cellfre
protein
express
base
extract
cho
cell
biotechnol
bioeng
v
thore
l
salzig
kubick
freitag
r
comparison
cellbas
vs
cellfre
mammalian
system
product
recombin
human
bone
morphogen
growth
factor
eng
life
sci
doi
background
recent
year
develop
novel
nonvir
vector
gene
deliveri
mammalian
cell
increasingli
becom
focu
recent
report
novel
pdmaemabas
nanostar
base
superparamagnet
maghemit
nanoparticl
core
preliminari
studi
show
correspond
polyplex
also
cell
came
contact
becam
magnet
manag
magnet
field
present
character
influenc
structur
composit
function
polym
use
librari
highli
homogen
paramagnet
nanostar
vari
arm
length
densiti
materi
method
paramagnet
nanostar
librari
synthes
coat
maghemit
nanoparticl
thin
silicashel
function
atom
transfer
radic
polymer
atrp
initi
pdmaema
arm
grown
core
particl
via
atrp
one
case
pdmaema
arm
endcap
pdegma
block
produc
second
atrp
step
nanostar
character
size
exclus
chromatographi
thermogravimetri
calcul
number
length
pdmaema
arm
core
diamet
determin
transmiss
electron
microscopi
dynam
light
scatter
dl
differ
variant
tabl
analyz
abil
complex
pdna
use
variou
physicochem
method
dl
zeta
sizer
transfect
efficiencycytotox
cell
determin
flow
cytometri
transfect
cell
place
magnet
field
influenc
polym
architectur
magnet
separ
investig
nonparametr
spearman
analysi
use
correl
arm
lengtharm
densiti
magnet
properti
cell
transfect
effici
result
base
hydrodynam
radii
polyplex
investig
nanostar
could
divid
three
subgroup
tabl
middl
also
high
arm
densiti
nanostar
form
smaller
polyplex
hydrodynam
radii
nm
size
consid
suitabl
endocytosi
transfect
transfect
effici
cytotox
vari
systemat
nanostar
architectur
viabil
show
pronounc
depend
characterist
transfect
agent
transfect
effici
arm
densiti
particularli
import
valu
approxim
yield
best
result
fig
endcap
polyc
arm
pdegma
significantli
improv
serum
compat
fig
gene
deliveri
potenti
given
nanostar
abil
render
cell
magnet
correl
although
compar
nonsepar
cell
egfpexpress
cell
consist
frequent
magnet
cell
fraction
nonmagnet
fraction
slightli
deplet
egfpexpress
cell
divid
low
middl
high
produc
statist
signific
shift
toward
high
produc
observ
magnet
cell
fraction
fig
nonparametr
spearman
correl
analysi
use
statist
evalu
possibl
link
molecular
characterist
nanostar
physicochem
properti
correspond
polyplex
transfect
condit
cellular
reaction
result
correlogram
shown
fig
conclus
transfect
agent
magnet
properti
enlarg
toolbox
studi
nonvir
gene
deliveri
sinc
cellular
magnet
ad
new
paramet
allow
inter
alia
distinct
mere
cellular
interact
actual
uptak
otherwis
difficult
viabil
show
much
pronounc
depend
characterist
transfect
agentpolyplex
transfect
effici
taken
account
method
optim
endcap
polycation
pdmaemaarm
pdegmablock
improv
compat
polycation
nanostar
serum
compon
futur
optim
bloodcompat
nanostar
retaineddirect
magnet
field
could
becom
option
nonvir
gene
deliveri
vivo
acknowledg
research
support
upper
franconian
trust
grant
pnr
refer
majewski
p
schallon
v
freitag
r
h
schmalz
h
dualrespons
magnet
coreshel
nanoparticl
nonvir
gene
deliveri
cell
separ
biomacromolecul
majewski
p
stahlschmidt
u
v
freitag
r
h
e
schmalz
h
pdmaemagraft
coreshellcorona
particl
nonvir
gene
deliveri
magnet
cell
separ
biomacromolecul
raup
stahlschmidt
u
v
synatschk
c
v
h
e
freitag
r
influenc
polyplex
format
perform
starshap
polycation
transfect
agent
mammalian
cell
polym
stahlschmidt
u
v
majewski
freitag
r
systemat
studi
librari
pdmaemabas
superparamagnet
nanostar
transfect
cell
polym
background
increas
demand
monoclon
antibodi
necessit
need
increas
product
current
industri
cell
line
earlier
studi
shown
treatment
erstress
induc
tunicamycin
significantli
increas
titer
product
recombin
cho
cell
line
simultan
upregul
mani
gene
unfold
protein
respons
pathway
upr
howev
loss
cell
viabil
prevent
sustain
increas
titer
current
studi
explor
effect
vari
concentr
tunicamycin
treatment
time
modul
increas
protein
fold
capac
prevent
induct
apoptosi
materi
method
antirhesu
iggsecret
cho
cell
cultur
sfcdm
ml
shake
flask
cell
treat
vari
concentr
ngml
tunicamycin
batch
cultur
effect
treatment
tunicamycin
short
period
time
hr
also
evalu
igg
titer
mrna
express
level
quantifi
use
elisa
qrtpcr
illumina
respect
result
cho
cell
treat
differ
concentr
tunicamycin
cultur
batch
day
refer
continu
treatmentct
figur
present
maximum
vcd
drop
viabil
treatment
dosedepend
inhibitori
effect
observ
growth
viabil
cell
ctecultur
minim
inhibit
lower
concentr
contrastingli
igg
titer
fig
higher
treat
cultur
wrt
control
initi
phase
cultur
concentr
tunicamycin
percel
product
fig
also
show
signific
increas
wrt
control
concentr
tunicamycin
howev
increas
product
due
tunicamycin
sustain
level
becom
similar
control
day
data
shown
prevent
loss
viabil
due
tunicamycin
effect
shortterm
treatment
ste
tunicamycin
explor
cell
treat
tunicamycin
hour
harvest
correspond
day
cte
cultur
inocul
fresh
media
stecultur
show
improv
viabil
higher
maximum
vcd
compar
ctecultur
fig
fold
increas
igg
titer
sustain
beyond
day
stecultur
fig
signific
increas
product
seen
initi
phase
fig
cell
adapt
continu
gener
tunicamycin
adapt
cell
overal
higher
product
compar
control
fig
batch
cultur
understand
molecular
basi
increas
product
mrna
express
level
key
gene
determin
transcript
factor
involv
activ
chaperon
like
calreticulin
apoptot
gene
chop
signific
increas
level
calreticulin
seen
treatment
tunicamycin
fig
margin
induc
treat
tunicamycin
cteand
stecultur
fig
significantli
upregul
treat
tunicamycin
chop
mrna
level
also
increas
increas
tunicamycin
concentr
level
stecultur
lower
ctecultur
fig
result
suggest
upr
induct
may
import
increas
product
ctestecultur
note
tunicamycin
effect
express
level
igg
heavychain
thu
elimin
involv
igghcmrna
increas
product
fig
conclus
tunicamycin
induc
erstress
increas
product
initi
phase
cultur
enhanc
uprmedi
fold
capac
attribut
one
reason
lower
concentr
tunicamycin
fine
balanc
optimum
upr
induct
apoptosi
achiev
seen
tunicamycin
stecultur
summari
studi
demonstr
altern
approach
enhanc
product
current
industri
cell
line
acknowledg
work
partial
fund
dbt
govt
india
vc
acknowledg
ugc
fellowship
refer
segar
kp
v
chandrawanshi
mehra
system
biolog
unfold
protein
respons
recombin
cho
cell
bmc
proceed
suppl
p
prashad
k
mehra
dynam
unfold
protein
respons
recombin
cho
cell
cytotechnolog
p
background
chines
hamster
ovari
cho
cell
wide
use
largescal
product
biopharmaceut
construct
antibodyproduc
cho
cell
exogen
gene
encod
antibodi
usual
integr
unspecifi
region
chromosom
random
integr
howev
chromatin
structur
differ
depend
locat
chromosom
region
affect
express
level
gene
interest
recent
genetarget
method
enabl
sitespecif
integr
express
vector
develop
howev
region
effici
exogen
gene
express
clarifi
previous
construct
cho
genom
bacteri
artifici
chromosom
bac
librari
gener
recombin
cell
line
expect
cover
entir
cho
genom
five
time
chromosom
cell
align
decreas
order
size
assign
letter
three
hundr
four
bac
clone
map
everi
chromosom
among
karyotyp
primari
chines
hamster
cell
chromosom
b
consid
sole
pair
chromosom
correspond
chromosom
primari
chines
hamster
cell
henc
chromosom
b
consid
stabl
studi
construct
antibodyproduc
cell
use
genetarget
method
focus
stabl
chromosom
materi
method
gene
map
chromosom
construct
combin
bacfluoresc
situ
hybrid
fish
base
chromosom
physic
map
sequenc
data
map
bac
clone
sequenc
bac
clone
search
blast
ncbi
chogenomeorg
databas
three
differ
region
chromosom
b
select
base
cho
genom
bac
librari
sequenc
target
site
cell
stabli
transfect
lipofect
target
sequenc
broken
use
cluster
regularli
interspac
short
palindrom
repeat
crispr
crisprassoci
protein
system
human
gene
integr
nonhomolog
end
join
recombin
transfect
without
use
system
also
perform
cell
pool
cultiv
six
day
serumsuppl
medium
level
antibodi
product
evalu
elisa
copi
number
analysi
also
perform
use
realtim
pcr
result
discuss
construct
gene
map
chromosom
eightythre
bac
clone
map
onto
chromosom
b
clone
contain
kb
cho
genom
sequenc
result
annot
bac
clone
sequenc
gene
map
chromosom
investig
differ
product
among
antibodyproduc
cell
construct
chromosom
target
andor
random
integr
cell
growth
affect
gene
target
site
specif
product
rate
antibodyproduc
cell
pool
construct
gene
target
chromosom
higher
cell
pool
construct
random
integr
cell
pool
construct
gene
target
show
lower
copi
number
heavi
chain
light
chain
genom
dna
cell
pool
construct
random
integr
despit
show
high
product
conclus
result
indic
high
product
cell
construct
gene
target
chromosom
depend
increas
antibodi
copi
number
environ
around
target
region
suitabl
exogen
gene
express
approach
use
gene
target
chromosom
may
promis
construct
antibodyproduc
cell
acknowledg
work
partial
support
project
focus
develop
key
technolog
discov
manufactur
drug
nextgener
treatment
diagnosi
ministri
economi
trade
industri
japan
meti
grantsinaid
scientif
research
japan
societi
promot
scienc
jsp
refer
wurm
fm
product
recombin
protein
therapeut
cultiv
mammalian
cell
nat
biotechnol
wilson
c
bellen
hj
gehr
wj
posit
effect
eukaryot
gene
express
annu
rev
cell
biol
omasa
cao
park
jy
takagi
kimura
yano
h
honda
k
asakawa
shimizu
n
ohtak
h
bacteri
artifici
chromosom
librari
genomewid
analysi
chines
hamster
ovari
cell
biotechnol
bioeng
cao
kimura
itoi
honda
k
ohtak
h
omasa
construct
bacbas
physic
map
analysi
chromosom
rearrang
chines
hamster
ovari
cell
line
biotechnol
bioeng
background
retrovir
vector
wide
use
gene
deliveri
tool
variou
biotechnolog
field
howev
random
integr
featur
retrovir
vector
seem
caus
problem
insert
mutagenesi
gene
silenc
previous
demonstr
cremedi
retrovir
transgen
insert
predetermin
site
founder
cell
use
integrasedefect
retrovir
vector
idrv
cre
express
plasmid
transfect
cell
prior
retrovir
transduct
recent
report
novel
hybrid
idrv
creidrv
incorpor
bioactiv
cre
recombinas
protein
valid
sitespecif
gene
integr
scfvfc
antibodi
express
unit
chines
hamster
ovari
cho
cell
genom
also
develop
accumul
sitespecif
gene
integr
system
enabl
repeat
integr
multipl
transgen
predetermin
locu
cell
genom
attempt
repeat
integr
transgen
use
creidrv
materi
method
viral
vector
plasmid
pqmscvhd
scfvfc
encod
report
gene
scfvfc
express
unit
flank
wildtyp
mutant
loxp
construct
product
idrv
creidrv
produc
describ
previous
cho
cell
chone
scfvfc
introduc
report
gene
atgdeletedneoriresegfp
scfvfc
express
unit
flank
compat
pair
loxp
use
founder
cell
second
round
sitespecif
integr
viral
solut
copieswel
mscvhd
scfvfc
infect
chone
scfvfc
cell
cellswel
cell
screen
day
presenc
hygromycin
b
form
coloni
observ
fluoresc
microscop
clone
isol
coloni
pick
method
genom
dna
extract
cell
subject
genom
pcr
analysi
result
discuss
figur
show
schemat
draw
round
target
transgen
integr
use
creidrv
harbor
scfvfc
express
unit
previous
establish
recombin
cho
cell
chone
scfvfc
express
report
neor
egfp
scfvfc
protein
use
creidrv
produc
pqmscvne
scfvfc
second
crermc
reaction
construct
viral
vector
plasmid
pqmscvhd
scfvfc
encod
marker
gene
atgdelet
hygriresdsr
scfvfc
express
unit
flank
correspond
loxp
site
second
round
cremedi
integr
circular
retrovir
dna
deriv
idrv
chone
scfvfc
cell
genom
neor
express
replac
hygr
express
red
fluoresc
protein
express
cell
expect
structur
transgen
crermc
reaction
idrv
cell
genom
also
shown
fig
chone
scfvfc
cell
infect
creidrv
produc
use
pqmscvhd
scfvfc
two
cell
coloni
isol
use
hygromycin
screen
chohd
scfvfc
cell
express
dsred
fig
genom
dna
extract
cell
subject
pcr
use
specif
primer
pair
confirm
sitespecif
integr
dna
fragment
expect
size
amplifi
cell
clone
fig
result
indic
sitespecif
repeat
integr
achiev
use
creidrv
contrast
scfvfc
product
chohd
scfvfc
cell
slightli
decreas
compar
chone
scfvfc
data
shown
although
reason
remain
unclear
repeatinduc
gene
silenc
might
occur
due
tandem
repeat
structur
express
unit
report
improv
recombin
antibodi
product
use
product
enhanc
element
cisregulatori
element
might
feasibl
approach
enhanc
product
conclus
demonstr
sitespecif
repeat
transgen
integr
predetermin
chromosom
locu
use
creidrv
product
scfvfc
antibodi
acknowledg
work
support
part
grant
develop
key
technolog
discov
manufactur
pharmaceut
use
nextgener
treatment
diagnos
ministri
economi
trade
industri
meti
japan
japan
agenc
medic
research
develop
ame
refer
huang
kawab
ito
kamihira
cre
recombinasemedi
sitespecif
modif
cellular
genom
use
integrasedefect
retrovir
vector
biotechnol
bioeng
kawab
shimomura
huang
imanishi
ito
kamihira
target
transgen
insert
cho
cell
genom
use
cre
recombinaseincorpor
integrasedefect
retrovir
vector
biotechnol
bioeng
kameyama
kawab
ito
kamihira
accumul
sitespecif
gene
integr
system
use
cre
recombinasemedi
cassett
exchang
biotechnol
bioeng
kawab
inao
komatsu
huang
ito
omasa
kamihira
improv
recombin
antibodi
product
cho
cell
use
product
enhanc
dna
element
repeat
transgen
integr
predetermin
chromosom
site
j
biosci
bioeng
background
lipid
role
cell
reduc
long
time
cell
membran
format
understood
lipid
play
also
role
energi
metabol
vesicular
transport
membran
structur
dynam
signal
howev
exact
mechan
composit
complex
affect
cell
homeostasi
remain
unclear
thank
recent
advanc
mass
spectrometri
possibl
studi
wide
rang
lipid
provid
better
understand
lipid
homeostasi
high
perform
cell
cultur
process
materi
method
purpos
work
develop
robust
lipidom
method
appli
mammalian
cell
cultur
three
step
method
extract
separ
detect
fig
matyash
folch
extract
method
perform
cell
reach
highest
yield
two
separ
techniqu
also
test
hydrophil
interact
liquid
chromatographi
hilic
revers
phase
chromatographi
final
lipid
class
identif
achiev
tandem
mass
spectrometri
analysi
thank
structurespecif
fragment
ion
result
yield
obtain
matyash
extract
method
higher
folch
method
lipid
class
test
besid
matyash
method
present
also
advantag
less
toxic
suitabl
high
throughput
analysi
sinc
organ
layer
aqueou
layer
lipid
separ
hilic
base
polar
head
sinc
lipid
class
defin
polar
head
lipid
elut
class
class
make
identif
easier
separ
lipid
revers
phase
correct
method
longer
observ
massiv
carryov
triglycerid
column
final
lipid
class
screen
msm
parent
ion
mode
target
daughter
ion
set
accord
lipid
class
structur
fragment
pattern
detect
techniqu
enabl
identif
differ
lipid
ensur
absolut
quantif
detect
lipid
guarante
compar
result
batch
label
intern
standard
ad
prior
extract
conclus
method
optim
stepwis
process
ensur
sensit
select
measur
lipid
lipid
extract
matyash
method
separ
hilic
detect
tandem
mass
spectrometri
method
suitabl
process
sampl
lipid
analysi
provid
inform
cell
lipid
content
harvest
sampl
enabl
follow
lipid
releas
differ
harvest
step
nontarget
lipidom
quantit
method
enabl
us
better
control
lipid
synthesi
biopharmaceut
fed
batch
product
clone
select
metabolom
studi
harvest
develop
acknowledg
mani
thank
stefano
grammatiko
support
whole
upstream
process
scienc
team
refer
matyash
v
liebisch
g
kurzchalia
v
shevchenko
schwudk
lipid
extract
methyltertbutyl
ether
highthroughput
lipidom
j
lipid
re
folch
j
lee
sloan
stanley
g
h
simpl
method
isol
purif
total
lipid
anim
tissu
j
biol
chem
background
human
mesenchym
stemstrom
cell
hmsc
easili
isol
eg
bone
marrow
fat
tissu
umbil
cord
blood
therefor
central
player
regen
medicin
gene
therapi
cell
therapi
necessari
gene
shuttl
mainli
provid
virus
associ
diseas
like
retroviru
adenoviru
possibl
pathogen
virus
demand
high
safeti
standard
also
prone
genom
alter
possibl
viru
inactiv
trigger
due
preexist
immun
patient
context
autographa
californica
multicapsid
nucleopolyhedroviru
acmnpv
safe
altern
viru
replic
hostspecif
insect
known
sinc
temporari
transduct
mammalian
cell
possibl
modif
viru
increas
applic
stem
cell
pseudotyp
viru
vesicular
stomat
glycoprotein
vsvg
led
expans
transduc
cell
integr
woodchuck
hepat
viru
posttranscript
regulatori
element
wpre
prolong
recombin
protein
express
achiev
baculovirusinduc
differenti
hmsc
promotor
express
strength
recombin
protein
crucial
factor
still
still
compar
promotor
studi
howev
success
viru
uptak
prerequisit
success
protein
express
therefor
investig
factor
significantli
influenc
transduct
process
appli
design
experi
fig
materi
method
experiment
design
compris
two
level
factori
screen
setup
use
design
expert
transduct
seed
plate
dmem
fc
incub
overnight
humidifi
atmospher
recombin
baculoviru
use
integr
promot
control
gfp
express
describ
elsewher
dilut
respect
concentr
differ
surround
fluid
discard
cultiv
medium
hmsctert
ml
viru
contain
solut
ad
cell
follow
incub
vari
durat
replac
viru
solut
growth
medium
incub
overnight
h
post
transduct
hpt
cell
wash
pb
trypsin
trypsinedta
incub
min
trypsin
stop
appli
soybean
trypsin
inhibitor
cell
analyz
use
flow
cytometri
result
shown
fig
viru
concentr
incub
time
exert
highest
influenc
transduct
effici
obvious
higher
concentr
viral
particl
longer
incub
cell
viru
increas
probabl
hit
cell
viru
particl
addit
surround
fluid
neg
impact
transduct
due
interact
medium
compon
baculoviru
therefor
pb
contain
recommend
surround
fluid
transduct
experi
fig
transduct
condit
result
highest
percentag
gfp
cell
display
viru
particl
per
cell
ppc
incub
time
h
hmsctert
conclus
experi
show
especi
viru
concentr
incub
time
cell
viru
influenc
transduct
effici
base
result
screen
optim
transduct
condit
done
use
face
center
central
composit
design
pb
contain
surround
fluid
incub
temperatur
acknowledg
author
thank
hessen
state
ministri
higher
educ
research
art
within
hessen
initi
scientif
econom
excel
loew
program
financi
support
refer
kim
n
cho
sg
clinic
applic
mesenchym
stem
cell
korean
j
intern
med
volarev
v
arsenijev
n
lukic
ml
stojkov
concis
review
mesenchym
stem
cell
treatment
complic
diabet
mellitu
stem
cell
mcguirk
jp
smith
jr
divin
cl
zuniga
weiss
ml
wharton
jellyderiv
mesenchym
stromal
cell
promis
cellular
therapeut
strategi
manag
graftversushost
diseas
pharmaceut
basel
verma
im
weitzman
md
gene
therapi
twentyfirst
centuri
medicin
annu
rev
biochem
kay
stateoftheart
genebas
therapi
road
ahead
nat
rev
genet
vannucci
l
lai
chiuppesi
f
ceccherininelli
l
pistello
viral
vector
look
back
ahead
gene
transfer
technolog
new
microbiol
balakrishnan
b
jayandharan
g
basic
biolog
adenoassoci
viru
aav
vector
use
gene
therapi
curr
gene
ther
roth
modlich
u
schambach
biosafeti
challeng
use
lentivir
vector
gene
therapi
curr
gene
ther
castro
mg
candolfi
wilson
tj
calinescu
paran
c
kamran
n
et
al
adenovir
vectormedi
gene
therapi
glioma
come
age
expert
opin
biol
ther
merten
ow
schweizer
chahal
p
kamen
aa
manufactur
viral
vector
gene
therapi
part
upstream
process
pharm
bioprocess
ayr
md
howard
sc
kuzio
j
lopezferb
posse
rd
complet
dna
sequenc
autographa
californica
nuclear
polyhedrosi
viru
virolog
hofmann
c
sandig
v
jen
g
rudolph
schlag
p
strauss
effici
gene
transfer
human
hepatocyt
baculoviru
vector
proc
natl
acad
sci
u
barsoum
j
brown
r
mckee
boyc
fm
effici
transduct
mammalian
cell
recombin
baculoviru
vesicular
stomat
viru
g
glycoprotein
hum
gene
ther
kost
condreay
jp
recombin
baculovirus
mammalian
cell
genedeliveri
vector
trend
biotechnol
aj
airenn
kj
purola
peltomaa
e
kaikkonen
mu
riekkinen
ms
et
al
posttranscript
regulatori
element
boost
baculovirusmedi
gene
express
vertebr
cell
j
biotechnol
zeng
j
du
j
zhao
palanisami
n
wang
baculovir
vectormedi
transient
stabl
transgen
express
human
embryon
stem
cell
stem
cell
qin
jy
zhang
l
clift
kl
hulur
xiang
ap
ren
bz
et
al
systemat
comparison
constitut
promot
doxycyclineinduc
promot
plo
one
sprick
g
weidner
salzig
czermak
p
baculovirusinduc
recombin
protein
express
human
mesenchym
stromal
stem
cell
promot
studi
n
biotechnol
background
breast
cancer
second
main
caus
cancer
relat
death
women
worldwid
among
tripl
neg
subtyp
tnbc
repres
clinic
challeng
associ
high
mortal
effect
therapi
accordingli
urgent
need
design
new
effect
drug
treat
breast
cancer
notch
signal
evolutionari
conserv
celltocel
commun
pathway
crucial
embryon
breast
develop
tissu
homeostasi
pathway
often
hyperactiv
overexpress
notch
receptor
andor
ligand
sever
type
cancer
breast
cancer
tnbc
includ
contribut
develop
progress
drug
resist
aim
gener
function
block
antibodi
notch
ligand
therapeut
efficaci
breast
cancer
materi
method
dna
human
full
length
extracellular
domain
truncat
version
contain
minim
bind
region
notch
receptor
clone
express
recombin
protein
purifi
cultur
media
proteina
affin
size
exclus
chromatographi
human
scfv
phage
display
tomlinson
ij
librari
use
select
specif
scfv
peptid
target
bind
region
notch
bind
abil
specif
select
scfv
clone
evalu
scfvonphag
elisa
result
strategi
allow
us
obtain
mg
pure
stabl
confirm
sd
page
thermofluor
assay
yield
low
buffer
screen
ongo
optim
protein
stabil
function
studi
perform
human
breast
cancer
cell
show
ligand
biolog
activ
increas
express
notchdepend
gene
heyl
recombin
peptid
use
select
monoclon
antibodi
phage
display
three
round
pan
peptid
identifi
scfv
posit
clone
present
high
affin
current
perform
phage
display
select
increas
number
posit
clone
scfv
higher
affin
reformat
igg
abil
inhibit
notch
pathway
evalu
antioncogen
effect
igg
assess
breast
cancer
cell
viabilityapoptosi
prolifer
migrat
invas
assay
conclus
igg
therapeut
efficaci
breast
cancer
demonstr
target
could
one
key
factor
success
target
breast
cancer
acknowledg
ibet
fct
refer
hudi
ca
gianni
l
tripleneg
breast
cancer
unmet
medic
need
oncologist
suppl
p
ecker
dm
jone
sd
levin
hl
therapeut
monoclon
antibodi
market
mab
p
sharma
paranjap
rangarajan
digh
rr
monoclon
antibodi
human
ligandbind
domain
deplet
subpopul
put
breast
cancer
stemlik
cell
mol
cancer
ther
p
v
mira
e
b
g
c
de
la
pompa
jl
notch
activ
stimul
migrat
breast
cancer
cell
promot
tumor
growth
breast
cancer
re
p
lami
ferreira
dia
js
braga
silva
g
barba
notchout
breast
cancer
therapi
n
biotechnol
epub
ahead
print
background
recombin
adenoassoci
viru
raav
approach
outstand
reput
gene
therapi
evalu
cancer
therapi
advantag
includ
longterm
gene
express
target
divid
nondivid
cell
low
immunogen
establish
raav
product
util
tripl
transfect
adher
hek
cell
hardli
meet
product
yield
requir
clinic
applic
transfer
aav
product
system
hek
suspens
cell
process
scalabl
use
serumfre
media
streamlin
downstream
procedur
optim
transfect
effici
shaker
cultiv
produc
titer
viral
genom
per
cell
l
bioreactor
materi
method
suspens
adapt
hekfreestyl
cell
line
use
experi
chemic
defin
anim
compon
free
media
hektf
hekgm
xell
ag
freestyl
thermo
fisher
scientif
sampl
viabl
cell
densiti
viabil
taken
daili
analyz
use
autom
cell
count
system
cedex
roch
diagnost
transient
transfect
cellsml
carri
polyethylenimin
max
dnapei
ratio
ww
dna
three
plasmid
pgoi
prepcap
phelper
appli
molar
ratio
fig
pretest
perform
orbit
shake
tube
spin
bioreactor
scaleup
batch
process
carri
ml
shake
flask
well
l
stir
bioreactor
air
satur
ph
transfect
effici
raav
product
quantifi
flow
cytometri
use
goi
code
fluoresc
protein
qpcr
genom
copi
respect
result
optim
dna
amount
transfect
cell
cell
reproduc
transfect
batch
cultiv
shaker
flask
reveal
raav
produc
first
h
transfect
figur
show
viabl
cell
densiti
viabil
relat
genom
titer
genom
titer
determin
raw
cell
extract
copiesml
repetit
achiev
decreas
viabil
mark
declin
genom
copi
per
ml
show
prolong
process
eg
addit
feed
would
probabl
increas
yield
first
scaleup
raav
product
transfer
l
bioreactor
fig
transfect
effici
bioreactor
compar
obtain
simultan
shaker
flask
experi
transfect
effici
lower
compar
prior
experi
due
control
condit
bioreactor
nonetheless
titer
genom
copi
per
cell
elev
compar
shaker
flask
conclus
first
experi
cell
hek
tf
medium
show
promis
result
transfer
raav
product
adher
system
suspens
improv
transfect
adjust
dna
amount
small
scale
experi
aav
product
analyz
shaker
flask
batch
process
show
expect
increas
cell
densiti
low
variabl
biolog
replic
fig
genom
titer
increas
accord
viabl
cell
densiti
day
four
sudden
drop
start
observ
made
aav
product
hektf
hekgm
freestyl
medium
optim
yield
assum
slight
decreas
viabil
mark
point
time
harvest
optim
protocol
batch
process
l
bioreactor
carri
interestingli
bioreactor
cultiv
result
lower
overal
viabl
cell
densiti
higher
genom
copi
per
cell
compar
shaker
flask
fig
result
compar
alreadi
publish
data
suspens
cell
subsequ
optim
bioreactor
protocol
lead
increas
raav
yield
acknowledg
author
thank
xell
ag
bielefeld
provid
hek
serumfre
media
hek
gm
hek
tf
fruit
discuss
refer
hagen
baumann
wagner
hj
morath
v
kaufmann
b
fischer
et
al
modular
adenoassoci
viru
raav
vector
use
cellular
virusdirect
enzym
prodrug
therapi
sci
rep
grieger
jc
solti
sm
samulski
rj
product
recombin
adenoassoci
viru
vector
use
suspens
cell
continu
harvest
vector
cultur
media
gmp
fix
clinic
vector
mol
ther
background
genethon
pall
collabor
assess
pall
singleus
icelli
fixedb
bioreactor
viral
vector
product
clinic
use
gene
therapi
treat
formerli
incur
genet
diseas
advanc
rapidli
viral
vector
import
tool
introduc
gene
target
cell
mani
gene
therapi
develop
use
adher
cell
flatwar
roller
bottl
use
technolog
reach
commercialscal
product
repres
signific
challeng
icelli
bioreactor
enabl
largescal
viral
vector
product
provid
matrix
cell
growth
compact
configur
fig
surfac
area
avail
compact
bioreactor
measur
mm
diamet
total
volum
l
ph
temperatur
control
key
featur
icelli
bioreactor
scale
increas
diamet
fixedb
keep
height
constant
chang
aspect
ratio
height
fixedb
vari
cm
well
densiti
carrier
pack
gml
gml
icelli
system
come
two
format
icelli
nano
bioreactor
icelli
bioreactor
process
develop
bench
top
icelli
nano
bioreactor
directli
transfer
correspond
icelli
system
icelli
nano
bioreactor
enabl
effici
platform
process
optim
materi
method
cell
icelli
nano
bioreactor
pall
part
pall
part
growth
medium
freestyl
express
medium
thermo
fisher
part
supplement
mm
supplement
thermo
fisher
part
transfect
reagent
transfect
reagent
polyplu
part
mix
proprietari
plasmid
construct
pgfp
phelper
genethon
product
medium
dulbecco
modifi
eagl
medium
dmem
thermo
fisher
part
supplement
mm
glutamax
supplement
thermo
fisher
part
lysi
buffer
triton
solut
merck
millipor
part
nacl
solut
sigma
aldrich
part
ph
adjust
naoh
merck
millipor
method
genethon
process
transfer
icelli
nano
bioreactor
cm
bed
height
gml
densiti
bioreactor
use
freestyl
media
initi
icelli
nano
process
establish
seed
day
transfect
day
harvest
day
yield
media
exchang
cell
densiti
transfect
pdnacel
ratio
lysi
method
chang
determin
effect
product
modifi
process
scale
cm
bed
height
gml
densiti
icelli
nano
bioreactor
result
media
media
exchang
hour
post
transfect
dmem
substitut
freestyl
medium
result
increas
specif
productivitycel
densiti
transfect
cell
seed
reach
day
determin
optim
cell
densiti
transfectionpdnacel
ratio
reduc
pdna
signific
effect
productivitylysi
use
trion
mm
nacl
ph
result
viru
recoveri
compar
sampl
carrierssc
specif
product
maintain
system
scale
averag
yield
achiev
conclus
icelli
technolog
adopt
wide
viral
vector
product
transfer
process
icelli
nano
bioreactor
easili
achiev
place
optim
provid
signific
product
increas
cost
save
reduc
pdna
icelli
nano
bioreactor
effici
benchtop
system
result
readili
scale
icelli
system
background
tissus
multiorganchip
moc
platform
contribut
ongo
advanc
system
substanc
test
vitro
current
vitro
anim
test
drug
develop
fail
emul
system
organ
complex
human
bodi
therefor
often
accur
predict
drug
toxic
especi
cardiotox
one
main
reason
new
compound
fail
clinic
trial
therefor
aim
establish
autolog
dynam
multiorgandevic
integr
cardiomyocyt
substanc
test
result
gener
monolay
suspens
ipsc
deriv
cardiomyocyt
differenti
protocol
establish
beat
cardiomyocyt
first
seen
day
monolay
well
spheroid
cultur
cardiomyocyt
show
cardiac
troponin
posit
cell
myosin
heavi
chain
posit
cell
flow
cytometri
fig
h
myosin
ii
heavi
chain
myosin
myosin
caldesmon
express
shown
immunohistochemistri
fig
due
exclus
lactat
enrich
cardiomyocyt
cardiac
fibroblast
also
express
spheroid
shown
vimentin
stain
cardiac
fibroblast
lead
physiolog
heterolog
cell
popul
similar
human
heart
beat
spheroid
cultiv
day
dynam
cultur
condit
multiorganchip
integr
onchip
micropump
provid
physiologicallik
pulsatil
circul
microlit
scale
lead
better
nutrit
oxygen
suppli
conclus
next
signific
step
combin
multipl
autolog
organ
equival
use
ipsc
differenti
technolog
differenti
cell
type
one
ipsc
donor
crucial
overcom
sourc
reject
problem
combin
multiorganchip
platform
ipsc
differenti
technolog
eventu
lead
person
system
drug
substanc
test
background
use
cellbas
assay
pharmaceut
industri
academ
research
grow
trend
drive
forc
reduc
cost
drug
develop
academ
research
gain
inform
intracellular
target
function
mechan
varieti
differ
assay
benefit
use
preclin
studi
furthermor
costli
latestag
drug
failur
may
reduc
use
cellbas
assay
use
autom
system
also
great
demand
chang
test
substanc
research
activ
nevertheless
lot
barrier
moment
limit
success
applic
autom
system
field
lack
flexibl
demand
skill
comput
scientist
engin
two
main
aspect
state
expert
shall
mention
strong
background
autom
cell
cultur
technolog
expertis
gain
sever
project
let
us
rethink
overal
process
chain
overcom
establish
principl
new
servic
orient
platform
execut
cellbas
assay
commonli
use
introduc
main
idea
give
access
autom
infrastructur
academ
research
spinoff
afford
special
infrastructur
materi
method
infrastructur
modularli
built
consist
autom
liquid
handl
robot
plate
tube
handl
robot
well
incub
refriger
analysi
system
exampl
imag
system
aim
address
need
reproduc
reliabl
result
offer
access
maxim
control
autom
environ
help
webbas
configur
assay
select
well
parameter
assay
done
easi
way
order
process
test
item
ship
lab
assay
execut
fulli
autom
platform
captur
process
data
well
environment
condit
real
complet
data
set
lead
comprehens
result
soon
result
avail
process
view
analys
done
secur
cloud
result
conclus
servic
use
singl
experi
low
throughput
applic
therefor
benefit
lab
afford
autom
infrastructur
staff
mainten
platform
extens
monitor
data
captur
run
lead
gapless
data
trail
possibl
detail
result
analysi
due
autom
process
reproduc
increas
associ
direct
reduct
cost
time
central
servic
pair
specif
knowhow
allow
upscal
process
time
webbas
interfac
provid
flexibl
guidanc
user
onlin
order
give
access
infrastructur
lead
fast
reliabl
result
gener
furthermor
secur
interact
addit
servic
eg
specif
data
analysi
tool
possibl
dynam
access
autom
offer
high
flexibl
low
throughput
experi
push
high
qualiti
research
drug
develop
earli
stage
background
nowaday
anim
cell
technolog
commonli
use
broad
rang
medic
pharmaceut
applic
one
main
topic
technolog
product
protein
use
therapeut
purpos
vivo
product
process
often
time
consum
limit
product
call
difficulttoexpress
protein
includ
pharmaceut
relev
class
membran
protein
overcom
issu
novel
cellfre
protein
synthesi
platform
develop
base
industri
work
hors
cho
cell
cell
lysat
provid
basi
technolog
includ
compon
translat
machineri
enabl
protein
product
within
hour
microsom
structur
present
cho
cell
lysat
enabl
posttransl
modif
target
protein
insert
membran
protein
lipid
bilay
materi
method
studi
cellfre
protein
synthesi
platform
develop
base
combin
cho
cell
lysat
continu
exchang
reaction
format
continu
exchang
reactor
consist
twochamb
system
reaction
feed
chamber
separ
semiperm
membran
due
concentr
gradient
energi
compon
diffus
reaction
chamber
inhibitori
byproduct
continu
remov
differ
class
protein
select
evalu
qualiti
cho
cecf
system
includ
transmembran
receptor
singl
chain
variabl
fragment
ion
channel
cellfre
protein
synthesi
perform
presenc
leucin
radio
label
synthes
protein
protein
yield
quantifi
tca
precipit
radio
label
protein
follow
scintil
measur
molecular
mass
detect
autoradiographi
posttransl
modif
activ
protein
estim
kinas
assay
elisa
endoglycosidas
treatment
electrophysiolog
measur
result
demonstr
result
show
protein
product
around
gl
detect
correct
molecular
weight
autoradiographi
analysi
product
use
differ
lysat
batch
product
membran
protein
egfr
reveal
minim
batchtobatch
variat
fig
posttransl
modif
protein
includ
phosphoryl
glycosyl
detect
use
western
blot
autoradiographi
fig
evalu
local
membran
embed
eyfp
fusion
protein
confoc
laser
scan
microscopi
result
detect
protein
microsom
fraction
cho
cell
lysat
produc
singl
chain
variabl
fragment
show
bind
specif
elisa
experi
activ
synthes
ion
channel
underlin
electrophysiolog
measur
detect
singl
channel
activ
cellfre
system
base
cho
cell
lysat
high
yield
product
protein
develop
provid
platform
effici
product
difficulttoexpress
protein
conclus
combin
cho
lysat
base
cellfre
system
continu
exchang
cellfre
system
lead
highli
effici
product
system
variou
class
difficulttoexpress
protein
approach
open
fast
costeffect
process
pipelin
product
difficulttoexpress
protein
show
high
potenti
industri
applic
includ
screen
technolog
protein
structur
determin
justintim
protein
product
process
acknowledg
author
would
like
thank
dana
wenzel
cho
lysat
prepar
fraunhof
izi
potsdamgolm
germani
work
support
european
region
develop
fund
efr
german
ministri
educ
research
bmbf
refer
thore
l
borowiak
stech
sonnabend
kubick
cellfre
system
base
cho
cell
lysat
optim
strategi
synthesi
difficulttoexpress
protein
futur
perspect
plo
one
k
sonnabend
kubick
cellfre
protein
express
base
extract
cho
cell
biotechnol
bioeng
biotechnolog
bioengin
jerom
v
thore
l
salzig
kubick
freitag
r
comparison
cellbas
vs
cellfre
mammalian
system
product
recombin
human
bone
morphogen
growth
factor
engin
life
scienc
k
sonnabend
robert
l
stech
kubick
iresmedi
translat
membran
protein
glycoprotein
eukaryot
cellfre
system
plo
one
background
nowaday
known
develop
inhibitori
antibodi
hemophiliac
patient
close
relat
immunogen
epitop
present
coagul
factor
protein
produc
hamster
cell
insert
differ
posttransl
modif
profil
compar
human
profil
patient
hightiterhighrespond
inhibitor
must
treat
bypass
agent
achiev
hemostasi
activ
factor
vii
fviia
attract
candid
hemostasi
independ
fviiifix
make
coagul
factor
altern
hemophilia
patient
inhibitori
antibodi
howev
recombin
factor
vii
produc
cell
babi
hamster
kidney
cell
well
other
coagul
factor
may
contain
immunogen
epitop
context
becom
extrem
import
produc
recombin
protein
complex
posttransl
modif
cell
line
yet
use
materi
method
use
human
cell
line
product
recombin
fvii
gener
recombin
cell
line
use
bicistron
lentivir
vector
contain
fvii
gene
gfp
select
marker
gene
master
cell
bank
work
cell
bank
gener
gmp
condit
rfvii
analys
made
elisa
assay
western
blot
gene
express
quantif
biolog
activ
use
prothrombin
time
pt
assay
rfvii
purif
affin
chromatographi
use
viiselect
ge
column
purif
rfvii
formul
dri
froze
use
vivo
experi
result
static
condit
cell
show
period
month
stabl
fvii
product
averag
iuml
fvii
cell
viabil
cell
express
gfp
gene
purif
viiselect
column
possibl
observ
recov
purifi
protein
degre
puriti
fig
recombin
purifi
fvii
use
vivo
experi
determin
pharmacokinet
paramet
evalu
posttransl
modif
profil
conclus
conclus
studi
report
use
cell
line
highlevel
product
recombin
factor
vii
cell
proven
effect
product
recombin
protein
use
new
platform
product
recombin
protein
acknowledg
author
acknowledg
paulo
research
foundat
fapesp
centro
de
pesquisa
e
cepid
nation
institut
scienc
technolog
stem
cell
cell
therapi
inctc
financi
support
refer
fliedl
l
grillari
j
grillarivoglau
r
human
cell
line
product
recombin
protein
horizon
n
biotechnol
wurm
fm
product
recombin
protein
therapeut
cultiv
mammalian
cell
nat
biotechnol
jayap
kp
wlaschin
kf
hu
ws
yap
mg
recombin
protein
therapeut
cho
cell
year
count
chem
eng
prog
halabian
r
roudkenar
mh
esmaeili
ns
masroori
n
roushandeh
najafabadi
aj
establish
cell
line
express
recombin
factor
vii
subsequ
convers
activ
form
fviia
hepsin
genet
engin
method
vox
sang
xiao
w
li
cq
xiao
xp
lin
fz
express
fast
prepar
biolog
activ
recombin
human
coagul
factor
vii
cell
genet
mol
re
ghaderi
taylor
padlerkaravani
v
diaz
varki
implic
presenc
nglycolylneuramin
acid
recombin
therapeut
glycoprotein
nat
biotechnol
varki
uniqu
human
evolut
sialic
acid
genet
biolog
proc
natl
acad
sci
suppl
ghaderi
zhang
hurtadoziola
n
varki
product
platform
biotherapeut
glycoprotein
occurr
impact
challeng
nonhuman
sialyl
biotechnol
genet
eng
ver
swiech
k
v
cova
dt
human
cell
new
platform
recombin
therapeut
protein
product
protein
expr
purif
lalond
duroch
therapeut
glycoprotein
product
mammalian
cell
j
biotechnol
background
emerg
stem
cellbas
regen
medicin
recent
lead
necess
reach
sustain
product
cell
henc
new
bioreactor
carrier
design
cell
expans
howev
meet
increas
demand
improv
qualiti
quantiti
stem
cell
remain
necessari
soft
biocompat
microcarri
mimick
extracellular
matrix
term
structur
stiff
valuabl
util
substrat
stiff
strongli
influenc
vitro
stem
cell
fate
differenti
materi
method
expertis
field
microbead
design
use
jetcut
technolog
enabl
us
engin
algin
bead
variou
gm
monom
ratio
use
jetcutt
genialab
gmbh
nozzl
max
speed
rpm
algin
solut
concentr
gelifi
etoh
solut
algin
estim
viscos
mpa
test
surfac
treatment
gelatin
polyllysin
carri
reach
optim
cell
anchor
human
adiposederiv
mesenchym
stem
cell
mesempro
rs
medium
gibco
result
conclus
jetcutt
technolog
allow
us
obtain
algin
microcarri
good
homogen
size
around
spheric
compar
commerci
carrier
tabl
best
adhes
human
adiposederiv
mesenchym
stem
cell
obtain
gelatin
coat
algin
carrier
fig
observ
limit
apoptosi
human
adiposederiv
mesenchym
cell
stem
conserv
day
cultur
data
shown
refer
jeanpaul
prieel
et
al
masther
industri
cell
therapi
product
bioprocess
intern
denni
e
discher
et
al
tissu
cell
feel
respond
stiff
substrat
scienc
adam
j
engler
et
al
matrix
elast
direct
stem
cell
lineag
specif
cell
nedov
va
et
al
continu
cider
ferment
coimmobil
yeast
leuconostoc
oeno
cell
enzym
microb
technolog
background
major
challeng
current
research
limit
avail
physiolog
relev
cell
thu
develop
relev
cellular
bioassay
robust
reproduc
scalabl
hinder
overcom
current
limit
develop
immort
strategi
allow
effici
reproduc
establish
novel
cell
line
show
vivolik
phenotyp
main
featur
ciscreen
technolog
abil
combin
advantag
cell
line
unlimit
cell
suppli
advantag
primari
cell
physiolog
relev
use
technolog
immort
amongst
other
human
osteoblast
cell
line
cihuob
present
studi
vivolik
phenotyp
function
novel
cihuob
examin
therefor
cihuob
cell
use
develop
cell
cultur
model
use
magnet
bioprint
technolog
bioscienc
houston
tx
usa
materi
method
cihuob
cell
line
recent
describ
cultiv
huob
mainten
medium
inscreenex
germani
spheroid
creation
cihuob
grown
monolay
magnet
ad
magnet
nanoparticl
assembl
nanoshuttl
ns
bioscienc
houston
tx
usa
concentr
growth
area
overnight
incub
magnet
cihuob
detach
seed
cellrepel
plate
greiner
bioon
frickenhausen
germani
help
mild
magnet
forc
cell
print
spheroid
within
consist
cell
cultur
period
day
cell
viabil
analyz
propidium
iodid
pi
calcein
stain
improv
spheroid
function
spheroid
cultiv
huob
differenti
medium
inscreenex
germani
mini
bone
tissu
function
thu
miner
analyz
alkalin
phosphatas
alkalin
phosphatas
activ
alizarin
red
stain
result
combin
cihuob
cell
magnet
bioprint
technolog
enabl
establish
reproduc
consist
spheroid
singl
spheroid
per
well
form
independ
amount
cell
cell
fig
form
spheroid
stabl
cultur
period
day
fig
neither
cell
death
cell
prolifer
observ
bioprint
spheroid
indic
stabl
size
spheroid
throughout
cultiv
fig
treatment
differenti
stimulu
bioprint
spheroid
becam
fulli
function
mini
bone
highlight
alkalin
phosphatas
activ
deposit
within
bioprint
spheroid
fig
e
conclus
taken
togeth
result
demonstr
function
immort
technolog
provid
physiolog
relev
cell
suffici
number
magnet
bioprint
technolog
enabl
fast
consist
cell
aggreg
format
stabl
uniform
spheroid
importantli
immort
cell
capabl
differenti
suitabl
stimulu
provid
differenti
mini
bone
spheroid
cultiv
addit
stimul
small
molecul
requir
combin
physiolog
relev
cell
system
three
dimension
cultur
help
gener
vitro
test
system
close
resembl
vivo
physiolog
therebi
support
futur
drug
discoveri
approach
acknowledg
work
support
grant
ministerium
wissenschaft
und
kultur
german
ministri
econom
affair
energi
igf
n
refer
lipp
c
may
hauser
h
wirth
etern
function
ration
access
physiolog
relev
cell
line
biol
chem
dec
fm
may
zauer
j
c
delgadocal
j
arozamena
j
berciano
mt
lafarga
riancho
ja
gener
character
two
immort
human
osteoblast
cell
line
use
epigenet
studi
j
bone
miner
metab
mar
doi
bioscienc
greiner
bioon
biocompat
nanoshuttletm
magnet
field
magnet
bioprint
onlin
avail
http
access
